Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
fea2d6904a028719194392e2bd0776357c362f76c59e27cb9106f847e1c3b3ab.png
complex
<table><tr><td>Variables</td><td>Case (<i>n</i> = 97) #(%)</td><td>Control (<i>n</i> = 194) #(%)</td><td>Crude OR (95 % CI)</td></tr><tr><td colspan="4">Ever heard of PITC</td></tr><tr><td> Yes</td><td>54 (55.7)</td><td>170 (87.6)</td><td>1</td></tr><tr><td> No</td><td>43 (44.3)</td><td>24 (12.4)</td><td>5.64 (3.14,10.13)<sup>a</sup></td></tr><tr><td colspan="4">Know PITC is given to all OPD patients</td></tr><tr><td> Yes</td><td>57 (58.8)</td><td>146 (75.3)</td><td>1</td></tr><tr><td> No</td><td>40 (41.2)</td><td>48 (24.7)</td><td>2.14 (1.27,3.59)<sup>a</sup></td></tr><tr><td colspan="4">Patient has right to refuse PITC</td></tr><tr><td> Yes</td><td>93 (95.9)</td><td>188 (96.9)</td><td>1</td></tr><tr><td> No</td><td>4 (4.1)</td><td>6 (3.1)</td><td>1.35 (0.37,4.89)</td></tr><tr><td colspan="4">Patients are benefited from PITC service</td></tr><tr><td> Yes</td><td>89 (91.8)</td><td>187 (96.4)</td><td>1</td></tr><tr><td> No</td><td>8 (8.2)</td><td>7 (3.6)</td><td>2.4 (0.84,6.83)</td></tr><tr><td colspan="4">Support provision of PITC service to all OPD patients</td></tr><tr><td> Yes</td><td>57 (58.8)</td><td>182 (93.8)</td><td>1</td></tr><tr><td> No</td><td>40 (41.2)</td><td>12 (6.2)</td><td>10.64 (5.23,21.66)<sup>a</sup></td></tr><tr><td colspan="4">Perceive the benefits of PITC</td></tr><tr><td> Yes</td><td>58 (59.8)</td><td>185 (95.4)</td><td>1</td></tr><tr><td> No</td><td>39 (40.2)</td><td>9 (4.6)</td><td>13.82 (6.32,30.23)<sup>a</sup></td></tr><tr><td colspan="4">PITC can affect health service utilization by patients</td></tr><tr><td> No</td><td>81 (83.5)</td><td>181 (93.3)</td><td>1</td></tr><tr><td> Yes</td><td>16 (16.5)</td><td>13 (6.7)</td><td>2.75 (1.26,5.98)<sup>a</sup></td></tr></table>
d6d342cecaf59c1c0ba1eea954733bdbb638bd5b7b0f0edb715a5bb2f6f80f9a.png
complex
<table><tr><td>Name</td><td colspan="3">2010</td><td colspan="3">2013</td><td colspan="3">Difference</td></tr><tr><td></td><td>h-core citations</td><td>h-index</td><td>Bh-index</td><td>h-core citations</td><td>h-Index</td><td>Bh-Index</td><td>h-core citations</td><td>h-Index</td><td>Bh-Index</td></tr><tr><td>Boyer PD</td><td>3103</td><td>29</td><td>48</td><td>3484</td><td>30</td><td>50</td><td>381</td><td>1</td><td>2</td></tr><tr><td>Kohn W</td><td>3215</td><td>20</td><td>53</td><td>4050</td><td>21</td><td>58</td><td>835</td><td>1</td><td>5</td></tr><tr><td>Hershko A</td><td>10410</td><td>39</td><td>97</td><td>12273</td><td>42</td><td>99</td><td>1863</td><td>3</td><td>2</td></tr><tr><td>Shimomura O</td><td>962</td><td>19</td><td>30</td><td>1246</td><td>22</td><td>37</td><td>284</td><td>3</td><td>7</td></tr><tr><td>Chalfie M</td><td>7301</td><td>35</td><td>78</td><td>8702</td><td>40</td><td>85</td><td>1401</td><td>5</td><td>7</td></tr><tr><td>Curl RF</td><td>4183</td><td>35</td><td>59</td><td>5027</td><td>40</td><td>68</td><td>844</td><td>5</td><td>9</td></tr><tr><td>Molina MJ</td><td>5399</td><td>44</td><td>80</td><td>6695</td><td>52</td><td>83</td><td>1296</td><td>8</td><td>3</td></tr><tr><td>Ertl G</td><td>13932</td><td>79</td><td>111</td><td>17198</td><td>87</td><td>128</td><td>3266</td><td>8</td><td>17</td></tr></table>
6fd1eae5d071fc5ac4398a3c104be291a423e2f691c89e2e7128ddb8caf42077.png
simple
<table><tr><td>abbreviation</td><td>muscle name</td><td>maximum isometric force (<i>F</i><sub>iso</sub>, N)</td><td>optimal fibre length (L<sub>fopt</sub>, m)</td><td>tendon slack length (<i>L</i><sub>tsl</sub>, m)</td><td>pennation angle (&#176;)</td></tr><tr><td>IC</td><td>M. iliotibialis cranialis</td><td>889</td><td>0.174</td><td>0.0451</td><td>0</td></tr><tr><td>ILa</td><td>M. iliotibialis lateralis (cranial part)</td><td>1265</td><td>0.174</td><td>0.2432</td><td>0</td></tr><tr><td>ILp</td><td>M. iliotibialis lateralis (caudal part)</td><td>1265</td><td>0.174</td><td>0.3099</td><td>0</td></tr><tr><td>AMB1</td><td>M. ambiens, ventral (pubic) head</td><td>971</td><td>0.039</td><td>0.1648</td><td>10</td></tr><tr><td>AMB2</td><td>M. ambiens, dorsal (iliac) head</td><td>1793</td><td>0.044</td><td>0.3941</td><td>15</td></tr><tr><td>FMTL</td><td>M. femorotibialis lateralis</td><td>1434</td><td>0.088</td><td>0.1746</td><td>15</td></tr><tr><td>FMTIM</td><td>M. femorotibialis intermedius</td><td>1706</td><td>0.084</td><td>0.1863</td><td>25</td></tr><tr><td>FMTM</td><td>M. femorotibialis medialis</td><td>1089</td><td>0.089</td><td>0.0603</td><td>30</td></tr><tr><td>ILFBa</td><td>M. iliofibularis (cranial part)</td><td>1254</td><td>0.176</td><td>0.2134</td><td>0</td></tr><tr><td>ILFBp</td><td>M. iliofibularis (caudal part)</td><td>1254</td><td>0.176</td><td>0.2733</td><td>0</td></tr><tr><td>ITCa</td><td>M. iliotrochantericus caudalis (cranial part)</td><td>897</td><td>0.064</td><td>0.0469</td><td>25</td></tr><tr><td>ITCp</td><td>M. iliotrochantericus caudalis (caudal part)</td><td>897</td><td>0.064</td><td>0.038</td><td>25</td></tr><tr><td>IFE</td><td>M. iliofemoralis externus</td><td>479</td><td>0.025</td><td>0.0667</td><td>25</td></tr><tr><td>ITM</td><td>M. iliotrochantericus medius</td><td>181</td><td>0.058</td><td>0.0241</td><td>0</td></tr><tr><td>ITCR</td><td>M. iliotrochantericus cranialis</td><td>330</td><td>0.053</td><td>0.0488</td><td>10</td></tr><tr><td>IFI</td><td>M. iliofemoralis internus</td><td>410</td><td>0.041</td><td>0.0533</td><td>0</td></tr><tr><td>FCM</td><td>M. flexor cruris medialis</td><td>1109</td><td>0.036</td><td>0.435</td><td>35</td></tr><tr><td>FCLP</td><td>M. flexor cruris lateralis pars pelvica</td><td>544</td><td>0.24</td><td>0.2449</td><td>0</td></tr><tr><td>ISF</td><td>M. ischiofemoralis</td><td>419</td><td>0.033</td><td>0.0816</td><td>15</td></tr><tr><td>PIFML</td><td>M. puboischiofemorales medialis + lateralis</td><td>816</td><td>0.089</td><td>0.1669</td><td>15</td></tr><tr><td>OM</td><td>M. obturatorius medialis</td><td>3124</td><td>0.055</td><td>0.1651</td><td>25</td></tr><tr><td>CFP</td><td>M. caudofemoralis pars pelvica (et caudalis)</td><td>1125</td><td>0.108</td><td>0.215</td><td>15</td></tr><tr><td>GL</td><td>M. gastrocnemius pars lateralis</td><td>1836</td><td>0.12</td><td>0.5818</td><td>20</td></tr><tr><td>GIM</td><td>M. gastrocnemius pars intermedius</td><td>798</td><td>0.125</td><td>0.507</td><td>15</td></tr><tr><td>GM</td><td>M. gastrocnemius pars medialis</td><td>3124</td><td>0.094</td><td>0.5957</td><td>20</td></tr><tr><td>FL</td><td>M. fibularis longus</td><td>2270</td><td>0.081</td><td>0.9633</td><td>20</td></tr><tr><td>FDL</td><td>M. flexor digitorum longus</td><td>1130</td><td>0.048</td><td>1.0366</td><td>20</td></tr><tr><td>FPPD3</td><td>M. flexor perforans et perforatus digitorum 3</td><td>1154</td><td>0.025</td><td>1.0737</td><td>30</td></tr><tr><td>FPD3</td><td>M. flexor perforans digitorum 3</td><td>3210</td><td>0.017</td><td>1.02</td><td>35</td></tr><tr><td>FPD4</td><td>M. flexor perforans digitorum 4</td><td>1434</td><td>0.026</td><td>1.004</td><td>20</td></tr><tr><td>FHL</td><td>M. flexor hallucis longus</td><td>469</td><td>0.04</td><td>1.0939</td><td>25</td></tr><tr><td>EDL</td><td>M. extensor digitorum longus</td><td>833</td><td>0.049</td><td>0.8512</td><td>30</td></tr><tr><td>TCf</td><td>M. tibialis cranialis (femoral head)</td><td>686</td><td>0.045</td><td>0.4791</td><td>25</td></tr><tr><td>TCt</td><td>M. tibialis cranialis (tibial head)</td><td>686</td><td>0.045</td><td>0.4215</td><td>25</td></tr></table>
13fb856f35b681de7a732ffe0d860ae0b1f6f22a843939cb73ef96fe9ae85879.png
simple
<table><tr><td></td><td>Group ofCOPD+PAH (n = 12)</td><td>Group of COPD (n = 36)</td><td>Group of HS (n = 15)</td></tr><tr><td>Sex, M/F</td><td>11/1</td><td>32/4</td><td>9/6</td></tr><tr><td>Age, Years</td><td>70.8 (6.7)</td><td>67.6 (9.2)</td><td>58 (9.2)</td></tr><tr><td>Smoking, pack-years</td><td>27 (7)</td><td>25 (6)</td><td>0</td></tr><tr><td>FEV<sub>1</sub>%</td><td>39.35 (11.45)</td><td>48.13 (18.04)</td><td>98.05 (11.65)</td></tr><tr><td>FVC%</td><td>64.89 (14.90)</td><td>69.39 (19.1)</td><td>95.07 (13.34)</td></tr><tr><td>FEV<sub>1</sub>/FVC %</td><td>46.95 (6.81)</td><td>54.27 (12.46)</td><td>101.37 (8.5)</td></tr><tr><td>RV%</td><td>151 (38)</td><td>143 (32)</td><td>108 (11)</td></tr><tr><td>PaO<sub>2 </sub>(mmHg)</td><td>60.83 (4.76)</td><td>64.58 (6.16)</td><td>97.2 (0.7)</td></tr><tr><td>PaCO<sub>2 </sub>(mmHg)</td><td>39.4 (4.27)</td><td>41.78 (5.01)</td><td>38.4 (1.5)</td></tr><tr><td>PaPs (mmHg)</td><td>51.08 (12.2)*</td><td>26.05 (3.39)</td><td>NA</td></tr><tr><td>ET-1 EBC (pg/ml)</td><td>22.36 (4)</td><td>7.25 (0.23)</td><td>5.24 (0.47)</td></tr><tr><td>ET-1 art (pg/ml)</td><td>12.41 (2.13)</td><td>7.22 (0.21)</td><td>0.84 (0.37)</td></tr><tr><td>ET-1 ven (pg/ml)</td><td>14.53 (2.76)</td><td>7.29 (0.16)</td><td>1 (0.42)</td></tr><tr><td>FENO (ppb)</td><td>22.92 (11.38)</td><td>35.07 (17.53)</td><td>20.56 (3.67)</td></tr><tr><td>6MWD</td><td>383 (34)<sup>&#167;</sup></td><td>NA</td><td>NA</td></tr></table>
6b5b20697c998265141f5be2c82f0ec32da5e36b49c1ea0c512a5f1467b52e6c.png
simple
<table><tr><td>Predictors (all T1 variables)</td><td>Odds Ratio</td><td>95% CI</td></tr><tr><td>Independent</td><td></td><td></td></tr><tr><td>Neighborhood crime</td><td>0.91</td><td>0.75&#8211;1.10</td></tr><tr><td>Neighborhood drug selling/use</td><td>1.39</td><td>1.16&#8211;1.66</td></tr><tr><td>Noxious neighborhood</td><td>1.03</td><td>0.90&#8211;1.19</td></tr><tr><td>Controls </td><td></td><td></td></tr><tr><td>Age</td><td>1.51</td><td>1.22&#8211;1.85</td></tr><tr><td>Sex (Ref = Male)</td><td>0.64</td><td>0.43&#8211;0.95</td></tr><tr><td>SES</td><td>1.08</td><td>0.88&#8211;1.30</td></tr><tr><td>Occasions of marijuana use</td><td>1.78</td><td>1.31&#8211;2.42</td></tr></table>
446f109488018ddcaf1d0ae8037ad5bf897e49272fac52aad8468a8ee1704fcc.png
simple
<table><tr><td></td><td>Sense primer (5&#8242; to 3&#8242;)</td><td>Anti-sense primer (5&#8242; to 3&#8242;)</td></tr><tr><td>Human CCL19</td><td>CCAACTCTGAGTGGCACCAA</td><td>TGAACACTACAGCAGGCACC</td></tr><tr><td>Human CCL21</td><td>TGGCCTCTTACTCACCCTCT</td><td>GCCTCTTGATCCCCTTAGCC</td></tr><tr><td>Human CCR7</td><td>GCCTACGACGTCACCTACAG</td><td>GGCAGAAGAGTCGCCTATGG</td></tr><tr><td>Beta-actin</td><td>CCATCGTCCACCGCAAAT</td><td>TGTCACCTTCACCGTTCC</td></tr><tr><td>ALP</td><td>ATCTTTGGTCTGGCTCCCATG</td><td>TTTCCCGTTCACCGTCCAC</td></tr><tr><td>Human OCN</td><td>GGCAGCGAGGTAGTGAAGAG</td><td>CTGGAGAGGAGCAGAACTGG</td></tr><tr><td>Human COL1</td><td>GAG AGC ATG ACC GAT GG</td><td>GTG ACG CTG TAG GTG AA</td></tr><tr><td>IBSP</td><td>CGCCAATGAATACGACAATG</td><td>GATGCAAAGCCAGAATGGAT</td></tr><tr><td>Human VEGF-A</td><td>GAGCCTTGCCTTGCTGCTCTA</td><td>CACCAGGGTCTCGATTGGAT</td></tr><tr><td>Runx-2</td><td>GCAGCAACCCAGAAACACTT</td><td>AACACATGACCCAGTGCAAA</td></tr><tr><td>Osterix</td><td>AGAGGAGAGACTCGGGACAG</td><td>GAGTTGTTGAGTCCCGCAGA</td></tr></table>
75d16279b2bec0ded3f83b37684470838f063b6a2f03d74e9c90abcaaf2ba5b8.png
complex
<table><tr><td></td><td colspan="2">ASD (<i>n</i> = 9)</td><td colspan="2">Neurotypical (<i>n</i> = 9)</td><td colspan="2">Group difference</td></tr><tr><td></td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td><i>t</i>(16)</td><td><i>p</i></td></tr><tr><td>Chronological age (years)</td><td>13.67</td><td>1.94</td><td>14.44</td><td>1.13</td><td>-1.04</td><td>0.31</td></tr><tr><td>WASI vocabulary</td><td>52</td><td>10.99</td><td>63.78</td><td>6.72</td><td>-2.74</td><td>0.01</td></tr><tr><td>WASI matrix</td><td>49.78</td><td>7.12</td><td>55.44</td><td>8.75</td><td>-1.51</td><td>0.15</td></tr><tr><td>WASI IQ</td><td>101.78</td><td>13.84</td><td>117.22</td><td>13.15</td><td>-2.43</td><td>0.03</td></tr><tr><td colspan="6">ADOS</td></tr><tr><td>Communication</td><td>3.11</td><td>0.93</td><td>0.22</td><td>0.44</td><td>8.44</td><td>&lt;0.001</td></tr><tr><td>Social interaction</td><td>5.44</td><td>2.19</td><td>0.11</td><td>0.33</td><td>7.24</td><td>&lt;0.001</td></tr><tr><td>Communication and social interaction total</td><td>8.56</td><td>2.92</td><td>0.33</td><td>0.5</td><td>8.33</td><td>&lt;0.001</td></tr><tr><td>Stereotyped behaviors and restricted interests</td><td>2.0</td><td>1.41</td><td>0</td><td>0</td><td>4.26</td><td>0.001</td></tr></table>
f2e378a909776ec26040345fc1c00f24f196cc836b3f816e80b4a9531b3fc243.png
simple
<table><tr><td>Characteristics</td><td>ORT corner users, n(%)</td><td>ORT corner non-users, n(%)</td><td>p value</td></tr><tr><td><i>Age:</i></td><td></td><td></td><td>0.4905</td></tr><tr><td> 18-19 years</td><td>9(8)</td><td>11(9)</td><td></td></tr><tr><td> 20-29 years</td><td>48(44)</td><td>63(53)</td><td></td></tr><tr><td> 30-39 years</td><td>33(39)</td><td>35(30)</td><td></td></tr><tr><td> 40 and over</td><td>10(9)</td><td>9(8)</td><td></td></tr><tr><td><i>Education:</i></td><td></td><td></td><td>0.1048</td></tr><tr><td> No formal education</td><td>59(54)</td><td>61(52)</td><td></td></tr><tr><td> Primary or secondary education</td><td>33(30)</td><td>34(29)</td><td></td></tr><tr><td> Tertiary education</td><td>10(9)</td><td>4(3)</td><td></td></tr><tr><td> Other</td><td>8(7)</td><td>18(15)</td><td></td></tr><tr><td><i>Occupation:</i></td><td></td><td></td><td>0.0016*</td></tr><tr><td> Housewives</td><td>35(32)</td><td>58(48)</td><td></td></tr><tr><td> Petty traders</td><td>58(53)</td><td>55(46)</td><td></td></tr><tr><td> Government employee</td><td>15(13)</td><td>2(2)</td><td></td></tr><tr><td> Students</td><td>0(0)</td><td>2(2)</td><td></td></tr><tr><td> Other</td><td>2(2)</td><td>2(2)</td><td></td></tr><tr><td>Religion<i>: Muslim</i></td><td>106(96)</td><td>112(94)</td><td>0.4271</td></tr><tr><td>Marital Status<i>: Married</i></td><td>101(92)</td><td>113(95)</td><td>0.3373</td></tr><tr><td>Number of children, Mean</td><td>4.2</td><td>3.3</td><td>0.0027*</td></tr></table>
bde201776502d52b21f3ec163ef107e10dad05bf9ed35fe1e1f1f27ba4cc5f3d.png
complex
<table><tr><td></td><td></td><td></td><td colspan="2">Schizophrenia</td><td colspan="2">Controls</td></tr><tr><td></td><td></td><td></td><td>Amplitudes (&#956;V)</td><td>Latency (ms)</td><td>Amplitudes (&#956;V)</td><td>Latency (ms)</td></tr><tr><td>Emotional syllables</td><td>Angry</td><td>F3</td><td>-1.77 &#177; 1.20</td><td>245.27 &#177; 57.25</td><td>-2.55 &#177; 1.12</td><td>251.00 &#177; 51.81</td></tr><tr><td></td><td></td><td>Fz</td><td>-1.94 &#177; 1.23</td><td>239.33 &#177; 54.31</td><td>-2.69 &#177; 1.19</td><td>247.93 &#177; 55.60</td></tr><tr><td></td><td></td><td>F4</td><td>-1.85 &#177; 1.30</td><td>244.87 &#177; 52.14</td><td>-2.58 &#177; 1.02</td><td>256.27 &#177; 55.67</td></tr><tr><td></td><td>Happy</td><td>F3</td><td>-1.04 &#177; 0.94</td><td>245.33 &#177; 49.34</td><td>-1.33 &#177; 0.68</td><td>259.33 &#177; 51.61</td></tr><tr><td></td><td></td><td>Fz</td><td>-1.17 &#177; 1.18</td><td>248.93 &#177; 51.43</td><td>-1.51 &#177; 0.76</td><td>255.47 &#177; 51.24</td></tr><tr><td></td><td></td><td>F4</td><td>-1.01 &#177; 1.10</td><td>244.21 &#177; 40.41</td><td>-1.45 &#177; 0.75</td><td>258.33 &#177; 47.54</td></tr><tr><td>Non-vocal sounds</td><td>Angry-derived</td><td>F3</td><td>-1.87 &#177; 1.15</td><td>245.13 &#177; 47.81</td><td>-2.65 &#177; 1.16</td><td>251.13 &#177; 36.40</td></tr><tr><td></td><td></td><td>Fz</td><td>-2.06 &#177; 1.14</td><td>245.00 &#177; 47.28</td><td>-2.89 &#177; 1.18</td><td>249.00 &#177; 37.76</td></tr><tr><td></td><td></td><td>F4</td><td>-2.00 &#177; 1.00</td><td>237.93 &#177; 47.46</td><td>-2.73 &#177; 1.20</td><td>248.07 &#177; 37.65</td></tr><tr><td></td><td>Happy-derived</td><td>F3</td><td>-0.75 &#177; 0.76</td><td>233.67 &#177; 54.83</td><td>-0.76 &#177; 0.53</td><td>262.13 &#177; 56.30</td></tr><tr><td></td><td></td><td>Fz</td><td>-0.64 &#177; 0.85</td><td>241.87 &#177; 50.72</td><td>-0.89 &#177; 0.57</td><td>261.60 &#177; 54.61</td></tr><tr><td></td><td></td><td>F4</td><td>0.67 &#177; 0.91</td><td>251.47 &#177; 56.04</td><td>-0.79 &#177; 0.55</td><td>253.07 &#177; 55.45</td></tr></table>
1fbb3f9563534e4efd4a5f52b4fd41ec0e6f59e0ff336550ce7ae451c0f8d773.png
simple
<table><tr><td></td><td>N = 137 patients (23 residents)</td></tr><tr><td>Physician's Use of Obesity Counseling</td><td></td></tr><tr><td> % Counseled about Obesity (n)</td><td>85.4 (117)</td></tr><tr><td> Mean Number of Counseling Practices<sup>1 </sup>(SD) (18 Items total)</td><td>5.3 (4.6)</td></tr><tr><td>5As</td><td></td></tr><tr><td> Mean Number of Assess<sup>2 </sup>Practices (SD) (6 items)</td><td>2.2 (2.0)</td></tr><tr><td> Mean Number of Advise<sup>3 </sup>Practices (SD) (4 items)</td><td>1.3 (1.3)</td></tr><tr><td> Mean Number of Agree<sup>4 </sup>Practices (SD) (3 items)</td><td>0.7 (1.2)</td></tr><tr><td> % Use Assist<sup>5 </sup>Practice (n) (1 item)</td><td>25.6 (35)</td></tr><tr><td> Mean Number of Arrange<sup>6 </sup>Practices (SD) (4 items)</td><td>0.8 (0.4)</td></tr></table>
42c760b7cb710a43e2b0d216f54e288fbe75014ebfa9fa77f120eb7ff8ff19ee.png
simple
<table><tr><td>Characteristics</td><td>No. of patients (%)</td></tr><tr><td>Age (years)</td><td></td></tr><tr><td> Median (range)</td><td>71.0 (65.0-81.0)</td></tr><tr><td>ECOG performance status</td><td></td></tr><tr><td> 0-1</td><td>108 (81.2)</td></tr><tr><td> &#8805; 2</td><td>25 (18.8)</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td></td></tr><tr><td> &lt; 30</td><td>96 (72.2)</td></tr><tr><td> &#8805; 30</td><td>37 (27.8)</td></tr><tr><td>WIC</td><td></td></tr><tr><td> &#8805; 1</td><td>52 (39.1)</td></tr><tr><td> &lt; 1</td><td>81 (60.9)</td></tr><tr><td>Baseline LVEF</td><td></td></tr><tr><td> Median (range)</td><td>61% (47.0&#8211;69.0)</td></tr><tr><td>TNM stage</td><td></td></tr><tr><td> I-II</td><td>39 (29.3)</td></tr><tr><td> III</td><td>61 (45.9)</td></tr><tr><td> IV</td><td>33 (24.8)</td></tr><tr><td>Anthracycline exposure</td><td></td></tr><tr><td> Previous</td><td>49 (36.8)</td></tr><tr><td> Concomitant</td><td>22 (16.5)</td></tr><tr><td> None</td><td>62 (46.6)</td></tr><tr><td>Anthracycline cumulative dose (mg/m2)</td><td>116 (0-540)</td></tr><tr><td>Previous radiotherapy (thoracic wall)</td><td></td></tr><tr><td> Yes</td><td>19 (14.3)</td></tr><tr><td> No</td><td>124 (93.2)</td></tr></table>
f2a2b149df841e9a9fa715106e3d7306d16484d9ebf75d810e30b75782cc5749.png
simple
<table><tr><td>Number of Procedures</td><td>&lt; 200h</td><td>&gt; 200h</td><td>p value</td></tr><tr><td>History Takings in Initial Patient Care</td><td>136.905</td><td>363.800</td><td>0.001075</td></tr><tr><td>Non-cast immobilizations</td><td>19.360</td><td>63.577</td><td>0.005303793</td></tr><tr><td>Cast immobilizations</td><td>32.811</td><td>102.160</td><td>0.000295235</td></tr><tr><td>Simple sutures</td><td>33.980</td><td>96.200</td><td>0.000032826369841</td></tr><tr><td>Donatti sutures</td><td>5.283</td><td>12.214</td><td>0.019836</td></tr><tr><td>Trauma Resuscitation Room visits</td><td>2.804</td><td>21.036</td><td>0.000045965</td></tr></table>
424021d6368b352afd689ebc3fee08edde4c08fcdb995c030c54feba80a3882c.png
complex
<table><tr><td></td><td>Adolescent population*</td><td colspan="4">Adolescents with emergency admission(s) for injury between 10 and 19 years of age, n (row %)</td></tr><tr><td>Characteristics</td><td>Total</td><td>Total</td><td>Adversity</td><td>Accidents only</td><td>Other causes</td></tr><tr><td>All</td><td>3 254 046</td><td>402 916 (100.0)</td><td>141 248 (35.1)</td><td>233 907 (58.1)</td><td>27 761 (6.9)</td></tr><tr><td colspan="6">Age&#8224;</td></tr><tr><td> Girls (years)</td><td>1 588 942</td><td>144 158 (100.0)</td><td>72 805 (50.5)</td><td>59 528 (41.3)</td><td>11 888 (8.2)</td></tr><tr><td>10&#8211;14</td><td></td><td>65 208 (100.0)</td><td>23 178 (35.5)</td><td>37 388 (57.3)</td><td>4642 (7.1)</td></tr><tr><td>15&#8211;17</td><td></td><td>48 286 (100.0)</td><td>31 573 (65.4)</td><td>12 922 (26.8)</td><td>3791 (7.9)</td></tr><tr><td>18&#8211;19</td><td></td><td>30 664 (100.0)</td><td>18 054 (58.9)</td><td>9155 (29.9)</td><td>3455 (11.3)</td></tr><tr><td> Boys (years)</td><td>1 665 104</td><td>258 503 (100.0)</td><td>68 403 (26.5)</td><td>174 267 (67.4)</td><td>15 833 (6.1)</td></tr><tr><td>10&#8211;14</td><td></td><td>121 821 (100.0)</td><td>17 667 (14.5)</td><td>97 478 (80.0)</td><td>6676 (5.5)</td></tr><tr><td>15&#8211;17</td><td></td><td>79 223 (100.0)</td><td>25 014 (31.6)</td><td>49 345 (62.3)</td><td>4864 (6.1)</td></tr><tr><td>18&#8211;19</td><td></td><td>57 459 (100.0)</td><td>25 722 (44.8)</td><td>27 444 (47.8)</td><td>4293 (7.5)</td></tr><tr><td> Missing (sex)</td><td></td><td>255 (100.0)</td><td>40 (15.7)</td><td>175 (68.6)</td><td>40 (15.7)</td></tr></table>
8ad63402e9e860b5c6649718c283f7d707973a3af0e6fddfa377c93904f499ae.png
simple
<table><tr><td>Index</td><td>Weekdays</td><td>Weekend</td><td><i>p</i></td></tr><tr><td>Bedtime (HH:MM)</td><td>11:46 p.m. &#177; 87.2</td><td>00:12 a.m. &#177; 102.0</td><td>&lt;0.001</td></tr><tr><td>Wake-up Time (HH:MM)</td><td>06:32 a.m. &#177; 80.6</td><td>07:26 a.m. &#177; 105.0</td><td>&lt;0.001</td></tr><tr><td>Sleep Midpoint (HH:MM)</td><td>03:09 a.m. &#177; 77.2</td><td>03:49 a.m. &#177; 96.4</td><td>&lt;0.001</td></tr><tr><td>Time in Bed (min)</td><td>406 &#177; 65.9</td><td>434 &#177; 75.4</td><td>&lt;0.001</td></tr><tr><td>Total Sleep Time (min)</td><td>354 &#177; 60.1</td><td>376 &#177; 70.2</td><td>&lt;0.001</td></tr><tr><td>Sleep Efficiency (%)</td><td>87.4 &#177; 8.2</td><td>87.1 &#177; 8.8</td><td>0.089</td></tr><tr><td>Initial Sleep Index (min)</td><td>38.8 &#177; 29.5</td><td>38.4 &#177; 33.7</td><td>0.613</td></tr></table>
5e223c30277d424960b6407b4cd933599a1ecd6ea374ccb69ce80091bcb49dbc.png
complex
<table><tr><td rowspan="2" colspan="2">Month</td><td colspan="2">Cross-validation (%)</td><td rowspan="2">Allometry (%)</td><td rowspan="2">Influential landmark</td></tr><tr><td>&#9794;</td><td>&#9792;</td></tr><tr><td rowspan="2">JAN/2009</td><td>Hilltop</td><td>81</td><td>93</td><td>10.470*</td><td>#10 and #17</td></tr><tr><td>Lowland</td><td>100</td><td>100</td><td>15.968*</td><td>#2 and #9</td></tr><tr><td rowspan="2">JAN/2012</td><td>Hilltop</td><td>87</td><td>96</td><td>5.853*</td><td>#2 and #9</td></tr><tr><td>Lowland</td><td>76</td><td>77</td><td>2.141</td><td>#10 and #17</td></tr><tr><td rowspan="2">JUL/2012</td><td>Hilltop</td><td>83</td><td>90</td><td>6.909*</td><td>#2 and #9</td></tr><tr><td>Lowland</td><td>92</td><td>95</td><td>5.924*</td><td>#9 and #10</td></tr><tr><td rowspan="2">JAN/2013</td><td>Hilltop</td><td>96</td><td>100</td><td>8.433*</td><td>#9 and #10</td></tr><tr><td>Lowland</td><td>100</td><td>100</td><td>3.962*</td><td>#9 and #10</td></tr></table>
a916db0a3aa6d08b66556657e9a431344374cbb70061cff8a2566b05dc756d61.png
simple
<table><tr><td>Country</td><td>Sample name</td><td>Latitude</td><td>Longitude</td></tr><tr><td>Poland</td><td>A</td><td>53&#176; 50&#8242;02.83&#8242;&#8242;N</td><td>21&#176; 03&#8242;30.36&#8242;&#8242;E</td></tr><tr><td>Poland</td><td>H</td><td>54&#176; 23&#8242;21.42&#8242;&#8242;N</td><td>18&#176; 28&#8242;42.18&#8242;&#8242;E</td></tr><tr><td>Germany</td><td>B</td><td>52&#176; 13&#8242;09.87&#8242;&#8242;N</td><td>11&#176; 42&#8242;25.14&#8242;&#8242;E</td></tr><tr><td>Germany</td><td>D</td><td>53&#176; 25&#8242;51.60&#8242;&#8242;N</td><td>09&#176; 46&#8242;39.78&#8242;&#8242;E</td></tr><tr><td>Denmark</td><td>I</td><td>56&#176; 12&#8242;13.48&#8242;&#8242;N</td><td>08&#176; 09&#8242;39.07&#8242;&#8242;E</td></tr><tr><td>Denmark</td><td>E</td><td>55&#176; 56&#8242;16.98&#8242;&#8242;N</td><td>12&#176; 28&#8242;35.70&#8242;&#8242;E</td></tr><tr><td>Sweden</td><td>F</td><td>58&#176; 52&#8242;20.04&#8242;&#8242;N</td><td>14&#176; 53&#8242;56.79&#8242;&#8242;E</td></tr><tr><td>Sweden</td><td>K</td><td>64&#176; 36&#8242;27.31&#8242;&#8242;N</td><td>20&#176; 57&#8242;04.32&#8242;&#8242;E</td></tr><tr><td>Ireland</td><td>G</td><td>53&#176; 35&#8242;24.27&#8242;&#8242;N</td><td>08&#176; 03&#8242;33.69&#8242;&#8242;W</td></tr><tr><td>UK</td><td>C</td><td>52&#176; 29&#8242;17.12&#8242;&#8242;N</td><td>00&#176; 55&#8242;59.12&#8242;&#8242;W</td></tr><tr><td>UK</td><td>J</td><td>52&#176; 44&#8242;34.76&#8242;&#8242;N</td><td>01&#176; 08&#8242;09.87&#8242;&#8242;W</td></tr></table>
8625bac6b418b8901b9c6fa6bdf825992f7d98c8e7baec4afb892436df5045dd.png
simple
<table><tr><td></td><td>ExpressHMM</td><td>ANTM</td></tr><tr><td>Probe sensitivity</td><td>65%</td><td>44%</td></tr><tr><td>Novel probes predicted</td><td>65%</td><td>49%</td></tr><tr><td>Overlap exon Sensitivity</td><td>58%</td><td>58%</td></tr><tr><td>Novel transfrags predicted</td><td>27%</td><td>58%</td></tr><tr><td>5' Splice site sensitivity</td><td>16%</td><td>9%</td></tr><tr><td>3' Splice site sensitivity</td><td>16%</td><td>13%</td></tr></table>
60f3df316538da8b59d3b8ed37f405e8fc869162530b99356997166c95e33962.png
simple
<table><tr><td></td><td>N</td><td>% of sample (N = 201)</td><td>95% C.I.</td></tr><tr><td>&lt; 2 weeks</td><td>57</td><td>28.4</td><td>22.3 &#8211; 35.1</td></tr><tr><td>2 weeks</td><td>42</td><td>20.9</td><td>15.5 &#8211; 27.2</td></tr><tr><td>1 month</td><td>31</td><td>15.4</td><td>10.7 &#8211; 21.2</td></tr><tr><td>2 months</td><td>15</td><td>7.5</td><td>4.2 &#8211; 12.0</td></tr><tr><td>3 months</td><td>16</td><td>7.9</td><td>4.6 &#8211; 12.5</td></tr><tr><td>4 months</td><td>40</td><td>19.9</td><td>14.6 &#8211; 26.1</td></tr><tr><td>Total</td><td>201</td><td>100.0</td><td></td></tr></table>
4479d863f6d895a877955c417bf0f56846606738f53642aba960a4a0bb5c7bcf.png
complex
<table><tr><td>Diagnosis</td><td>Parasite</td><td>Early [n (%)]</td><td>Peak [n (%)]</td><td>Late [n (%)]</td><td>Total [n (%)]</td><td>P value<sup>1</sup></td></tr><tr><td rowspan="4">Microscopy</td><td><i>P. vivax</i></td><td>9 (1.7)</td><td>13 (2.3)</td><td>3 (0.5)</td><td>25 (1.5)</td><td>0.066</td></tr><tr><td><i>P. falciparum</i></td><td>0</td><td>0</td><td>0</td><td>0</td><td>&#8211;</td></tr><tr><td>Mixed infection</td><td>0</td><td>0</td><td>0</td><td>0</td><td>&#8211;</td></tr><tr><td>Total</td><td>9 (1.7)</td><td>13 (2.3)</td><td>3 (0.5)</td><td>25 (1.5)</td><td>0.066</td></tr><tr><td rowspan="4">nRT-PCR</td><td><i>P. vivax</i></td><td>95 (18.4)</td><td>152 (26.3)</td><td>105 (17.9)</td><td>352 (21.0)</td><td>0.001</td></tr><tr><td><i>P. falciparum</i></td><td>0</td><td>14 (2.4)</td><td>18 (3.1)</td><td>32 (1.9)</td><td>&lt; 0.001</td></tr><tr><td>Mixed infection</td><td>0</td><td>8 (1.4)</td><td>1 (0.2)</td><td>9 (0.5)</td><td>0.002</td></tr><tr><td>Total</td><td>95 (18.4)</td><td>174 (30.1)</td><td>124 (21.2)</td><td>393 (23.4)</td><td>0.001</td></tr></table>
73462abd091d13084520236e16cf879d21b9ee66f20ac3c87efb7ccc4e7d43b0.png
simple
<table><tr><td>Tandem repeat Family</td><td>Repeat Length</td><td>GC Content (%)</td><td>Genome Coverage (%)<sup>a</sup></td><td>Consensus Sequence<sup>b</sup></td><td>Distribution</td></tr><tr><td>pBuM189</td><td>189</td><td>29</td><td>0.039</td><td>GCAAAAGACTCCGTCAATTA GAAAACAAAAAATGTTATAGTTTTGAGGATTAACC GGCAAAAACCGTATTATTTGTTATAT GATTTCTGTATGGAATACCGTTTTAGAA GCGTCTTTTATCGTATTACTCAGATATATCT TAAGATTTAGCATAATCTAAGAACTTTT TGAAATATTCACATTTGTCCA</td><td><i>D. buzzatii</i> cluster species <i>D. mojavensis</i></td></tr><tr><td>DbuTR198</td><td>198</td><td>34</td><td>0.027</td><td>AAGGTAGAAAGGTAGTTGGTGAGATAAACCAGAAAAA GAGCTAAAAACGGCTAAAAACGGCTAGAAAATAGCCA GAAAGGTAGATTGAACATTAATGGGCAAATGG ATGGATAAATAAGACTGGTCATCATCCAA TGAACAGAATCATGATTAAGAGATAGAAATA TGATTAGAAAGTAGGATAGAAAGGTTAGAAAG</td><td><i>D. buzzatii</i></td></tr></table>
ebe4a23bd73164f427e2b14b826b42163b1a5062f4048e5cbd2ee067173f97a4.png
simple
<table><tr><td>Policosanol (Chemical formula)</td><td>Percent</td></tr><tr><td>Docosan-1-ol (C<sub>22</sub>-OH)</td><td>1.52 &#177; 0.24</td></tr><tr><td>Tricosan-1-ol (C<sub>23</sub>-OH)</td><td>2.12 &#177; 0.39</td></tr><tr><td>Tetracosan-1-ol (C<sub>24</sub>-OH)</td><td>2.02 &#177; 0.50</td></tr><tr><td>Hexacosan-1-ol (C<sub>26</sub> -OH)</td><td>2.50 &#177; 0.16</td></tr><tr><td>Heptacosan-1-ol (C<sub>27&#8722;</sub>OH)</td><td>1.90 &#177; 0.25</td></tr><tr><td>Octacosan-1-ol (C<sub>28</sub>-OH)</td><td>75.44 &#177; 2.41</td></tr><tr><td>Nonacosan-1-ol (C<sub>29</sub>-OH)</td><td>2.55 &#177; 0.62</td></tr><tr><td>Triacontan-1-ol (C<sub>30</sub>-OH)</td><td>8.61 &#177; 1.20</td></tr><tr><td>Dotriacontan-1-ol (C<sub>32</sub>-OH)</td><td>3.34 &#177; 0.56</td></tr></table>
9bf4c8bbfb474d9692c8f2aa1df1712b593f0036895c3843ce4d8da7e0984a72.png
complex
<table><tr><td rowspan="2" colspan="2">Experimental groups</td><td colspan="7">Lipid parameters (mg/dL)</td></tr><tr><td>TC</td><td>TG</td><td>VLDL-c</td><td>HDL-c</td><td>LDL-c</td><td>LDL/HDL</td><td>CT/HDL</td></tr><tr><td colspan="2">HC rats + dH<sub>2</sub>O</td><td>156.09 &#177; 0.92</td><td>141.01 &#177; 0.63</td><td>28.21 &#177; 0.73</td><td>31.05 &#177; 0.48*</td><td>109.28 &#177; 0.49</td><td>5.87 &#177; 0.05</td><td>8.44 &#177; 0.82</td></tr><tr><td rowspan="3">HC +4 weeks treatment</td><td>240 mg/kg</td><td>135.51 &#177; 0.51*</td><td>101.62 &#177; 0.98*</td><td>20.33 &#177; 0.79*</td><td>26.73 &#177; 0.47</td><td>81.53 &#177; 0.5*</td><td>3.05 &#177; 0.07*</td><td>6.25 &#177; 0.34*</td></tr><tr><td>320 mg/kg</td><td>116.63 &#177; 0,54*</td><td>95.06 &#177; 0.57*</td><td>19.02 &#177; 0.66*</td><td>28.35 &#177; 0.58*</td><td>53.02 &#177; 0.83*</td><td>1.87 &#177; 0.06*</td><td>4.59 &#177; 0.16*</td></tr><tr><td>400 mg/kg</td><td>106.07 &#177; 0.69*</td><td>85.15 &#177; 0.64*</td><td>16.65 &#177; 0.38*</td><td>34.77 &#177; 0.6*</td><td>36.17 &#177; 0.34*</td><td>0.96 &#177; 0.04*</td><td>3.96 &#177; 0.15*</td></tr><tr><td rowspan="3">HC 4 weeks after treatment</td><td>240 mg/kg</td><td>130.12 &#177; 0.11*</td><td>98.13 &#177; 0.30*</td><td>18.30 &#177; 0.70*</td><td>27.12 &#177; 0.17</td><td>80.31 &#177; 0.15*</td><td>2.96 &#177; 0.02*</td><td>4.79 &#177; 0.13*</td></tr><tr><td>320 mg/kg</td><td>110.22 &#177; 0,34*</td><td>89.16 &#177; 0.33*</td><td>16.12 &#177; 0.25*</td><td>30.22 &#177; 0.32*</td><td>48.22 &#177; 0.23*</td><td>1.59 &#177; 0.03*</td><td>3.64 &#177; 0.11*</td></tr><tr><td>400 mg/kg</td><td>99.14 &#177; 0.44*</td><td>79.17 &#177; 0.24*</td><td>14.25 &#177; 0.31*</td><td>36.43 &#177; 0.21*</td><td>33.27 &#177; 0.14*</td><td>0.91 &#177; 0.02*</td><td>2.72 &#177; 0.12*</td></tr><tr><td>HC + Atorvastatin</td><td>1 mg/kg</td><td>95.23 &#177; 0.57*</td><td>86.84 &#177; 0.84*</td><td>17.27 &#177; 0.63*</td><td>31.05 &#177; 0.48*</td><td>39.06 &#177; 0.97*</td><td>1.26 &#177; 0.04*</td><td>3.29 &#177; 0.42*</td></tr><tr><td colspan="2">NC rats</td><td>69.61 &#177; 0.92</td><td>69.46 &#177; 0.58</td><td>14.39 &#177; 0.57</td><td>30.83 &#177; 0.39</td><td>25.38 &#177; 0.66</td><td>0.83 &#177; 0.07</td><td>2.28 &#177; 0.07</td></tr></table>
037cc4376798a2fb6e0766765fc7dc00daaa15b1116c3277b70667d4e0680289.png
complex
<table><tr><td>Anatomical region</td><td colspan="4">Healthy</td><td rowspan="3">CS1 LWP LI</td><td rowspan="3">CS2 RWP LI</td><td rowspan="3">CS3 RWP LI</td></tr><tr><td></td><td colspan="2">LWP LI (<i>n</i> = 12)</td><td colspan="2">RWP LI (<i>n</i> = 6)</td></tr><tr><td></td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td></tr><tr><td>SMG</td><td>0.41</td><td>0.22</td><td>0.29</td><td>0.21</td><td>&#8722;0.18</td><td>&#8722;0.19</td><td>&#8722;0.05</td></tr><tr><td>PMd</td><td>0.34</td><td>0.17</td><td>&#8722;0.13</td><td>0.25</td><td>&#8722;0.06</td><td>0.02</td><td>0.18</td></tr><tr><td>SI</td><td>0.56</td><td>0.32</td><td>&#8722;0.34</td><td>0.30</td><td>&#8722;0.56</td><td>0.42</td><td>0.19</td></tr><tr><td>MI</td><td>0.64</td><td>0.24</td><td>&#8722;0.62</td><td>0.30</td><td>&#8722;0.77</td><td>0.66</td><td>0.59</td></tr></table>
43ee5178e5264d3f886d9fead9d3d245a273969596925176ff40a540aded17cc.png
complex
<table><tr><td></td><td>Based on parent ATS report</td><td>Based on child ATS report</td></tr><tr><td rowspan="4">MVPA of trips during the times reported by the parent</td><td><i>U</i> = 390.5, <i>p</i> = 0.02*</td><td><i>U</i> = 596.5, <i>p</i> = 0.02*</td></tr><tr><td>ATS trips (<i>n</i> = 99) 2.46 min (2.83)</td><td>ATS trips (<i>n</i> = 128) 2.40 min (2.68)</td></tr><tr><td>Non-ATS trips (<i>n</i> = 13) 0.76 min (0.95)</td><td>Non-ATS trips (<i>n</i> = 15) 0.81 min (0.87)</td></tr><tr><td>Missing trips = 170 (60.3%)</td><td>Missing trips = 139 (49.3%)</td></tr><tr><td rowspan="4">MVPA of trips during the hour before the classes (7:56&#8211;8:55)</td><td><i>U</i> = 665.5, <i>p</i> = 0.02*</td><td><i>U</i> = 955.0, <i>p</i> = 0.01*</td></tr><tr><td>ATS trips (<i>n</i> = 104) 4.99 min (4.11)</td><td>ATS trips (<i>n</i> = 146) 4.99 min (3.91)</td></tr><tr><td>Non-ATS trips (n = 19) 2.55 min (1.69)</td><td>Non-ATS trips (<i>n</i> = 20) 2.59 min (1.60)</td></tr><tr><td>Missing trips = 159 (56.4%)</td><td>Missing trips = 116 (41.1%)</td></tr></table>
38f5ee99424668e3b3bc605be7492a3648c6b143adcec1546a10e1011d781b14.png
simple
<table><tr><td>Case</td><td>Sex, Age (years)</td><td>Previous operations</td><td>Fusion length</td><td>ASF</td><td>Cause and further treatment</td></tr><tr><td>1</td><td>M, 62</td><td>Yes</td><td>2</td><td>Yes</td><td>Patient had persitant back pain postoperatively and paresthesia in the lower extremity. MRI showed an adjacent vertebral fracture leading to an elongation of the initial fusion of up to 4 segments and second explorative operation due to persistant paresthesia. No specific cause was identifed for this. Sensation returned to normal in the further course.</td></tr><tr><td>2</td><td>F, 67</td><td>No</td><td>6</td><td>Yes</td><td>Early adjacent failure was caused by an osteoporotic cut out of the upper uncemented pedicle screws. This led to an elongation of the fusion by two segements with cement-augmentation.</td></tr><tr><td>3</td><td>F, 74</td><td>No</td><td>5</td><td>Yes</td><td>After the inital dorsoventral fusion, an osteoporotic adjacent segment failure in the upper instrumented vertebra caused the need of a fusion extension of one more segment with pedicle screw cement augmention. Thereafter, the patient developed a wound dehiscence. This led to a further operation for wound debridement and closure.</td></tr><tr><td>4</td><td>M, 65</td><td>No</td><td>6</td><td>Yes</td><td>This adjacent segment failure included a pedicle fracture causing a transient paresis of the hip flexion requiring immediate screw removal and nerve exploration. There was no nerve root damage. The fusion was elongated by 2 levels. The muscle regained full function in the follow-ups.</td></tr><tr><td>5</td><td>F, 72</td><td>No</td><td>4</td><td>Yes</td><td>This patient had a screw misplacement as idenfied by the CT-scan. The screw was causing irritation of the nerve root and had a cut out through upper vertebral plate. This complex cause of adjacent segment failure and spinal nerve compression lead to an early revision and elongation by one segment.</td></tr><tr><td>6</td><td>M, 85</td><td>No</td><td>5</td><td>Yes</td><td>This patient showed during the primary operation a poor bone quality (osteoporosis) with the need to use cement augmentation of the upper instrumented vertebra. During the early mobilisation process, the patient suffered an adjacent vertebral fracture with progression needing a revision with elongation of 2 more segments with careful cement augmentation.</td></tr><tr><td>7</td><td>F, 67</td><td>No</td><td>6</td><td>Yes</td><td>Due to osteoporotic bone, the upper pedicle screws were cement augmented. However, the poor bone quality caused an osteoporotic fracture with nerve irritation needing a revision surgery with elongation of the fusion by 2 segments. Unfortunately thereafter, a wound healing defect caused a further superfical wound revision.</td></tr><tr><td>8</td><td>F, 83</td><td>No</td><td>3</td><td>Yes</td><td>Due to a collapse of the upper vertebral plate during the mobilisation process, a surgical revision with elongation of 1 segment with cement augmentation was necessary.</td></tr></table>
0865258b7b2524a578496a86378429ecdc2c8ea011d395305bf22e2b15533703.png
complex
<table><tr><td></td><td></td><td colspan="2">Leisure-time physical activity</td><td rowspan="2"><i>p</i></td></tr><tr><td></td><td>Total <i>N</i> (%)</td><td>Yes (%)</td><td>No (%)</td></tr><tr><td>Feel too tired</td><td>62 (63.3)</td><td>59.3</td><td>64.8</td><td>0.612</td></tr><tr><td>Chronic kidney disease</td><td>50 (51.0)</td><td>51.9</td><td>50.7</td><td>0.919</td></tr><tr><td>Hemodialysis treatment</td><td>47 (48.0)</td><td>44.4</td><td>49.3</td><td>0.821</td></tr><tr><td>Lack of time</td><td>39 (39.8)</td><td>33.3</td><td>42.3</td><td>0.493</td></tr><tr><td>Lack of company</td><td>37 (37.8)</td><td>29.6</td><td>40.8</td><td>0.357</td></tr><tr><td>Lack of money</td><td>36 (36.7)</td><td>44.4</td><td>33.8</td><td>0.329</td></tr><tr><td>Fear of injury</td><td>35 (35.7)</td><td>40.7</td><td>33.8</td><td>0.522</td></tr><tr><td>Disliking exercise</td><td>25 (25.5)</td><td>12.0</td><td>88.0</td><td>0.068*</td></tr><tr><td>Feel too old</td><td>18 (18.4)</td><td>14.8</td><td>19.7</td><td>0.772</td></tr><tr><td>Having an injury/disease</td><td>14 (14.3)</td><td>11.1</td><td>15.5</td><td>0.752</td></tr></table>
ecdb33cee3f620ddb2b4788dc222ddf48aaaf29515d37f307d2c25d11d038eb3.png
simple
<table><tr><td>Active ingredient</td><td>Abbreviation/Pharmaceutical preparation</td><td>Trade name (US)</td><td>Manufacturer</td><td>Approval status (US)</td><td>Notes</td></tr><tr><td>Methylphenidate hydrochloride</td><td>MPH-MR08 (modified-release preparation)</td><td>Ritalin<sup>R </sup>LA (using SODAS delivery system developed by Elan)</td><td>Novartis</td><td>available in US and Switzerland</td><td></td></tr><tr><td>Methylphenidate hydrochloride</td><td>MPH-TDS Patch for transdermal drug delivery (o.a.d); 12 h duration of action</td><td>Daytrana<sup>R </sup>DOT matrix transdermal technology</td><td>Shire (in license from Noven)</td><td>US approval (children age 6&#8211;12 years) April 2006; 2nd line to oral drugs</td><td>Skin sensitization reported in 13&#8211;22% of subjects wearing the patch; product had been deemed non-approvable by FDA before (April 2003)</td></tr><tr><td>Dexmethylphenidate, a non-racemic form of methylphenidate:</td><td>d-MPH (the active isomer of methylphenidate)</td><td>Focalin<sup>R</sup></td><td>Novartis (in license from Celgene)</td><td>Approved in US</td><td></td></tr><tr><td>Dexmethylphenidate, a non-racemic form of methylphenidate:</td><td>d-MPH-ER (extended release formulation)</td><td>Focalin<sup>R </sup>XR</td><td>Novartis (in license from Celgene)</td><td>US approval (for "children, adolescents, and adults") May 2005</td><td></td></tr><tr><td>Lisdexamphetamine dimesylate</td><td>LisDEX; (pharmaceutical preparation with a o.a.d. dosing schedule)</td><td>NRP104</td><td>Shire (in license from New River Pharmaceuticals)</td><td>US approval (for children age 6&#8211;12 years) granted in 2007</td><td>Reduced abuse potential expected because amphetamine is linked to L-lysine and does no become active until metabolized in the gastrointestinal tract</td></tr><tr><td>Mixed amphetamine salts</td><td>MAS (immediate and extended release formulations</td><td>Adderall<sup>R</sup>, Adderall<sup>R </sup>XR</td><td>Shire</td><td>Available in US</td><td>Unlikely to be approved in Europe</td></tr><tr><td>ModafinilSuccessor compound: Armodafinil</td><td>MOD; dopamine reuptake inhibitor; effects on neuropetides possibleARM</td><td>Sparlon<sup>R </sup>(licensed in US and UK as Provigil<sup>R </sup>for narcolepsy)Nuvigil<sup>R</sup></td><td>Cephalon(Sparlon<sup>R </sup>was planned to be co-promoted in the US by McNeil, a sister company of Janssen-Cilag)</td><td>After receiving a non-approvable letter for modafinil in ADHD from the FDA in August 2006, Cephalon refocused its R&amp;D on armodafinil [61]</td><td>Suspected serious adverse events (skin rash/Stevens-Johnson syndrome) in association with modafinil</td></tr></table>
ccb5ff98bcb6fa650fdf009ca73b77b6f7e570fc0858b4a3ae084053cf42f313.png
complex
<table><tr><td colspan="3">Current UK Vaccination Against Invasive Meningococcal Disease</td></tr><tr><td>Vaccine (Serogroups)</td><td>Year Introduced into schedule</td><td>Age given</td></tr><tr><td>B</td><td>2015</td><td>8 weeks, 16 weeks, 1 year</td></tr><tr><td>C</td><td>1999</td><td>1 year<sup>a</sup></td></tr><tr><td>ACWY</td><td>2015</td><td>14 years, University students 19&#8211;25 years</td></tr></table>
3f967922169b6c2effa838b3999c82ab63bde3c9dd7b2e65cac2ad3b8eafeb31.png
complex
<table><tr><td>Cell type</td><td>AR expression (method)</td><td>Reference</td></tr><tr><td colspan="3">Stem cells and progenitor cells</td></tr><tr><td>Hematopoietic stem cell</td><td>Yes (RT-PCR, IF)</td><td>(33, 34)</td></tr><tr><td>Common myeloid progenitor</td><td>Yes (RT-PCR)</td><td>(33)</td></tr><tr><td>Common lymphoid progenitor</td><td>Yes (RT-PCR)</td><td>(33)</td></tr><tr><td>Granulocyte-macrophage progenitor</td><td>ND</td><td></td></tr><tr><td>Common dendritic cell (DC) progenitor</td><td>ND</td><td></td></tr><tr><td>Megakaryocyte-erythroid progenitor</td><td>ND</td><td></td></tr><tr><td>Erythroblast</td><td>Yes (binding assay)</td><td>(32)</td></tr><tr><td>Early T cell progenitor</td><td>ND</td><td></td></tr><tr><td colspan="3">Myeloid-derived cells</td></tr><tr><td>Megakaryocyte</td><td>Yes (IHC, RT-PCR, IF)</td><td>(37, 38)</td></tr><tr><td>Platelet</td><td>Yes (IF)</td><td>(38)</td></tr><tr><td>Erythroid cell (nucleated and enucleated)</td><td><i>Not expressed</i> (IHC)</td><td>(37)</td></tr><tr><td>Monocyte</td><td>Yes (RT-PCR)</td><td>(37)</td></tr><tr><td>Macrophage</td><td>Yes (C+NC) (flow, IF, IHC, RT-PCR)</td><td>(16, 36, 37, 39)</td></tr><tr><td>Myeloid-derived DC</td><td><i>Not expressed</i> (WB)</td><td>(40)</td></tr><tr><td>Myelocyte</td><td>Yes (IHC)</td><td>(37)</td></tr><tr><td>Metamyelocyte</td><td>Yes (IHC)</td><td>(37)</td></tr><tr><td>Neutrophil (band cell)</td><td>Yes (IHC)</td><td>(37)</td></tr><tr><td>Neutrophil (segmented)</td><td>Yes (IHC)</td><td>(37)</td></tr><tr><td>Mature eosinophil</td><td><i>Not expressed</i> (IHC)</td><td>(37)</td></tr><tr><td>Basophil</td><td>ND</td><td></td></tr><tr><td>Mature mast cell</td><td>Yes (ImmGold)</td><td>(35, 41)</td></tr><tr><td colspan="3">Lymphoid-derived cells</td></tr><tr><td>DN T cell</td><td>Yes (binding assay)</td><td>(42)</td></tr><tr><td>DP T cell</td><td>Yes (binding assay)</td><td>(42)</td></tr><tr><td>CD4+ T cell</td><td>Yes (C+NC) (flow, IF, binding assay)</td><td>(17, 28, 42)</td></tr><tr><td>CD8+ T cell</td><td>Yes (C+NC) (binding assay)</td><td>(17, 42)</td></tr><tr><td>Plasmacytoid DC</td><td>ND</td><td></td></tr><tr><td>Pro-B cell</td><td>Yes (WB)</td><td>(43)</td></tr><tr><td>Pre-B cell</td><td>Yes (WB)</td><td>(43)</td></tr><tr><td>Immature B cell</td><td>ND</td><td></td></tr><tr><td>Mature B cell</td><td><i>Not expressed</i> (IHC, WB)</td><td>(37, 43)</td></tr><tr><td colspan="3">Other</td></tr><tr><td>Thymic epithelial cells</td><td>Yes (IF)</td><td>(44)</td></tr><tr><td>Bone marrow stromal cells</td><td>Yes (IHC, WB)</td><td>(37, 43)</td></tr></table>
aeccd4ea5bffc0c0db74080028bb7a37738670a5692458455dbf6131545e2045.png
simple
<table><tr><td>Name</td><td>Dock score</td><td>-PLP1</td><td>-PLP2</td><td>-PMF</td></tr><tr><td>Tryptophan</td><td>171.283</td><td>27.71</td><td>27.51</td><td>23.06</td></tr><tr><td>Diiodotyrosine</td><td>171.000</td><td>20.22</td><td>20.27</td><td>23.51</td></tr><tr><td>Saussureamine C</td><td>170.814</td><td>27.27</td><td>24.71</td><td>42.2</td></tr><tr><td>Eupachinilide J</td><td>170.774</td><td>32.62</td><td>27.11</td><td>25.13</td></tr><tr><td>Tryptophan</td><td>169.656</td><td>36.05</td><td>32.98</td><td>21.91</td></tr><tr><td>Diiodotyrosine</td><td>168.307</td><td>33.24</td><td>27.04</td><td>16.58</td></tr><tr><td>5-Hydroxy-L-tryptophan</td><td>166.948</td><td>30.73</td><td>32.06</td><td>27.43</td></tr><tr><td>L-Tyrosine</td><td>165.590</td><td>33.52</td><td>33.82</td><td>20.64</td></tr><tr><td>S-Allylmercaptocysteine</td><td>165.014</td><td>17.05</td><td>18.65</td><td>16.6</td></tr><tr><td>Emetine</td><td>162.586</td><td>29.04</td><td>27.44</td><td>8.71</td></tr></table>
3a3848f24c6f94764b27927ebf3d3c57b472d704195270ef4d449b3694cad59e.png
simple
<table><tr><td>Query</td><td>Parameters inquired</td><td>Fluorescent wavelengths</td></tr><tr><td>1</td><td>FS, SS</td><td>2, 3 or 4</td></tr><tr><td>2</td><td>FS, SS, CD5</td><td>2, 3 or 4</td></tr><tr><td>3</td><td>FS, SS, CD5, CD20</td><td>2, 3 or 4</td></tr><tr><td>4</td><td>FS, SS, CD5, CD20, CD19, CD34</td><td>4</td></tr></table>
2d5cf23de93d6503fbc51321c208517c776fd77c89566fa14ae6aa4815242728.png
complex
<table><tr><td> </td><td colspan="3">LOS (days)</td><td colspan="3">Av. daily weight gain (gr)</td></tr><tr><td> </td><td>&#946;</td><td>95% C.I.</td><td>Pr(&gt;|t|)</td><td>&#946;</td><td>95% C.I.</td><td>Pr(&gt;|t|)</td></tr><tr><td>Male</td><td>-1.899</td><td>-3.930 , 0.127</td><td>0.07</td><td>0.708</td><td>-3.067 , 4.483</td><td>0.71</td></tr><tr><td>Gestational Age</td><td>-3.373</td><td>-3.916 , 2.830</td><td>&lt;0.001</td><td>-0.338</td><td>-1.344 , 0.668</td><td>0.51</td></tr><tr><td>Birth Weight (gr)</td><td>-0.014</td><td>-0.016 , -0.009</td><td>&lt;0.001</td><td>-0.018</td><td>-0.022 , -0.014</td><td>&lt;0.001</td></tr><tr><td>Milk Volume at Study Enrollment (mL)</td><td>0.002</td><td>-0.004 , 0.009</td><td>0.44</td><td>0.059</td><td>0.045 , 0.072</td><td>&lt;0.001</td></tr><tr><td>OMT</td><td>-5.906</td><td>-7.944 , -3.869</td><td>&lt;0.001</td><td>3.707</td><td>-0.065 , 7.479</td><td>0.06</td></tr></table>
9afb1ecd16b603f15af9272cfa580e81c52a041a3053576c122b6c220b174bde.png
complex
<table><tr><td>Housing arrangements</td><td colspan="9">No. of chickens (score <sup>a</sup>, liver/body weight ratio <sup>b</sup>)</td></tr><tr><td>Cage-free (Inoculated)</td><td>1(1, 23.16)</td><td>2(4, 40.92)</td><td>3(2, 23.44)</td><td>4(2, 32.19)</td><td>5(4, 37.98)</td><td>6(3, 33.25)</td><td>7(2, 24.01)</td><td>8(4, 36.78)</td><td>9(2, 23.48)</td></tr><tr><td>Caged (Inoculated)</td><td>10(0, 24.84)</td><td>11(4, 36.47)</td><td>12(1, 23.39)</td><td>13(0, 22.08)</td><td>14(4, 35.88)</td><td>15(0, 24.12)</td><td>16(2, 23.98)</td><td>17 (1, 22.68)</td><td>18(4, 38.11)</td></tr><tr><td>Cage-free (Negative)</td><td>19(0, 23.98)</td><td>20(0, 24.12)</td><td>21(1, 22.65)</td><td>22(0, 23.65)</td><td>23(1, 24.09)</td><td>24(0, 23.51)</td><td>25(0, 22.98)</td><td>26(1, 23.65)</td><td>27(0, 24.01)</td></tr><tr><td>Caged (Negative)</td><td>28(1, 22.99)</td><td>29(0, 25.01)</td><td>30(0, 23.98)</td><td>31(0, 24.19)</td><td>32(1, 24.67)</td><td>33(2, 24.88)</td><td>34(0, 22.87)</td><td>35(1, 23.13)</td><td>36(0, 24..35)</td></tr></table>
6ab952e6205dbdf1406bcf7d9f25a383f0ce583b6ee34c0f37ef309c5103a388.png
simple
<table><tr><td>AKI progression</td><td>Number of patients</td><td>ICU mortality</td><td>p</td></tr><tr><td>AKI I (n = 4259)</td><td></td><td></td><td></td></tr><tr><td>with rising creatinine values</td><td>1995 (46.8%)</td><td>522 (26.2%)</td><td>&lt; 0.0001</td></tr><tr><td>with falling creatinine values</td><td>2264 (53.2%)</td><td>334 (14.8%)</td><td></td></tr><tr><td>AKI II (n = 857)</td><td></td><td></td><td></td></tr><tr><td>with rising creatinine values</td><td>439 (51.2%)</td><td>157 (35.8%)</td><td>&lt; 0.0001</td></tr><tr><td>with falling creatinine values</td><td>418 (48.8%)</td><td>65 (15.6%)</td><td></td></tr><tr><td>AKI III (n = 2782)</td><td></td><td></td><td></td></tr><tr><td>with rising creatinine values</td><td>639 (23%)</td><td>318 (49.8%)</td><td>&lt; 0.0001</td></tr><tr><td>with falling creatinine values</td><td>296 (10.6%)</td><td>62 (20.9%)</td><td></td></tr><tr><td>AKI III based on RRT criteria</td><td>1847 (66.4%)</td><td>999 (54.1%)</td><td></td></tr><tr><td>AKI I/AKI II progressing to AKI III</td><td>1664 (59.8%)</td><td>796 (47.8%)</td><td>p = 0.029</td></tr><tr><td>AKI III without prior AKI I/AKI II</td><td>1118 (40.2%)</td><td>583 (46.2%)</td><td></td></tr></table>
5b10e2ceaff89ac66a79acc241b7c801e6261fead6355294864219f96024f0cc.png
simple
<table><tr><td></td><td><i>d</i> [g cm<sup>&#8722;3</sup>]</td><td>Porosity [&#966;]</td><td>&#961;<sub>323 K</sub> [m&#937; cm]</td><td><i>S</i><sub>323 K</sub> [&#956;V K<sup>&#8722;1</sup>]</td><td>&#954;<sub>L,773 K</sub> [W m<sup>&#8722;1</sup> K<sup>&#8722;1</sup>]</td></tr><tr><td>OM</td><td>7.1</td><td>14.1%</td><td>1.12</td><td>&#8722;100</td><td>0.6</td></tr><tr><td>RM</td><td>7.9</td><td>4.5%</td><td>0.63</td><td>&#8722;88</td><td>0.7</td></tr></table>
11d5839599ce4fb9f610e53c60159449aeb15fba76e66079eebf1bed33c0f583.png
simple
<table><tr><td></td><td>PMO (<i>n</i> = 149)</td><td>CON (<i>n</i> = 172)</td><td><i>p-</i>Value</td></tr><tr><td>Age, years</td><td>61.4 (6.5)<sup>a</sup></td><td>57.5 (7.3)<sup>a</sup></td><td>&gt;0.05</td></tr><tr><td>Height, cm</td><td>159.2 (8.3)<sup>a</sup></td><td>165.1 (5.8)<sup>a</sup></td><td>&gt;0.05</td></tr><tr><td>Weight, kg</td><td>64.5 (7.2)<sup>a</sup></td><td>73.3 (5.1)<sup>a</sup></td><td>&gt;0.05</td></tr><tr><td>Body mass index, kg/m<sup>2</sup></td><td>26.7 (3.2)<sup>a</sup></td><td>27.3 (4.7)<sup>a</sup></td><td>&gt;0.05</td></tr><tr><td>Years after menopause</td><td>11.3 (4.5)<sup>a</sup></td><td>8.2 (2.7)<sup>a</sup></td><td>&gt;0.05</td></tr><tr><td>Spine bone mineral density (BMD), g/cm<sup>2</sup></td><td>0.944 (0.831; 1.090)<sup>b</sup></td><td>1.152 (1.024; 1.240)<sup>b</sup></td><td>&lt;0.01</td></tr><tr><td>Femoral neck BMD, g/cm<sup>2</sup></td><td>0.803 (0.707; 0.914)<sup>b</sup></td><td>0.983 (0.913; 1.13)<sup>b</sup></td><td>&lt;0.01</td></tr></table>
e17c2bc47ea52ad47437262db834e804384089f87c830a60ca97b6be86cb494e.png
simple
<table><tr><td></td><td>Comm</td><td>Accom</td><td>Isol</td><td>NWI-NPRS</td><td>TeamVal</td><td>TeamEff</td><td>SharedLdr</td></tr><tr><td>Comm</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Accom</td><td>0.81</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Isol</td><td>0.84</td><td>0.75</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>NWI-NPRS</td><td>0.38</td><td>0.36</td><td>0.25</td><td></td><td></td><td></td><td></td></tr><tr><td>TeamVal</td><td>0.27</td><td>0.24</td><td>0.19</td><td>0.17</td><td></td><td></td><td></td></tr><tr><td>TeamEff</td><td>0.51</td><td>0.38</td><td>0.39</td><td>0.12^</td><td>0.75</td><td></td><td></td></tr><tr><td>SharedLdr</td><td>-0.05^</td><td>-0.07^</td><td>0.01^</td><td>-0.25</td><td>0.02^</td><td>0.39</td><td></td></tr></table>
835608484037771220d9bf8af1b64e38489e21ab08df47cc8faebd91f3c13e37.png
complex
<table><tr><td>Yes (+)</td><td>LBP+</td><td>LBP+</td><td>LBP&#8722;</td><td>LBP&#8722;</td><td rowspan="2">Missing answers on pain </td><td>LBP</td><td>SP </td><td>LBP </td><td>SP </td></tr><tr><td>No (&#8722;)</td><td>SP+</td><td>SP&#8722;</td><td>SP+</td><td>SP&#8722;</td><td>PIW+</td><td>PIW+</td><td>PINT+</td><td>PINT+</td></tr><tr><td>Number of workers <i>n</i> (%)</td><td>238 (45)</td><td>101 (19) </td><td>47 (9)</td><td>79 (15)</td><td>60 (12)</td><td>156 (30)</td><td>96 (18)</td><td>180 (34)</td><td>147 (28)</td></tr></table>
2992304a2d539cfb6f9449e9bc4aec6f4691d989e710a7106556df16378ef113.png
simple
<table><tr><td>Lactate</td><td>&lt;2 mmol/L (n = 138)</td><td>&#8805;6 mmol/L (n = 29)</td><td><i>P </i>value</td></tr><tr><td>Major resection (%)</td><td>26 (18.8)</td><td>26 (89.7)</td><td>&lt;0.001*</td></tr><tr><td>Pre-operative chemotherapy (%)</td><td>38 (27.5)</td><td>5 (17.2)</td><td>0.351</td></tr><tr><td>Pre-operative diabetes (%)</td><td>6 (4.3)</td><td>8 (27.6)</td><td>&lt;0.001*</td></tr><tr><td>Post-operative renal dysfunction (%)</td><td>3 (2.2)</td><td>8 (27.6)</td><td>&lt;0.001*</td></tr><tr><td>90-day mortality (%)</td><td>1 (0.7)</td><td>8 (27.6)</td><td>&lt;0.001*</td></tr></table>
f115f7a132b5eb44903a7dc3cb1cfcac1a777b09271c7d57040b641e21bf3093.png
complex
<table><tr><td></td><td colspan="2">Profile Width</td><td colspan="2">Neff</td></tr><tr><td>Superfamily</td><td>Full</td><td>Trimmed</td><td>Full</td><td>Trimmed</td></tr><tr><td>(Trans)glycosidases</td><td>410.4</td><td>23.93</td><td>13.11</td><td>3.21</td></tr><tr><td>4-helical cytokines</td><td>85.71</td><td>43.57</td><td>4.3</td><td>2.86</td></tr><tr><td>alpha/beta-Hydrolases</td><td>509.43</td><td>22.32</td><td>16.32</td><td>3.65</td></tr><tr><td>Cytochrome c</td><td>413.62</td><td>18.86</td><td>12.64</td><td>3.7</td></tr><tr><td>E Set domains</td><td>182.73</td><td>33.27</td><td>7.99</td><td>3.16</td></tr><tr><td>FAD/NAD(P)-binding</td><td>616.52</td><td>20.57</td><td>15.33</td><td>3.68</td></tr><tr><td>Fibronectin type</td><td>1661.67</td><td>24.83</td><td>11.44</td><td>3.55</td></tr><tr><td>Homeodomain-like</td><td>255.21</td><td>39.33</td><td>7</td><td>3.34</td></tr><tr><td>Immunoglobulin</td><td>1614.7</td><td>69.04</td><td>11.33</td><td>3.65</td></tr><tr><td>NAD(P)-binding</td><td>463.14</td><td>29.55</td><td>12.32</td><td>3.27</td></tr><tr><td>Nucleic acid-binding</td><td>224.09</td><td>23.57</td><td>8.21</td><td>3.11</td></tr><tr><td>P-loop</td><td>483.03</td><td>26.44</td><td>11.64</td><td>2.92</td></tr><tr><td>S-adenosyl</td><td>472.42</td><td>22.08</td><td>14.88</td><td>3.22</td></tr><tr><td>Thioredoxin-like</td><td>471.72</td><td>25.28</td><td>12.61</td><td>3.58</td></tr><tr><td>Viral coat</td><td>265.28</td><td>35.93</td><td>6.11</td><td>2.96</td></tr><tr><td>Winged helix</td><td>206.94</td><td>24.81</td><td>8.11</td><td>3.13</td></tr></table>
4455ce6d91bfbe35e74be1e38cfcd772da801789a0718027fe27fd079f690559.png
complex
<table><tr><td rowspan="2">Zones</td><td colspan="5">Most Used Pesticides (Top 5) in %</td><td rowspan="2">Cumulative %</td></tr><tr><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr><tr><td>Obala</td><td>Ridomil (8%)</td><td>Onex (6.3%)</td><td>Actara (5.7%)</td><td>Callomil (5%)</td><td>Lamida Gold, Parastar and Plantomil (4.7% each)</td><td>39.4</td></tr><tr><td>Foumbot</td><td>Gramoxone (12.6%)</td><td>Timide (7.4%)</td><td>K-optimal (7.1%)</td><td>Roundup (6.7%)</td><td>Cigogne and Pencozeb (4.1% each)</td><td>42</td></tr><tr><td>Santa</td><td>Gramoxone (12.7%)</td><td>Banko (12%)</td><td>Pencozeb (8%)</td><td>Roundup and Mancozan (6.7% each)</td><td>Parastar (4.7%)</td><td>50.8</td></tr><tr><td>Njombe&#8211;Penja</td><td>Gramoxone (12.8%)</td><td>Pyriforce (9.4%)</td><td>Glyphader (7.2%)</td><td>Ridomil and Supraxone (4.7% each)</td><td>Roundup and Capsidor (4.3% each)</td><td>47.4</td></tr><tr><td>Ngong&#8211;Garoua</td><td>Roundup (23.7%)</td><td>Atrazine (20.1%)</td><td>Gramoxone (15.9%)</td><td>Diuron (14.8%)</td><td>Biosec Roundup 720 (3.2%)</td><td>80.9</td></tr></table>
f7afcb0bfa194bdf47c4d21a20bc951c943a7fff34e9893ed60c999c752b71ba.png
simple
<table><tr><td>F0</td><td>F1</td><td>F2</td><td>F3</td></tr><tr><td>Hip center speed (m/s)</td><td>Shoulder center speed (m/s)</td><td>Right hip speed (&#952;/s) Frontal plane</td><td>Right hip angle (&#952;) Frontal plane</td></tr></table>
8682b566a062d7e57184960f0b2fba7859d61c1a0c1b34ca941f41d3b746c4a1.png
complex
<table><tr><td rowspan="2">Item</td><td colspan="4">Item clearly stated</td><td colspan="4">Agreement with item</td></tr><tr><td>Total n</td><td>Strongly agree</td><td>Somewhat agree</td><td>Combined agreement</td><td>Total n</td><td>Strongly agree</td><td>Somewhat agree</td><td>Combined agreement</td></tr><tr><td>Figure</td><td>85</td><td>45 (53%)</td><td>37 (44%)</td><td>82 (96%)</td><td>85</td><td>41 (48%)</td><td>33 (39%)</td><td>74 (87%)</td></tr><tr><td colspan="9">Stationary Behavior</td></tr><tr><td> Definition</td><td>86</td><td>62 (72%)</td><td>17 (20%)</td><td>79 (92%)</td><td>84</td><td>56 (67%)</td><td>20 (24%)</td><td>65 (76%)</td></tr><tr><td> Caveats</td><td>85</td><td>49 (58%)</td><td>25 (29%)</td><td>74 (87%)</td><td>86</td><td>51 (59%)</td><td>23 (27%)</td><td>74 (86%)</td></tr><tr><td> Examples</td><td>83</td><td>52 (63%)</td><td>20 (24%)</td><td>72 (87%)</td><td>84</td><td>51 (61%)</td><td>29 (35%)</td><td>80 (95%)</td></tr><tr><td colspan="9">Sedentary Behavior</td></tr><tr><td> Definition</td><td>86</td><td>74 (86%)</td><td>12 (14%)</td><td>86 (100%)</td><td>86</td><td>74 (86%)</td><td>10 (12%)</td><td>84 (98%)</td></tr><tr><td> Caveats</td><td>86</td><td>63 (73%)</td><td>21 (24%)</td><td>84 (98%)</td><td>86</td><td>68 (79%)</td><td>14 (16%)</td><td>82 (95%)</td></tr><tr><td> Examples</td><td>86</td><td>72 (84%)</td><td>12 (14%)</td><td>84 (98%)</td><td>86</td><td>69 (80%)</td><td>15 (17%)</td><td>84 (98%)</td></tr><tr><td colspan="9">Standing Still</td></tr><tr><td> Definition</td><td>85</td><td>64 (75%)</td><td>17 (20%)</td><td>81 (95%)</td><td>86</td><td>65 (76%)</td><td>19 (22%)</td><td>84 (98%)</td></tr><tr><td> Caveats</td><td>86</td><td>69 (80%)</td><td>12 (14%)</td><td>81 (94%)</td><td>86</td><td>69 (80%)</td><td>12 (14%)</td><td>81 (94%)</td></tr><tr><td> Examples</td><td>85</td><td>65 (76%)</td><td>18 (21%)</td><td>83 (98%)</td><td>86</td><td>66 (77%)</td><td>19 (22%)</td><td>85 (99%)</td></tr><tr><td colspan="9">Screen Time</td></tr><tr><td> Definition</td><td>85</td><td>70 (82%)</td><td>12 (14%)</td><td>82 (96%)</td><td>84</td><td>71 (85%)</td><td>10 (12%)</td><td>81 (96%)</td></tr><tr><td> Caveats</td><td>84</td><td>60 (71%)</td><td>17 (20%)</td><td>77 (92%)</td><td>82</td><td>60 (73%)</td><td>15 (18%)</td><td>75 (91%)</td></tr><tr><td> Examples</td><td>84</td><td>65 (77%)</td><td>14 (20%)</td><td>79 (94%)</td><td>83</td><td>62 (75%)</td><td>15 (18%)</td><td>77 (93%)</td></tr><tr><td colspan="9">Non-Screen-Based Sedentary Time</td></tr><tr><td> Definition</td><td>85</td><td>73 (86%)</td><td>9 (11%)</td><td>82 (96%)</td><td>85</td><td>71 (84%)</td><td>8 (9%)</td><td>79 (93%)</td></tr><tr><td> Caveats</td><td>85</td><td>66 (78%)</td><td>11 (13%)</td><td>77 (91%)</td><td>86</td><td>64 (74%)</td><td>15 (17%)</td><td>79 (92%)</td></tr><tr><td> Examples</td><td>85</td><td>66 (78%)</td><td>13 (15%)</td><td>79 (93%)</td><td>86</td><td>63 (73%)</td><td>14 (16%)</td><td>77 (90%)</td></tr><tr><td colspan="9">Sitting</td></tr><tr><td> Definition</td><td>85</td><td>72 (85%)</td><td>9 (11%)</td><td>81 (95%)</td><td>86</td><td>70 (81%)</td><td>11 (13%)</td><td>81 (94%)</td></tr><tr><td> Caveats</td><td>85</td><td>14 (16%)</td><td>11 (13%)</td><td>75 (88%)</td><td>84</td><td>59 (70%)</td><td>15 (18%)</td><td>74 (88%)</td></tr><tr><td> Examples</td><td>85</td><td>61 (72%)</td><td>14 (16%)</td><td>75 (88%)</td><td>85</td><td>55 (65%)</td><td>21 (25%)</td><td>76 (89%)</td></tr><tr><td colspan="9">Reclining</td></tr><tr><td> Definition</td><td>84</td><td>68 (81%)</td><td>10 (12%)</td><td>78 (93%)</td><td>83</td><td>68 (82%)</td><td>8 (10%)</td><td>76 (92%)</td></tr><tr><td> Caveats</td><td>84</td><td>70 (83%)</td><td>8 (10%)</td><td>78 (93%)</td><td>83</td><td>69 (83%)</td><td>7 (8%)</td><td>76 (92%)</td></tr><tr><td> Examples</td><td>84</td><td>70 (83%)</td><td>9 (11%)</td><td>79 (94%)</td><td>83</td><td>67 (81%)</td><td>10 (12%)</td><td>77 (93%)</td></tr><tr><td colspan="9">Lying</td></tr><tr><td> Definition</td><td>85</td><td>75 (88%)</td><td>6 (7%)</td><td>81 (95%)</td><td>85</td><td>75 (88%)</td><td>6 (7%)</td><td>81 (95%)</td></tr><tr><td> Caveats</td><td>84</td><td>76 (90%)</td><td>3 (4%)</td><td>79 (94%)</td><td>85</td><td>76 (89%)</td><td>4 (5%)</td><td>80 (94%)</td></tr><tr><td> Examples</td><td>85</td><td>75 (88%)</td><td>6 (7%)</td><td>81 (95%)</td><td>85</td><td>75 (88%)</td><td>6 (7%)</td><td>81 (95%)</td></tr><tr><td colspan="9">Sedentary Behavior Pattern</td></tr><tr><td> Definition</td><td>86</td><td>78 (91%)</td><td>6 (7%)</td><td>84 (98%)</td><td>86</td><td>76 (88%)</td><td>9 (10%)</td><td>85 (99%)</td></tr><tr><td> Caveats</td><td>86</td><td>72 (84%)</td><td>9 (10%)</td><td>81 (94%)</td><td>85</td><td>71 (84%)</td><td>9 (11%)</td><td>80 (94%)</td></tr><tr><td> Examples</td><td>86</td><td>60 (70%)</td><td>19 (22%)</td><td>79 (92%)</td><td>85</td><td>58 (68%)</td><td>19 (22%)</td><td>77 (91%)</td></tr><tr><td colspan="9">Average</td></tr><tr><td> Definition</td><td rowspan="3"></td><td>71 (83%)</td><td>11 (13%)</td><td>82 (96%)</td><td rowspan="3"></td><td>70 (82%)</td><td>11 (13%)</td><td>81 (95%)</td></tr><tr><td> Caveats</td><td>65 (77%)</td><td>13 (15%)</td><td>78 (92%)</td><td>65 (77%)</td><td>13 (15%)</td><td>78 (92%)</td></tr><tr><td> Examples</td><td>65 (77%)</td><td>14 (16%)</td><td>79 (93%)</td><td>63 (74%)</td><td>16 (19%)</td><td>79 (94%)</td></tr></table>
18768233d1a13cd8d0d58f550d7caf4e012912e843b6ee0bb2ab782559263365.png
simple
<table><tr><td>Variables</td><td>GLM resultsinteraction effect<sup>a</sup></td><td>Statistical changes over time(p value)</td><td>Adjusted mean differences between groups over time<sup>b</sup>(Clinical changes)</td></tr><tr><td></td><td>Group * Time</td><td>T1 &#8594; T2</td><td>T1 &#8594; T2</td></tr><tr><td>EORTCQLQ-C30:</td><td></td><td></td><td></td></tr><tr><td>Global quality of life</td><td>12.5</td><td>.000</td><td>+8.2</td></tr><tr><td>Functional scales:</td><td></td><td></td><td></td></tr><tr><td>Physical</td><td>118.5</td><td>.000</td><td>- 16.2</td></tr><tr><td>Role</td><td>30.1</td><td>.000</td><td>- 11.0</td></tr><tr><td>Emotional</td><td>9.8</td><td>.002</td><td>+8.5</td></tr><tr><td>Cognitive</td><td>7.9</td><td>.005</td><td>- 6.0</td></tr><tr><td>Social</td><td>8.4</td><td>.004</td><td>- 7.0</td></tr><tr><td>Symptom scales:</td><td></td><td></td><td></td></tr><tr><td>Fatigue</td><td>22.7</td><td>.000</td><td>+12.0</td></tr><tr><td>Nausea/vomiting</td><td>4.7</td><td>.030</td><td>+3.4</td></tr><tr><td>Pain</td><td>13.3</td><td>.000</td><td>+8.6</td></tr><tr><td>Dyspnea</td><td>0.6</td><td>.419</td><td>+1.7</td></tr><tr><td>Insomnia</td><td>1.7</td><td>.184</td><td>+4.0</td></tr><tr><td>Appetite loss</td><td>0.1</td><td>.707</td><td>- 1.0</td></tr><tr><td>Constipation</td><td>8.6</td><td>.004</td><td>+7.5</td></tr><tr><td>Diarrhea</td><td>0.4</td><td>.545</td><td>- 1.1</td></tr><tr><td>Financial difficulties</td><td>51.7</td><td>.000</td><td>+21.7</td></tr><tr><td>Sense of Coherence</td><td>17.3</td><td>.000</td><td>- 6.5</td></tr><tr><td>Spiritual Perspective Scale</td><td>31.0</td><td>.000</td><td>- 6.6</td></tr><tr><td>Religious Coping (+)</td><td>9.8</td><td>.002</td><td>- 6.5</td></tr><tr><td>Religious Coping (&#8722;)</td><td>3.5</td><td>.060</td><td>+4.3</td></tr></table>
836b805b12d3dd56adf7619205ead6beb1cf789c1fe72d604642c7344bc83886.png
simple
<table><tr><td>Days in EB formation</td><td>Post EB differentiation</td><td>Differentiation conditions</td><td>Chondrogenic markers studied</td><td>Cells line(s)</td><td>Reference</td></tr><tr><td>5</td><td>Encapsulation of EBs in PEG hydrogel for 17 days</td><td>The EBs in hydrogel were differentiated in presence of chondrogenic medium (CM) treated with BMP-2 and TGF-<i>&#946;</i>1</td><td>Type I, II, X collagen, and osteocalcin. Proteoglycans content measurement</td><td>Mouse-D3 and human-BG03</td><td>[12&#8211;15]</td></tr><tr><td>N/R</td><td>EB cells were seeded on ceramic particles</td><td>Cells on the ceramic scaffold was differentiated <i>in vitro</i> for 21 days in CM supplemented with TGF-<i>&#946;</i>3 and 21 days of <i>in vivo </i>maturation</td><td>Morphology was studied and proteoglycans content was analyzed</td><td>Mouse-IB10, human MSC, and Goat MSCs</td><td>[4]</td></tr><tr><td>7 RA from day 2</td><td>EBs were plated</td><td>RA-treated EB outgrowth culture was treated with TGF-<i>&#946;</i>3</td><td>D15: proteoglycans, Col2a1, Sox9, Col10a1 and MMP13</td><td>Mouse-CGR8, E14Tg2a, EFC1</td><td>[16]</td></tr><tr><td>28</td><td>After 4 weeks the EBs were dissociated and self-assembled for additional 4 weeks</td><td>EBs were differentiated in chondrogenic medium supplemented with combinations of TGF-<i>&#946;</i>1, TGF-<i>&#946;</i>3, BMP-2, and IGF-1 (100 ng/mL)</td><td>Sox9, Col1a1, Col2a1</td><td>Human-BG01V</td><td>[17]</td></tr></table>
a58452d215753a0bf5b65996dfe89a299944bb3c1070cf33552854e0b658b7f2.png
simple
<table><tr><td></td><td>Anteparturm hemorrhage</td><td>Transverse lie</td><td>Placenta previa</td><td>Breech presentation</td><td>Ectopic pregnancy</td><td>Twins</td><td>Poly /oligo hydromnious</td></tr><tr><td>Very confident</td><td>23.3</td><td>13.3</td><td>10</td><td>13.3</td><td>3.3</td><td>13.3</td><td>0</td></tr><tr><td>Confident</td><td>50</td><td>60</td><td>23.3</td><td>56.7</td><td>16.7</td><td>60</td><td>33.3</td></tr><tr><td>Not confident</td><td>10</td><td>13.3</td><td>46.7</td><td>23.3</td><td>40</td><td>27.3</td><td>43.3</td></tr><tr><td>Cannot measure/diagnose</td><td>16.7</td><td>13.3</td><td>20</td><td>6.7</td><td>40</td><td>0</td><td>23.3</td></tr></table>
1d888557e42660c3da9e6637065bdf5595243b1c4aaefbd5b380c9e0b351edfd.png
complex
<table><tr><td>EEG indices</td><td>Site</td><td>Before inhalation (<i>&#956;</i>V<sup>2</sup>)</td><td>During inhalation (<i>&#956;</i>V<sup>2</sup>)</td><td><i>t</i>-test</td><td><i>P</i>value<sup><i>&#8727;</i></sup></td></tr><tr><td colspan="6"><i>Both nostrils</i></td></tr><tr><td rowspan="2">RA</td><td>T3: left temporal</td><td>0.4271 &#177; 0.066</td><td>0.5103 &#177; 0.070</td><td>&#8722;2.593</td><td>0.029</td></tr><tr><td>T4: right temporal</td><td>0.4273 &#177; 0.073</td><td>0.5066 &#177; 0.080</td><td>&#8722;2.459</td><td>0.036</td></tr><tr><td>RG</td><td>P3: left parietal</td><td>0.0998 &#177; 0.033</td><td>0.0805 &#177; 0.032</td><td>&#8722;2.400</td><td>0.040</td></tr><tr><td colspan="6"><i>Left nostril</i></td></tr><tr><td>ALB</td><td>P3: left parietal</td><td>4.8147 &#177; 0.648</td><td>4.0104 &#177; 0.542</td><td>3.295</td><td>0.009</td></tr><tr><td rowspan="3">RLB</td><td>Fp1: left prefrontal</td><td>0.0326 &#177; 0.007</td><td>0.0437 &#177; 0.009</td><td>&#8722;3.819</td><td>0.004</td></tr><tr><td>Fp2: right prefrontal</td><td>0.0334 &#177; 0.008</td><td>0.0438 &#177; 0.010</td><td>&#8722;2.824</td><td>0.020</td></tr><tr><td>F3: left frontal</td><td>0.0370 &#177; 0.010</td><td>0.0433 &#177; 0.011</td><td>&#8722;2.394</td><td>0.40</td></tr><tr><td colspan="6"><i>Right nostril</i></td></tr><tr><td rowspan="2">AT</td><td>F3: left frontal</td><td>22.2562 &#177; 5.108</td><td>18.1241 &#177; 3.968</td><td>2.330</td><td>0.045</td></tr><tr><td>P4: right parietal</td><td>17.9657 &#177; 7.698</td><td>14.1190 &#177; 3.306</td><td>2.532</td><td>0.032</td></tr></table>
99c30fa0f5109037460fda13b2340932ace561524401db308cd7fa4f5e474cea.png
simple
<table><tr><td>Bacterial strain</td><td>Source</td><td>Reference</td></tr><tr><td><i>L. sakei </i>23K</td><td>Sausage</td><td>[66,67]</td></tr><tr><td><i>L. sakei </i>MF1053</td><td>Fermented fish (Norwegian "Rakfisk")</td><td>[30]</td></tr><tr><td><i>L. sakei </i>LS 25</td><td>Commercial starter culture for salami sausage</td><td>[68]</td></tr><tr><td><i>L. sakei </i>Lb790x</td><td>Meat</td><td>[69]</td></tr><tr><td><i>L. sakei </i>LTH673</td><td>Fermented sausage</td><td>[70,71]</td></tr><tr><td><i>L. sakei </i>MF1328</td><td>Fermented sausage</td><td>[30]</td></tr><tr><td><i>L. sakei </i>MF1058 (TH1)</td><td>Vakuum-packed cooked meat, protective culture</td><td>[9,10]</td></tr><tr><td><i>L. sakei </i>CCUG 31331<sup>a </sup>(DSM 15831<sup>b</sup>, R 14 b/a)</td><td>Fermented sausage, type strain for <i>L. sakei </i>subsp. <i>carnosus</i></td><td>[27,72]</td></tr><tr><td><i>L. sakei </i>DSM 20017<sup>b </sup>(ATCC 15521<sup>c</sup>)</td><td>Sake, alcoholic beverage made by fermenting rice, type strain for <i>L. sakei </i>subsp. <i>Sakei</i></td><td>[27]</td></tr><tr><td><i>L. sakei </i>Lb16 (Lb1048<sup>d</sup>, CCUG 42687<sup>a</sup>)</td><td>Minced meat</td><td>[31,73]</td></tr></table>
aa1d8db243dc680ab7bbfe8632c0d9f31d8f8f52ccd459908f7bbfea30d75c9f.png
complex
<table><tr><td rowspan="3"></td><td colspan="9">Sex</td></tr><tr><td colspan="3">T</td><td colspan="3">M</td><td colspan="3">F</td></tr><tr><td>N</td><td>Mean difference &#177; SD(mm)</td><td>P</td><td>N</td><td>Mean &#177; SD</td><td>P</td><td>N</td><td>Mean &#177; SD</td><td>P</td></tr><tr><td>UCPM</td><td rowspan="2">359</td><td>&#8722;0.41 &#177; 0.88</td><td>***</td><td rowspan="2">169</td><td>&#8722;0.21 &#177; 0.88</td><td>**</td><td rowspan="2">190</td><td>&#8722;0.59 &#177; 0.85</td><td>***</td></tr><tr><td>LCPM</td><td>&#8722;0.42 &#177; 0.91</td><td>***</td><td>&#8722;0.20 &#177; 0.91</td><td>**</td><td>&#8722;0.61 &#177; 0.86</td><td>***</td></tr></table>
4518b05fa9fe03a2450c7f5ae8108ee9e67b4a1d82406fc0d48ac3675f66bd26.png
complex
<table><tr><td rowspan="2">Ligands</td><td colspan="2">XPGScore</td><td rowspan="2">Winning score</td><td rowspan="2">CDM</td></tr><tr><td>2XYT-based &#945;7 nAChR-LBD</td><td>3SQ6-based &#945;7 nAChR-LBD</td></tr><tr><td>Acetylcholine</td><td>&#8722;4.68</td><td>&#8722;4.812</td><td>&#8722;4.812</td><td>0.132</td></tr><tr><td>epibatidine</td><td>&#8722;5.2</td><td>&#8722;8.725</td><td>&#8722;8.725</td><td>1.000</td></tr><tr><td>nicotine</td><td>&#8722;3.1</td><td>&#8722;7.512</td><td>&#8722;7.512</td><td>0.731</td></tr><tr><td>cytisine</td><td>&#8722;3.65</td><td>&#8722;6.362</td><td>&#8722;6.362</td><td>0.476</td></tr><tr><td>PNU282987</td><td>&#8722;4.518</td><td>&#8722;5.878</td><td>&#8722;5.878</td><td>0.368</td></tr><tr><td>mecamylamine</td><td>&#8722;3.564</td><td>&#8722;4.873</td><td>&#8722;4.873</td><td>0.145</td></tr><tr><td>MG624</td><td>&#8722;4.954</td><td>failed to dock</td><td>&#8722;4.954</td><td>0.163</td></tr><tr><td>methyllycaconitine</td><td>&#8722;5.829</td><td>failed to dock</td><td>&#8722;5.829</td><td>0.357</td></tr><tr><td>Hexamethonium</td><td>&#8722;2.786</td><td>&#8722;1.001</td><td>&#8722;2.786</td><td>&#8722;0.318</td></tr><tr><td>NS1738</td><td>&#8722;7.108</td><td>&#8722;8.513</td><td>&#8722;8.513</td><td>0.953</td></tr><tr><td>PNU120596</td><td>&#8722;4.992</td><td>&#8722;6.188</td><td>&#8722;6.188</td><td>0.437</td></tr><tr><td>SB206553</td><td>&#8722;4.373</td><td>&#8722;6.671</td><td>&#8722;6.671</td><td>0.544</td></tr></table>
a9678fd4845a4cf0301163e5521c7117d9fd196e25c0a810145d7b1b9f39fd58.png
simple
<table><tr><td>Predictors</td><td><i>B</i></td><td>SE <i>B</i></td><td>&#946;</td><td><i>t</i></td><td><i>p</i></td></tr><tr><td>Preference</td><td>0.21</td><td>0.05</td><td>0.13</td><td>3.79</td><td>&lt;.0001</td></tr><tr><td>Originality</td><td>0.58</td><td>0.08</td><td>0.47</td><td>7.17</td><td>&lt;.0001</td></tr><tr><td>Ambiguity</td><td>0.32</td><td>0.06</td><td>0.29</td><td>5.05</td><td>&lt;.0001</td></tr><tr><td>Understanding</td><td>&#8722; 0.39</td><td>0.02</td><td>&#8722; 0.34</td><td>&#8722; 14.05</td><td>&lt;.0001</td></tr></table>
abcd28a357aae78a89c54542303b9fd5b3dab6ff47a04db57a88a7f071dc4d3f.png
simple
<table><tr><td>Methylated bases in 100 bp</td><td><i>SCREAM2</i></td><td><i>FAMAa</i></td><td><i>FAMAb</i></td><td><i>SPCHa</i></td><td><i>SPCHb</i></td></tr><tr><td>LRH (Parent)</td><td>0</td><td>17</td><td>14</td><td>0</td><td>30.2</td></tr><tr><td>LRH-control</td><td>0.1</td><td>13.5</td><td>12.9</td><td>0</td><td>29.2</td></tr><tr><td><i>Entropy (H</i>&#967;<i>)</i></td><td>0.004</td><td>0.08</td><td>0.17</td><td>0.001</td><td>0.02</td></tr><tr><td>LRH-LRH</td><td>0.13</td><td>16.6</td><td>13.5</td><td>0.03</td><td>11.4</td></tr><tr><td><i>Entropy (H</i>&#967;<i>)</i></td><td>0.003</td><td>0.05</td><td>0.05</td><td>0.001</td><td>0.02</td></tr><tr><td>Control-control</td><td>0</td><td>11.5</td><td>7.2</td><td>0</td><td>11.3</td></tr><tr><td><i>Entropy (H</i>&#967;<i>)</i></td><td>0.000</td><td>0.08</td><td>0.07</td><td>0.015</td><td>0.000</td></tr><tr><td>&#967;<sup>2</sup> treatment</td><td>ns</td><td>&lt;0.001</td><td>&lt;0.001</td><td>ns</td><td>&lt;0.001</td></tr><tr><td>&#967;<sup>2</sup> inheritance</td><td>ns</td><td>ns</td><td>ns</td><td>ns</td><td>&lt;0.001</td></tr></table>
5504607b9433071ba4f94cbba2637337309ee0f6e117c57997f018e8ee64652e.png
simple
<table><tr><td>ESTs per unigene</td><td><i>H. erato</i></td><td><i>H. melpomene</i></td></tr><tr><td>1 (singletons)</td><td>319</td><td>256</td></tr><tr><td>2</td><td>13</td><td>31</td></tr><tr><td>3</td><td>5</td><td>12</td></tr><tr><td>4</td><td>9</td><td>10</td></tr><tr><td>5&#8211;10</td><td>14</td><td>17</td></tr><tr><td>11&#8211;20</td><td>7</td><td>9</td></tr><tr><td>21&#8211;50</td><td>3</td><td>3</td></tr><tr><td>&gt;51</td><td>1</td><td>2</td></tr><tr><td>Total:</td><td>371</td><td>340</td></tr></table>
893eee127fcbabf69bcd80e179c467fd3254de00b34d2d36a9acea1758cf24bb.png
simple
<table><tr><td>Gene </td><td>Sequence</td><td>bp </td></tr><tr><td>Beclin-1</td><td>Sense 5&#8242; CCAGATGCGTTATGCCCAGAC 3&#8242; Anti-sense 5&#8242; CATTCCATTCCACGGGAACAC 3&#8242;</td><td>149</td></tr><tr><td>mTOR</td><td>Sense 5&#8242; AAACTGCACGTCAGCACCATC 3&#8242; Anti-sense 5&#8242; AGCCGTCTCAGCCATTCCA 3&#8242;</td><td>192</td></tr><tr><td>ATG5</td><td>Sense 5&#8242;CCATCAATCGGAAACTCATGGA 3&#8242; Anti-sense 5&#8242;ATCTGCAGCCACAGGACGAA 3&#8242;</td><td>128</td></tr><tr><td>ATG7</td><td>Sense 5&#8242; CTGTAACTTAGCCCAGTACCCTGGA 3&#8242; Anti-sense 5&#8242;TACGGTCACGGAAGCAAACAAC 3&#8242;</td><td>113</td></tr><tr><td>Actin</td><td>Sense 5&#8242;TGGCACCCAGCACAATGAA 3&#8242; Anti-sense 5&#8242;CTAAGTCATAGTCCGCCTAGAAGCA 3&#8242;</td><td>128</td></tr></table>
7fed621b34482151519ac282277cc5ff6f2235a5ea1be88d8ef27fab92788c21.png
simple
<table><tr><td></td><td>TIV</td><td>GM volume</td><td>WM volume</td><td>CSF volume</td></tr><tr><td>FIS total</td><td>&#8722; 0.3540.023</td><td>&#8722; 0.5870.011</td><td>0.3490.138</td><td>&#8722; 0.4200.015</td></tr><tr><td>FIS cognitive</td><td>&#8722; 0.3360.032</td><td>&#8722; 0.6630.004</td><td>0.399<i>0</i>.<i>089</i></td><td>&#8722; 0.3710.030</td></tr><tr><td>FIS physical</td><td>&#8722; 0.1740.276</td><td>&#8722; 0.3040.206</td><td>0.3040.226</td><td>&#8722; 0.3950.031</td></tr><tr><td>FIS social</td><td>&#8722; 0.4000.010</td><td>&#8722; 0.5980.009</td><td>0.3010.139</td><td>&#8722; 0.4110.016</td></tr><tr><td>COMPASS-31</td><td>&#8722; 0.261<i>0</i>.<i>099</i></td><td>&#8722; 0.3330.163</td><td>0.2300.352</td><td>&#8722; 0.3950.030</td></tr><tr><td>CFQ</td><td>&#8722; 0.4830.001</td><td>&#8722; 0.6890.002</td><td>0.3400.114</td><td>&#8722; 0.5000.002</td></tr><tr><td>Duration of symptoms</td><td>&#8722; 0.0200.901</td><td>&#8722; 0.384<i>0</i>.<i>096</i></td><td>0.1320.579</td><td>0.2420.159</td></tr><tr><td>Age at onset</td><td>0.266<i>0</i>.<i>089</i></td><td>&#8722; 0.1390.545</td><td>0.2130.377</td><td>0.301<i>0</i>.<i>087</i></td></tr></table>
38741eec998ad6c085000aac486bd3fb13b5f358770060bffcbd690b40a48bd6.png
complex
<table><tr><td></td><td>Education<sup>a</sup></td><td>Household income (LICO)<sup>b</sup></td><td>Neihgbourhood SEP<sup>c</sup></td><td>Combined SEP<sup>d</sup></td></tr><tr><td colspan="5"><i>A- Maternal and infant health status indicators</i></td></tr><tr><td>1. Preterm Birth</td><td>+</td><td>NS</td><td>NS</td><td>+ (*) (low-high)</td></tr><tr><td>2. Small for gestational Age</td><td>NS</td><td>+</td><td>+</td><td>+ (low-low)</td></tr><tr><td>3. Self rated health</td><td>+</td><td>+</td><td>+</td><td>+ (low-low)</td></tr><tr><td>4. Postpartum Depression</td><td>+</td><td>+</td><td>+</td><td>+ (low-low)</td></tr><tr><td>5. Pre-pregnancy BMI (&lt;18.5)</td><td>+</td><td>+</td><td>+</td><td>+ (low-low)</td></tr><tr><td>6. Pre-pregnancy BMI (&gt;24.5)</td><td>+</td><td>+</td><td>NS</td><td>+ (low-high)</td></tr><tr><td colspan="5"><i>B- Prenatal care</i></td></tr><tr><td>7. First prenatal care visit</td><td>+</td><td>+</td><td>+</td><td>+ (low-low)</td></tr><tr><td>8. Timing of ultrasound</td><td>-</td><td>NS</td><td>NS</td><td>NS</td></tr><tr><td>9. HIV testing (no)</td><td>NS</td><td>-</td><td>NS</td><td>+ (low-low)</td></tr><tr><td>10. Received enough information during pregnancy</td><td>+</td><td>+</td><td>+</td><td>+ (low-low)</td></tr><tr><td>11. Weight gained during pregnancy (kg) - (Below recommended range)</td><td>+</td><td>+ (*)</td><td>NS</td><td>+ (*) (low-high)</td></tr><tr><td>12. Weight gained during pregnancy (kg)-more (Above recommended range)</td><td>+</td><td>+</td><td>NS</td><td>+ (low-high)</td></tr><tr><td colspan="5"><i>C- Labor and delivery</i>expereinces</td></tr><tr><td>13. Type of birth (caesarean)</td><td>NS</td><td>-</td><td>NS</td><td>+ (low-high)</td></tr><tr><td>14. Epidural for a vaginal birth</td><td>-</td><td>-</td><td>NS</td><td>+ (low-high)</td></tr><tr><td>15. Shaving for a vaginal birth</td><td>+</td><td>+</td><td>+</td><td>+ (low-high)</td></tr><tr><td>16. Position for vaginal birth (not laying flat)</td><td>NS</td><td>+</td><td>+</td><td>+ (low-low)</td></tr><tr><td colspan="5"><i>D- Medical care during the neonatal period</i></td></tr><tr><td>17. Infant hospital readmission</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td></tr><tr><td>18. Infant needing non-routine neonatal care after discharge?</td><td>-</td><td>-</td><td>-</td><td>- (low-low)</td></tr><tr><td>19. Baby admitted to NICU after birth</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td></tr><tr><td>20. Length of hospital stay after caesarean birth (More than average)</td><td>NS</td><td>NS</td><td>+</td><td>+ (high-low)</td></tr><tr><td>21. Length of hospital stay after vaginal birth (More than average)</td><td>+ (*)</td><td>NS</td><td>NS</td><td>NS</td></tr><tr><td colspan="5"><i>E- Postpartum infant care &amp; maternal reflections on the overall experience of health care</i></td></tr><tr><td>22. Any breastfeeding at 3 months</td><td>+</td><td>+</td><td>-</td><td>+ (low-high)</td></tr><tr><td>23. Any breastfeeding at 6 months</td><td>+</td><td>+</td><td>-</td><td>+ (low-high)</td></tr><tr><td>24. Overall experience of labor and birth</td><td>NS</td><td>+</td><td>NS</td><td>+ (low-high)</td></tr><tr><td>25. Satisfaction with previous aspects of maternity care</td><td>+</td><td>+(*)</td><td>NS</td><td>NS</td></tr></table>
a7145f591a43a1d3afce9d780e7b0d13afd531a885328abe102a554ad26f157d.png
simple
<table><tr><td>Demographic Variables</td><td>Number</td></tr><tr><td>Ages</td><td></td></tr><tr><td>15-19</td><td>2</td></tr><tr><td>20-24</td><td>2</td></tr><tr><td>25-29</td><td>2</td></tr><tr><td>30-34</td><td>1</td></tr><tr><td>35-39</td><td>2</td></tr><tr><td>40-44</td><td>1</td></tr><tr><td>45-49</td><td>0</td></tr><tr><td>Total</td><td>10</td></tr><tr><td>Educational Attainment</td><td></td></tr><tr><td>None</td><td>1</td></tr><tr><td>Grades 1-4</td><td>1</td></tr><tr><td>Grades 5-8</td><td>3</td></tr><tr><td>Grades 9-12</td><td>5</td></tr><tr><td>Tertiary education</td><td>0</td></tr><tr><td>Total</td><td>10</td></tr><tr><td>Age at first birth</td><td></td></tr><tr><td>15-19</td><td>6</td></tr><tr><td>20-24</td><td>3</td></tr><tr><td>25-29</td><td>1</td></tr><tr><td>30-34</td><td>0</td></tr><tr><td>35-39</td><td>0</td></tr><tr><td>40-44</td><td>0</td></tr><tr><td>45-49</td><td>0</td></tr><tr><td>Total</td><td>10</td></tr><tr><td>Marital Status</td><td></td></tr><tr><td>Single</td><td>8</td></tr><tr><td>Customary marriage</td><td>0</td></tr><tr><td>Civil Marriage</td><td>0</td></tr><tr><td>Cohabiting</td><td>2</td></tr><tr><td>Total</td><td>10</td></tr><tr><td>Number of live births</td><td></td></tr><tr><td>0-2</td><td>2</td></tr><tr><td>04-Mar</td><td>6</td></tr><tr><td>5+</td><td>2</td></tr><tr><td>Total</td><td>10</td></tr><tr><td>Employment Status</td><td></td></tr><tr><td>Unemployed</td><td>7</td></tr><tr><td>Employed</td><td>2</td></tr><tr><td>Other: e.g. self-employed as petty trader</td><td>1</td></tr><tr><td>Total</td><td>10</td></tr></table>
a99a06632fd0e85cd6915e2cd31769a611a9d1cfab6bab49ec3bbfd09698264a.png
complex
<table><tr><td><i>C</i><sub>i</sub>(phenol), mg&#183;L<sup>&#8722;1</sup></td><td>15</td><td>40</td><td>100</td><td>150</td><td>200</td><td>250</td><td>300</td></tr><tr><td colspan="8">MIP 3 (EGDMA)</td></tr><tr><td><i>Q</i>(MIP), mg&#183;g<sup>&#8722;</sup><sup>1</sup></td><td>2.60</td><td>6.30</td><td>13.0</td><td>17.0</td><td>21.7</td><td>23.7</td><td>26.2</td></tr><tr><td><i>Q</i>(NIP), mg&#183;g<sup>&#8722;</sup><sup>1</sup></td><td>2.60</td><td>6.51</td><td>13.7</td><td>17.3</td><td>22.4</td><td>24.6</td><td>27.2</td></tr><tr><td>IF</td><td>1.00</td><td>1.03</td><td>1.05</td><td>1.02</td><td>1.03</td><td>1.04</td><td>1.04</td></tr><tr><td colspan="8">MIP 4 (TEGDMA)</td></tr><tr><td><i>Q</i>(MIP), mg&#183;g<sup>&#8722;</sup><sup>1</sup></td><td>1.79</td><td>4.91</td><td>10.1</td><td>14.9</td><td>18.4</td><td>22.3</td><td>27.1</td></tr><tr><td><i>Q</i>(NIP), mg&#183;g<sup>&#8722;</sup><sup>1</sup></td><td>1.72</td><td>4.76</td><td>9.7</td><td>14.2</td><td>17.4</td><td>21.2</td><td>25.6</td></tr><tr><td>IF</td><td>1.04</td><td>1.03</td><td>1.04</td><td>1.05</td><td>1.06</td><td>1.05</td><td>1.06</td></tr><tr><td colspan="8">MIP 5 (PETA)</td></tr><tr><td><i>Q</i>(MIP), mg&#183;g<sup>&#8722;</sup><sup>1</sup></td><td>2.52</td><td>5.41</td><td>11.5</td><td>15.4</td><td>18.2</td><td>21.9</td><td>24.6</td></tr><tr><td><i>Q</i>(NIP), mg&#183;g<sup>&#8722;</sup><sup>1</sup></td><td>2.31</td><td>5.20</td><td>10.7</td><td>14.2</td><td>16.9</td><td>19.8</td><td>22.1</td></tr><tr><td><i>IF</i></td><td>1.09</td><td>1.04</td><td>1.07</td><td>1.09</td><td>1.08</td><td>1.11</td><td>1.12</td></tr></table>
37725ddc93c7fce3fa2dc50e24fe8f5b192371f81c8ed53c4d32b544be1e2c51.png
simple
<table><tr><td>Group</td><td>Base</td><td>2 h</td><td>8 h</td><td>24 h</td><td>48 h</td></tr><tr><td>Ctrl</td><td>0 (0&#8211;0)</td><td>3 (3&#8211;4)</td><td>3 (3&#8211;4)</td><td>3 (2&#8211;4)</td><td>3 (2&#8211;3)</td></tr><tr><td>Z-VEID</td><td>0 (0&#8211;0)</td><td>3 (2&#8211;4)</td><td>3 (2&#8211;3)</td><td>2 (1&#8211;3)</td><td>2 (1&#8211;2)a</td></tr><tr><td>Z-IETD</td><td>0 (0&#8211;0)</td><td>3 (3&#8211;4)</td><td>3 (2&#8211;3)</td><td>2 (2&#8211;3)</td><td>2 (1&#8211;2)a</td></tr></table>
b60bc0c37bd25cf6f8720df541bc26bf5cbb67343118af049861a3a57f54306e.png
complex
<table><tr><td>Ingredient</td><td colspan="2">Fish oil-based diet<sup>1</sup></td><td colspan="2">Saturated fat-based diet<sup>2</sup></td></tr><tr><td></td><td><i>g (%)</i></td><td><i>Kcal</i></td><td><i>g (%)</i></td><td><i>Kcal (%)</i></td></tr><tr><td>Protein</td><td>23.7</td><td>20</td><td>23.7</td><td>20</td></tr><tr><td>Carbohydrate</td><td>41.4</td><td>35</td><td>41.4</td><td>35</td></tr><tr><td>Fat<sup>1</sup></td><td>23.6</td><td>45</td><td>23.6</td><td>45</td></tr><tr><td>Casein</td><td>200 (23.3)</td><td>800</td><td>200 (23.3)</td><td>800</td></tr><tr><td>L-Cystine</td><td>3 (0.35)</td><td>12</td><td>3 (0.35)</td><td>12</td></tr><tr><td>Corn starch</td><td>72.8 (9.88)</td><td>291</td><td>72.8 (9.88)</td><td>291</td></tr><tr><td>Maltodextrin</td><td>100 (11.65)</td><td>400</td><td>100 (11.65)</td><td>400</td></tr><tr><td>Sucrose</td><td>172.8 (20.14)</td><td>691</td><td>172.8 (20.14)</td><td>691</td></tr><tr><td>Cellulose</td><td>50 (5.83)</td><td>0</td><td>50 (5.83)</td><td>0</td></tr><tr><td>Soybean Oil</td><td>25 (2.91)</td><td>225</td><td>25 (2.91)</td><td>225</td></tr><tr><td>Lard</td><td>0</td><td>0</td><td>177.5 (20.68)</td><td>1598</td></tr><tr><td>Menhaden oil</td><td>177.5 (20.68)</td><td>1598</td><td>0</td><td>0</td></tr><tr><td>Mineral mix</td><td>10 (1.17)</td><td>0</td><td>10 (1.17)</td><td>0</td></tr><tr><td>Vitamin mix</td><td>10 (1.17)</td><td>40</td><td>10 (1.17)</td><td>40</td></tr><tr><td>Choline bitartrate</td><td>2 (0.23)</td><td>0</td><td>2 (0.23)</td><td>0</td></tr><tr><td>Cholesterol</td><td>0.17 (0.02)</td><td>0</td><td>0.71 (0.08)</td><td>0</td></tr><tr><td>Total</td><td>858.2</td><td>4057</td><td>858.2</td><td>4057</td></tr></table>
946c2a3cf4817d9405e4c4d8ecfd323722259459ac5f5445dfb0c5a3a127f9e0.png
simple
<table><tr><td>Agent*</td><td>Time (s)</td><td>Capping efficiency</td></tr><tr><td>Acetic anhydride</td><td>15</td><td>60 &#177; 4%</td></tr><tr><td>Acetic anhydride</td><td>30</td><td>81 &#177; 2%</td></tr><tr><td>Acetic anhydride</td><td>60</td><td>92 &#177; 2%</td></tr><tr><td>Acetic anhydride</td><td>120</td><td>95 &#177; 2%</td></tr><tr><td>DMT-dT</td><td>15</td><td>91 &#177; 2%</td></tr><tr><td>DMT-dT</td><td>30</td><td>94 &#177; 1%</td></tr><tr><td>DMT-dT</td><td>60</td><td>97 &#177; 1%</td></tr></table>
70918a4d27bdd06d590fc74c117458d68e58653077a034f67c2bd095b57ddd94.png
complex
<table><tr><td></td><td></td><td>Abnormalcardiometabolic profile</td><td>Normalcardiometabolic profile</td><td>TOTAL</td></tr><tr><td>Untreated</td><td>"Normal" weight(BMI = 18.5 - 24.9)</td><td>23.5%(16.3 million people)<sup>b</sup></td><td>76.5%(53.0 million people)</td><td>100%(69.3 million people)</td></tr><tr><td>Treated</td><td>"Overweight"(BMI = 25.0 - 29.9)</td><td>48.7%(34.1 million people)</td><td>51.3%(35.9 million people)<sup>c</sup></td><td>100%(70.0 million people)</td></tr><tr><td></td><td>"Obese"(BMI &#8805; 30.0)</td><td>68.3%(42.0 million people)</td><td>31.7%(19.5 million people)<sup>c</sup></td><td>100%(61.5 million people)</td></tr><tr><td colspan="2">TOTAL</td><td>46%92.4 million people</td><td>54%108.4 million people</td><td>100%200.8 million people</td></tr></table>
c1f157bc02605c72f4b4c49df42418f56bd87ec263de20f44652525bd74ab85d.png
complex
<table><tr><td></td><td colspan="5">Number of controls</td></tr><tr><td></td><td>10</td><td>60</td><td>110</td><td>160</td><td>210</td></tr><tr><td>Percentage of results that included the mutation (%)</td><td>100</td><td>100</td><td>100</td><td>100</td><td>100</td></tr><tr><td>Percentage of mutation loci in the top hit (%)</td><td>46</td><td>43</td><td>37</td><td>38</td><td>37</td></tr><tr><td>Mean length of haplotypes (number of SNPs)</td><td>629</td><td>546</td><td>441</td><td>410</td><td>383</td></tr></table>
5031f4602d6fcf2b7690daf0cfcfaf8e88550436e0502256f94771f3247a8d40.png
simple
<table><tr><td>Cantilever ID</td><td><i>L</i> &#956;m</td><td>-Sphere -material</td><td>Sphere number</td><td>Sphere diameter, &#956;m</td><td>Resonance Frequency -kHz</td><td>&#916;Lm &#956;m</td></tr><tr><td>DNP 6A</td><td>108</td><td>Gold</td><td>&#8211;</td><td>0</td><td>62.8</td><td>&#8211;</td></tr><tr><td></td><td></td><td>19300</td><td>1</td><td>3.8</td><td>56.0</td><td>+1.9</td></tr><tr><td></td><td></td><td>kg&#183;m<sup>&#8722;3</sup></td><td>2</td><td>5.7</td><td>46.8</td><td>&#8722;1.4</td></tr><tr><td></td><td></td><td></td><td>3</td><td>9.5</td><td>31.2</td><td>&#8722;1.1</td></tr><tr><td></td><td></td><td></td><td>&#8211;</td><td>0</td><td>62.8</td><td>&#8211;</td></tr></table>
015b85a7bf77b899abe494b8823b81202f915fd2af1eee4b5c57ee552932c88d.png
complex
<table><tr><td rowspan="2">Variable</td><td colspan="4">Before matching</td><td colspan="4">After matching</td></tr><tr><td>Atypical cohort N = 648</td><td>Typical cohort N = 483</td><td>p-value</td><td>Standardized difference</td><td>Atypical cohort N = 400</td><td>Typical cohort N = 400</td><td>p-value</td><td>Standardized difference</td></tr><tr><td>Demographic characteristics</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Mean age (in years) [Mean(SD)]</td><td>51.3 (13.0)</td><td>52.6 (11.9)</td><td>0.081</td><td>&#8722;0.106</td><td>52.1 (11.8)</td><td>51.7 (11.7)</td><td>0.144</td><td>0.035</td></tr><tr><td>Female [n(%)]</td><td>357 (55.1%)</td><td>267 (55.3%)</td><td>0.950</td><td>&#8722;0.004</td><td>226 (56.5%)</td><td>224 (56.0%)</td><td>0.715</td><td>0.010</td></tr><tr><td>Retired [n(%)]</td><td>338 (52.2%)</td><td>282 (58.4%)</td><td>0.037</td><td>&#8722;0.125</td><td>222 (55.5%)</td><td>228 (57.0%)</td><td>0.109</td><td>&#8722;0.030</td></tr><tr><td>Concomitant medications [n(%)]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Anxiolytics</td><td>74 (11.4%)</td><td>57 (11.8%)</td><td>0.843</td><td>&#8722;0.012</td><td>18 (4.5%)</td><td>22 (5.5%)</td><td>0.541</td><td>&#8722;0.046</td></tr><tr><td>Anticholinergics</td><td>28 (4.3%)</td><td>15 (3.1%)</td><td>0.290</td><td>0.064</td><td>1 (0.3%)</td><td>1 (0.3%)</td><td>1.000</td><td>&lt;0.001</td></tr><tr><td>Antidepressants</td><td>24 (3.7%)</td><td>22 (4.6%)</td><td>0.473</td><td>&#8722;0.043</td><td>1 (0.3%)</td><td>4 (1.0%)</td><td>0.375</td><td>&#8722;0.095</td></tr><tr><td>Sedative-hypnotics</td><td>9 (1.4%)</td><td>17 (3.5%)</td><td>0.018</td><td>&#8722;0.138</td><td>1 (0.3%)</td><td>3 (0.8%)</td><td>0.625</td><td>&#8722;0.071</td></tr><tr><td>Mood stabilizers</td><td>7 (1.1%)</td><td>6 (1.2%)</td><td>0.787</td><td>&#8722;0.015</td><td>2 (0.5%)</td><td>1 (0.3%)</td><td>1.000</td><td>0.041</td></tr><tr><td>Mental comorbidities [n(%)]</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Sleep disorder</td><td>38 (5.9%)</td><td>29 (6.0%)</td><td>0.921</td><td>&#8722;0.006</td><td>14 (3.5%)</td><td>10 (2.5%)</td><td>0.481</td><td>0.059</td></tr><tr><td>Depression</td><td>15 (2.3%)</td><td>16 (3.3%)</td><td>0.309</td><td>&#8722;0.060</td><td>1 (0.3%)</td><td>4 (1.0%)</td><td>0.375</td><td>&#8722;0.095</td></tr><tr><td>Anxiety disorder</td><td>8 (1.2%)</td><td>9 (1.9%)</td><td>0.462</td><td>&#8722;0.051</td><td>3 (0.8%)</td><td>2 (0.5%)</td><td>1.000</td><td>0.032</td></tr><tr><td>Other psychotic disorder<sup>#</sup></td><td>6 (0.9%)</td><td>3 (0.6%)</td><td>0.740</td><td>0.035</td><td>1 (0.3%)</td><td>0 (0.0%)</td><td>1.000</td><td>0.071</td></tr><tr><td colspan="2">Resource utilization and cost (prior 3 months)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Mean number of hospitalizations</td><td>0.02 (0.15)</td><td>0.05 (0.25)</td><td>0.028</td><td>&#8722;0.128</td><td>0.01 (0.07)</td><td>0.01 (0.07)</td><td>1.000</td><td>&lt;0.001</td></tr><tr><td>Mean number of outpatient visits</td><td>0.17 (0.58)</td><td>0.22 (0.83)</td><td>0.332</td><td>&#8722;0.069</td><td>0.08 (0.34)</td><td>0.05 (0.36)</td><td>0.298</td><td>0.071</td></tr><tr><td>Direct medical cost ($) [Mean(SD)]</td><td>20 (124)</td><td>42 (200)</td><td>0.027</td><td>&#8722;0.129</td><td>4 (45)</td><td>3 (46)</td><td>0.287</td><td>0.021</td></tr></table>
e5a7942a44f624703e5e630307e740606a7e9f5e804d8554bd4dd34c63eec7c8.png
complex
<table><tr><td colspan="2">All Sounds &gt; Baseline</td></tr><tr><td>Region</td><td>Number of Voxels</td></tr><tr><td>Right Frontal Cortex</td><td>14335</td></tr><tr><td>Frontal pole</td><td></td></tr><tr><td>Frontal orbital cortex</td><td></td></tr><tr><td>Middle frontal gyrus</td><td></td></tr><tr><td>Pars opercularis</td><td></td></tr><tr><td>Pars triangularis</td><td></td></tr><tr><td>Right Temporal Cortex</td><td>2243</td></tr><tr><td>Middle temporal gyrus, posterior division and temporoccipital part</td><td></td></tr><tr><td>Superior temporal gyrus, posterior division</td><td></td></tr><tr><td>Heschl&#8217;s gyrus</td><td></td></tr><tr><td>Left Temporal Cortex</td><td>874</td></tr><tr><td>Middle temporal gyrus, posterior division</td><td></td></tr><tr><td>Superior temporal gyrus, posterior division</td><td></td></tr><tr><td>Heschl&#8217;s gyrus</td><td></td></tr><tr><td>Left Frontal Pole</td><td>48</td></tr></table>
1e28fa0ba7e3994a9e487ba5dadaf447dbcd9ec75ce06e547e471c0f692bb8c2.png
complex
<table><tr><td rowspan="2"></td><td>Total</td><td colspan="2">Recognise pregnancy warning signs<sup>b</sup></td><td colspan="2">Recognise pregnancy hypertension warning signs</td><td colspan="2">Recognise convulsions</td></tr><tr><td>N (%)</td><td>N (%)</td><td>OR (95 % CI)<sup>a</sup></td><td>N (%)</td><td>OR (95 % CI)<sup>a</sup></td><td>N (%)</td><td>OR (95 % CI)<sup>a</sup></td></tr><tr><td>Total</td><td>81 (100.0)</td><td>75 (92.6)</td><td></td><td>33 (40.7)</td><td></td><td>57 (70.4)</td><td></td></tr><tr><td colspan="8">Sex</td></tr><tr><td> Male</td><td>20 (24.7)</td><td>19 (95.0)</td><td>1.00</td><td>13 (65.0)</td><td>1.00</td><td>18 (90.0)</td><td>1.00</td></tr><tr><td> Female</td><td>53 (65.4)</td><td>50 (94.3)</td><td>0.88 (0.02 - 11.74)</td><td>18 (34.0)</td><td>0.28 (0.08 - 0.92)*</td><td>34 (64.2)</td><td>0.20 (0.02 - 1.00)</td></tr><tr><td> Missing</td><td>8 (9.9)</td><td>6 (75.0)</td><td>0.17 (0.00 - 3.82)</td><td>2 (25.0)</td><td>0.19 (0.02 - 1.44)</td><td>5 (62.5)</td><td>0.20 (0.01 - 2.24)</td></tr><tr><td colspan="8">Age</td></tr><tr><td> Median (IQR)</td><td>46.0 (35.5 - 50.0)</td><td>-</td><td>1.14 (1.02 - 1.34)*</td><td>-</td><td>0.99 (0.95 - 1.03)</td><td>-</td><td>0.99 (0.95 - 1.03)</td></tr><tr><td colspan="8">Education</td></tr><tr><td> Primary</td><td>54 (66.7)</td><td>52 (96.3)</td><td>1.00</td><td>22 (40.7)</td><td>1.00</td><td>38 (70.4)</td><td>1.00</td></tr><tr><td> Secondary</td><td>15 (18.5)</td><td>14 (93.3)</td><td>0.54 (0.03 - 34.01)</td><td>7 (46.7)</td><td>1.27 (0.34 - 4.68)</td><td>11 (73.3)</td><td>1.16 (0.28 - 5.73)</td></tr><tr><td> Missing</td><td>12 (14.8)</td><td>9 (75.0)</td><td>0.12 (0.01 - 1.21)</td><td>4 (33.3)</td><td>0.73 (0.14 - 3.15)</td><td>8 (66.7)</td><td>0.84 (0.19 - 4.39)</td></tr><tr><td colspan="8">Years working as community health worker</td></tr><tr><td> Median (IQR)</td><td>2 (1&#8211;8)</td><td>-</td><td>1.19 (0.93 - 1.94)</td><td>-</td><td>1.04 (0.97 - 1.12)</td><td>-</td><td>1.09 (0.99 - 1.24)</td></tr></table>
1d24b2d6b6d32cfec2b74ef4a517a3c0cf1e5ff4b02467039ae1ce72206477b0.png
complex
<table><tr><td></td><td colspan="3">Any GI problem</td><td colspan="3">Constipation</td><td colspan="3">Reflux</td><td colspan="3">Air swallowing</td></tr><tr><td></td><td colspan="3">(<i>n</i> = 94)</td><td colspan="3">(<i>n</i> = 73)</td><td colspan="3">(<i>n</i> = 51)</td><td colspan="3">(<i>n</i> = 25)</td></tr><tr><td></td><td><i>n</i> (%)</td><td>OR (95 % CI)</td><td><i>p</i> value</td><td><i>n</i> (%)</td><td>OR (95 % CI)</td><td><i>p</i> value</td><td><i>n</i> (%)</td><td>OR (95 % CI)</td><td><i>p</i> value</td><td><i>n</i> (%)</td><td>OR (95 % CI)</td><td><i>p</i> value</td></tr><tr><td></td><td><i>N</i> = 125</td><td></td><td></td><td><i>N</i> = 129</td><td></td><td></td><td><i>N</i> = 116</td><td></td><td></td><td><i>N</i> = 110</td><td></td><td></td></tr><tr><td>Age group</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0 to &lt;5 years</td><td>50 (40.0)</td><td>baseline</td><td>&#8211;</td><td>52 (40.3)</td><td>baseline</td><td>&#8211;</td><td>48 (41.4)</td><td>baseline</td><td>&#8211;</td><td>44 (40.0)</td><td>baseline</td><td>&#8211;</td></tr><tr><td> 5 to &lt; 10 years</td><td>42 (33.6)</td><td>2.03 (0.83,4.94)</td><td>0.12</td><td>42 (32.6)</td><td>2.12 (0.90,5.00)</td><td>0.08</td><td>36 (31.0)</td><td>1.07 (0.42,2.72)</td><td>0.88</td><td>37 (33.6)</td><td>1.35 (0.37,4.86)</td><td>0.65</td></tr><tr><td> 10 years or older</td><td>33 (26.4)</td><td>3.5 (1.22,10.08)</td><td>0.02</td><td>35 (27.1)</td><td>2.78 (1.14,6.74)</td><td>0.02</td><td>32 (27.6)</td><td>2.24 (0.88,5.71)</td><td>0.09</td><td>29 (26.4)</td><td>7.48 (1.96,28.53)</td><td>0.003</td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Female</td><td>112 (89.6)</td><td>baseline</td><td>&#8211;</td><td>115 (89.2)</td><td>baseline</td><td>&#8211;</td><td>102 (87.9)</td><td>baseline</td><td>&#8211;</td><td>110 (100)</td><td>baseline</td><td>&#8211;</td></tr><tr><td> Male</td><td>13 (10.4)</td><td>0.92 (0.25,3.44)</td><td>0.90</td><td>14 (10.9)</td><td>0.90 (0.28,2.90)</td><td>0.85</td><td>14 (12.1)</td><td>1.01 (0.31,3.34)</td><td>0.99</td><td>0</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td>Mutation group</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No functional protein</td><td>43 (34.4)</td><td>baseline</td><td>&#8211;</td><td>43 (33.3)</td><td>baseline</td><td>&#8211;</td><td>40 (34.5)</td><td>baseline</td><td>&#8211;</td><td>34 (30.9)</td><td>baseline</td><td>&#8211;</td></tr><tr><td> Missense/in-frame mutation within catalytic domain</td><td>38 (30.4)</td><td>1.27 (0.46,3.50)</td><td>0.64</td><td>40 (31.0)</td><td>1.62 (0.65,4.03)</td><td>0.30</td><td>34 (29.3)</td><td>1.73 (0.66,4.51)</td><td>0.27</td><td>34 (30.9)</td><td>12.14 (2.08,70.68)</td><td>0.01</td></tr><tr><td> Truncation between aa172 and aa781</td><td>30 (24.0)</td><td>0.67 (0.24,1.89)</td><td>0.45</td><td>31 (24.0)</td><td>2.17 (0.80,5.91)</td><td>0.13</td><td>29 (25.0)</td><td>1.01 (0.36,2.82)</td><td>0.98</td><td>29 (26.4)</td><td>8.03 (1.35,48.00)</td><td>0.02</td></tr><tr><td> Truncation after aa781</td><td>14 (11.2)</td><td>0.81 (0.21,3.07)</td><td>0.76</td><td>15 (11.6)</td><td>0.74 (0.21,2.58)</td><td>0.64</td><td>13 (11.2)</td><td>0.49 (0.11,2.13)</td><td>0.34</td><td>13 (11.8)</td><td>14.21 (1.83,110.22)</td><td>0.01</td></tr></table>
c5dfb62a25457b7853b5e28e2da6a91b811a2c7a45795dfeebdf09838cfbd3bf.png
complex
<table><tr><td rowspan="2" colspan="2"></td><td colspan="3">9-y-olds</td><td colspan="3">15-y-olds</td></tr><tr><td>MVPA (b (95% CI))</td><td><i>p</i></td><td><i>n</i></td><td>MVPA (b (95% CI))</td><td><i>p</i></td><td><i>n</i></td></tr><tr><td colspan="2">Sleep</td><td>0.3 (&#8722;1.5, 2.2)</td><td>0.740</td><td>2053</td><td>1.3 (&#8722; 1.0, 3.6)</td><td>0.274</td><td>1120</td></tr><tr><td colspan="2">Screen time</td><td>&#8722;2.2 (&#8722;3.1, &#8722;1.3)</td><td>&lt; 0.001</td><td>2033</td><td>&#8722;1.7 (&#8722;2.7, &#8722;0.8)</td><td>&lt; 0.001</td><td>1162</td></tr><tr><td colspan="8">Active transport</td></tr><tr><td colspan="2">&#8804; 5 min/d</td><td>ref.</td><td></td><td>900</td><td>ref.</td><td></td><td>619</td></tr><tr><td colspan="2"> 6&#8211;15 min/d</td><td>3.6 (0.9, 6.3)</td><td>0.009</td><td>742</td><td>3.3 (0.4, 6.2)</td><td>0.027</td><td>440</td></tr><tr><td colspan="2"> &#8805; 16 min/d</td><td>7.2 (4.0, 10.4) <sup>&#9792;&#9794;</sup></td><td>&lt; 0.001</td><td>424</td><td>9.0 (3.8, 14.1)</td><td>0.001</td><td>137</td></tr><tr><td rowspan="3"> Girls</td><td>&#8804;5 min/d</td><td>ref.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>6&#8211;15 min/d</td><td>4.6 (1.5, 7.8)</td><td>0.004</td><td></td><td></td><td></td><td></td></tr><tr><td>&#8805; 16 min/d</td><td>10.5 (6.8, 14.3)</td><td>&lt; 0.001</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="3"> Boys</td><td>&#8804;5 min/d</td><td>ref.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>6&#8211;15 min/d</td><td>2.4 (&#8722;1.7, 6.6)</td><td>0.253</td><td></td><td></td><td></td><td></td></tr><tr><td>&#8805; 16 min/d</td><td>5.0 (0.4, 9.7)</td><td>0.033</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Sports/exercise</td></tr><tr><td colspan="2"> &#8804; 2 h/week</td><td>ref.</td><td></td><td>736</td><td>ref.</td><td></td><td>350</td></tr><tr><td colspan="2"> 3&#8211;7 h/week</td><td>2.2 (&#8722;0.1, 4.5)</td><td>0.062</td><td>1098</td><td>7.6 (4.3, 10.8)</td><td>&lt; 0.001</td><td>555</td></tr><tr><td colspan="2">&#8805; 8 h/week</td><td>9.2 (4.7, 13.7) <sup>&#9792;&#9794;</sup></td><td>&lt; 0.001</td><td>225</td><td>17.9 (14.0, 21.8)</td><td>&lt; 0.001</td><td>279</td></tr><tr><td rowspan="3"> Girls</td><td>&#8804;2 h/week</td><td>ref.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>3&#8211;7 h/week</td><td>1.1 (&#8722;2.2, 4.4)</td><td>0.508</td><td></td><td></td><td></td><td></td></tr><tr><td>&#8805; 8 h/week</td><td>1.3 (&#8722;3.9, 6.5)</td><td>0.635</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="3"> Boys</td><td>&#8804;2 h/week</td><td>ref.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>3&#8211;7 h/week</td><td>4.5 (0.9, 8.2)</td><td>0.014</td><td></td><td></td><td></td><td></td></tr><tr><td>&#8805; 8 h/week</td><td>14.7 (8.2, 21.3)</td><td>&lt; 0.001</td><td></td><td></td><td></td><td></td></tr></table>
b7ad7daf435c20acbc27272ffdf82e15dae4b4a0602952754b9d1684451a8c66.png
simple
<table><tr><td>Cytology</td><td>Mean Age</td><td>No. of SpecimensN,(%)</td><td>Overall HPV (+)%</td></tr><tr><td>Normal</td><td>38.1 &#177; 9.4 (20-67)</td><td>310 (77%)</td><td>20%</td></tr><tr><td>Abnormal Cytology</td><td>35.6 &#177; 8.7(19-58)</td><td>93 (23%)</td><td>36%</td></tr><tr><td> ASCUS</td><td>37.0 &#177; 8.8</td><td>39 (42%)</td><td>22%</td></tr><tr><td> LSIL</td><td>33.6 &#177; 8.9</td><td>43 (46%)</td><td>51%</td></tr><tr><td> HSIL</td><td>38.0 &#177; 6.9</td><td>10 (11%)</td><td>60%</td></tr></table>
6dcd72a6e9b5ddf1773eb90f16193b8fadb4876533d18b4725477358ae5bf103.png
simple
<table><tr><td></td><td>General evidence</td><td>Managerial Accounting tools</td><td>HRM tools</td><td>ICT tools</td><td>Outcomes</td><td>Open issues</td></tr><tr><td>Progressive patient care model</td><td>In some contexts implementation by law (e.g. Tuscany)Great autonomy of organizations on how to implement modelForms of implementation:poles; separation elective/unscheduled/emergency patients; distinct inpatient/outpatient pathways; emphasis on ED; pool beds; centralization of functions</td><td>Integrated Planning, Budgeting and Control systems (e.g. BSC)In concrete, however, MA tools not aligned to model (e.g. budgets still assigned to clinical wards)</td><td>New professional roles and a general reassignment of responsibilities (nurses and physicians)Need for:Competency based model;Separate professional/managerial career paths;Multi-source and 360&#176; feedback system</td><td>Integrated electronic health records, to be jointly used and updated by physicians and nurses</td><td>Improved efficiency indicatorsIncreased patient satisfaction (medical and/or nursing tutor)More coordination between medical and surgical staffBetter implementation of clinical pathwaysLack of evidence in terms of improved clinical outcomes</td><td>Effective allocation of nurses to different settingsCorrect triage activity in ED and efficient allocations of patientsDesirability of medical day- or week- hospitalsInvolving professionals and of overcoming cultural barriersDefinition of clear repartition of responsibilities among professionals</td></tr><tr><td>Patient centered approach</td><td>The most analyzed aspect of PC is related to continuity of care among different settings (poorly explored within hospitals)An exception: analysis of general process improvements within EDs</td><td></td><td>New professional roles in hospitals (e.g. liason nurse)</td><td>ICT tools should ideally:prioritize information and detect individuals&#8217; contextual situations,promote stronger inter-professional relationships with adequate exchange of information,enable interoperability and scalability between and within institutions,function across different platforms.Few pioneer experiences (e.g. Shared care platform)ICT tools still rudimental if compared to their potential</td><td>Significant relationships between specific elements of PC and outcomes, or between PC approach in general and a reduced ED utilization.Liason activities are associated with slightly higher (not significant), quality care transitions.Greater patient satisfactionImproved communication among professionalsGeneral evidence about the effects of PCC on clinical outcomes very limited</td><td>Poor attention of literature to PC within hospitalsNecessary switch from hospital information systems to health care information systemsNon exhaustive informationIndividuals involved are not tracedLack of tools to clearly assess PC</td></tr><tr><td>Lean approach</td><td>Application of various features of lean such as new employee roles, staffing and scheduling, communication and coordination, workspace layout, process design etc.Application of lean tools within settings (EDs, ORs, outpatient settings)Only few examples of lean applied to pathways</td><td></td><td>Staff empowerment and &#8220;bottom-up approach&#8221;, by allowing the frontline staff to identify problems and come up with appropriate solutions</td><td></td><td>Many examples of improvement in efficiency indicatorsFewer examples of improvement in clinical outcomesA number of studies find inconsistent the evidence about lean&#8217;s contribution to higher organizational performance</td><td>Lean is often felt to be &#8220;a constellation of disjointed and poorly connected activities&#8221;Lack of &#8220;system-wide&#8221; improvement philosophyThe &#8220;bottom-up approach&#8221; is not fully implemented in concrete and barriers to implementation persistNeed of more formation for inter-professional collaboration</td></tr></table>
adf91701d47b7245ebe6b64c0db09391c82116a89a6c707be2f2db2846313db2.png
complex
<table><tr><td colspan="7">Chroma C* at 8 &#176;C</td></tr><tr><td rowspan="2">Days</td><td colspan="3">Without HPP Treatment</td><td colspan="3">With HPP Treatment</td></tr><tr><td>Control</td><td>PF Film</td><td>PS Film</td><td>Control</td><td>PF Film</td><td>PS Film</td></tr><tr><td>0</td><td>26.99 <sup>A,a</sup> &#177; 2.48</td><td>26.99 <sup>A,a</sup> &#177; 2.48 </td><td>26.99 <sup>A,a</sup> &#177; 2.48</td><td>25.05 <sup>A,a</sup> &#177; 0.87</td><td>25.05 <sup>A,a</sup> &#177; 0.87</td><td>25.05 <sup>A,a</sup> &#177; 0.87</td></tr><tr><td>4</td><td>25.42 <sup>A,a</sup> &#177; 0.06</td><td>26.04 <sup>A,a</sup> &#177; 0.55</td><td>27.81 <sup>A,a</sup> &#177; 1.93 </td><td>25.06 <sup>A,a</sup> &#177; 0.09</td><td>28.38 <sup>A,a</sup> &#177; 3.25</td><td>28.17 <sup>A,a</sup> &#177; 2.42 </td></tr><tr><td>8</td><td>26.34 <sup>A,a</sup> &#177; 1.00</td><td>25.95 <sup>A,a</sup> &#177; 0.81</td><td>28.38 <sup>A,a</sup> &#177; 2.22</td><td>25.68 <sup>A,a</sup> &#177; 0.22</td><td>26.46 <sup>A,a</sup> &#177; 0.46</td><td>28.62 <sup>A,a</sup> &#177; 1.78</td></tr><tr><td>12</td><td>24.95 <sup>A,a</sup> &#177; 0.15</td><td>26.19 <sup>A,a</sup> &#177; 0.31</td><td>28.25 <sup>A,a</sup> &#177; 2.41</td><td>25.24 <sup>A,a</sup> &#177; 0.02</td><td>25.99 <sup>A,a</sup> &#177; 0.77</td><td>28.05 <sup>A,a</sup> &#177; 3.70</td></tr><tr><td>17</td><td>25.42 <sup>A,a</sup> &#177; 0.77</td><td>26.18 <sup>A,a</sup> &#177; 0.31</td><td>27.17 <sup>A,a</sup> &#177; 2.98</td><td>25.35 <sup>A,a</sup> &#177; 0.90</td><td>26.42 <sup>A,a</sup> &#177; 1.11</td><td>27.26 <sup>A,a</sup> &#177; 3.31</td></tr><tr><td>21</td><td>25.19 <sup>A,a</sup> &#177; 0.85</td><td>25.96 <sup>A,a</sup> &#177; 0.34</td><td>27.59 <sup>A,a</sup> &#177; 2.92</td><td>26.02 <sup>A,a</sup> &#177; 1.05</td><td>28.27 <sup>A,a</sup> &#177; 3.10</td><td>24.63 <sup>A,a</sup> &#177; 0.14</td></tr><tr><td>25</td><td>24.91 <sup>A,a</sup> &#177; 0.17</td><td>25.92 <sup>A,a</sup> &#177; 0.32</td><td>26.53 <sup>A,a</sup> &#177; 4.29</td><td>25.42 <sup>A,a</sup> &#177; 1.00</td><td>25.94 <sup>A,a</sup> &#177; 0.61</td><td>28.11 <sup>A,a</sup> &#177; 2.62</td></tr><tr><td>29</td><td>25.86 <sup>A,a</sup> &#177; 1.01</td><td>25.84 <sup>A,a</sup> &#177; 0.31</td><td>27.05 <sup>A,a</sup> &#177; 3.47</td><td>25.09 <sup>A,a</sup> &#177; 0.71</td><td>27.65 <sup>A,a</sup> &#177; 2.65</td><td>24.57 <sup>A,a</sup> &#177; 0.47</td></tr><tr><td>35</td><td>24.88 <sup>A,a</sup> &#177; 1.57 </td><td>25.52 <sup>A,a</sup> &#177; 0.24</td><td>27.46 <sup>A,a</sup> &#177; 2.14</td><td>24.88 <sup>A,a</sup> &#177; 0.08</td><td>25.90 <sup>A,a</sup> &#177; 0.10</td><td>24.43 <sup>A,a</sup> &#177; 0.24</td></tr><tr><td>41</td><td>24.85 <sup>A,a</sup> &#177; 1.60</td><td>24.86 <sup>A,a</sup> &#177; 1.46</td><td>27.48 <sup>A,a</sup> &#177; 2.72</td><td>25.31 <sup>A,a</sup> &#177; 0.59</td><td>25.76 <sup>A,a</sup> &#177; 0.64</td><td>24.75 <sup>A,a</sup> &#177; 1.29</td></tr><tr><td>47</td><td>25.67 <sup>A,a</sup> &#177; 1.50</td><td>25.31 <sup>A,a</sup> &#177; 0.05</td><td>27.83 <sup>A,a</sup> &#177; 1.13</td><td>25.87 <sup>A,a</sup> &#177; 0.38</td><td>25.22 <sup>A,a</sup> &#177; 0.58</td><td>23.66 <sup>A,a</sup> &#177; 0.15</td></tr></table>
f2e0aeab191e719b67b8b39028c8adc1c598d5fcadc7b207c1d2c420b46dd215.png
complex
<table><tr><td>Unigene No.</td><td>Gene name</td><td>Copies</td><td>%*</td></tr><tr><td colspan="4">Fetal pituitary</td></tr><tr><td>Hs.1905</td><td>prolactin+#</td><td>312</td><td>9.46</td></tr><tr><td>Hs.119689</td><td>glycoprotein hormones, alpha +#</td><td>146</td><td>4.43</td></tr><tr><td>Hs.115352</td><td>growth hormone 1+#</td><td>48</td><td>1.46</td></tr><tr><td>Hs.274460</td><td>olfactory receptor 5V1#</td><td>48</td><td>1.46</td></tr><tr><td>Hs.195453</td><td>ribosomal protein S27+#</td><td>24</td><td>0.73</td></tr><tr><td>Hs.75415</td><td>beta-2-microglobulin+#</td><td>22</td><td>0.67</td></tr><tr><td>Hs.70312</td><td>cytochrome c oxidase 7A2+#</td><td>15</td><td>0.46</td></tr><tr><td>Hs.315164</td><td>hypothetical protein#</td><td>14</td><td>0.42</td></tr><tr><td>Hs.83484</td><td>sex determining region Y-box 4#</td><td>8</td><td>0.24</td></tr><tr><td>Hs.7917</td><td>DKFZP564K247 protein#</td><td>7</td><td>0.21</td></tr><tr><td>Hs.273385</td><td>guanine nucleotide binding protein alpha+#</td><td>7</td><td>0.21</td></tr><tr><td>Hs.165590</td><td>ribosomal protein S13#</td><td>7</td><td>0.21</td></tr><tr><td>Hs.131814</td><td>tankyrase#</td><td>7</td><td>0.21</td></tr><tr><td>Hs.173912</td><td>eukaryotic translation initiation factor+</td><td>6</td><td>0.18</td></tr><tr><td>Hs.119222</td><td>suppression of tumorigenicity 13+#</td><td>6</td><td>0.18</td></tr><tr><td>Hs.177530</td><td>ATP synthase+</td><td>5</td><td>0.15</td></tr><tr><td>Hs.177656</td><td>calmodulin 1+</td><td>5</td><td>0.15</td></tr><tr><td>Hs.241429</td><td>cDNA DKFZp586C1923#</td><td>5</td><td>0.12</td></tr><tr><td>Hs.330994</td><td>RAB9#</td><td>4</td><td>0.12</td></tr><tr><td>Hs.46328</td><td>fucosyltransferase 2#</td><td>4</td><td>0.12</td></tr><tr><td colspan="4">Adult pituitary</td></tr><tr><td>Hs.115352</td><td>growth hormone 1+#</td><td>358</td><td>6.09</td></tr><tr><td>Hs.1905</td><td>prolactin+#</td><td>288</td><td>4.9</td></tr><tr><td>Hs.1897</td><td>proopiomelanocortin#</td><td>46</td><td>0.78</td></tr><tr><td>Hs.181165</td><td>eukaryotic translation elongation factor1#</td><td>45</td><td>0.77</td></tr><tr><td>Hs.273385</td><td>guanine nucleotide binding protein AS1+#</td><td>44</td><td>0.75</td></tr><tr><td>Hs.65149</td><td>growth hormone 2#</td><td>42</td><td>0.71</td></tr><tr><td>Hs.279789</td><td>glucose phosphate isomerase#</td><td>41</td><td>0.7</td></tr><tr><td>Hs.119689</td><td>glycoprotein hormones, alpha+#</td><td>37</td><td>0.63</td></tr><tr><td>Hs.77385</td><td>myosin, light polypeptide 6+#</td><td>30</td><td>0.51</td></tr><tr><td>Hs.278959</td><td>galanin-related peptide LOC51083#</td><td>25</td><td>0.43</td></tr><tr><td>Hs.247474</td><td>hypothetical protein FLJ21032#</td><td>21</td><td>0.36</td></tr><tr><td>Hs.180450</td><td>ribosomal protein S24#</td><td>20</td><td>0.34</td></tr><tr><td>Hs.155482</td><td>hydroxyacyl glutathione hydrolase#</td><td>19</td><td>0.32</td></tr><tr><td>Hs.76053</td><td>DEAD/H box polypeptide 5#</td><td>19</td><td>0.32</td></tr><tr><td>Hs.75360</td><td>carboxypeptidase E+#</td><td>18</td><td>0.31</td></tr><tr><td>Hs.112844</td><td>maternally expressed 3#</td><td>16</td><td>0.27</td></tr><tr><td>Hs.117950</td><td>phosphoribosylaminoimidazole carboxylase#</td><td>16</td><td>0.27</td></tr><tr><td>Hs.119598</td><td>ribosomal protein L3#</td><td>16</td><td>0.27</td></tr><tr><td>Hs.5464</td><td>skeletal muscle abundant protein#</td><td>16</td><td>0.27</td></tr><tr><td>Hs.179526</td><td>thioredoxin interacting protein #</td><td>15</td><td>0.26</td></tr></table>
4790eb7044a56aa6742066ede6f95f463b30dae14f8d596ddaa2d0e09f0feb6d.png
simple
<table><tr><td>Variable</td><td>PFNA (<i>n</i> = 72)</td><td>DHS (<i>n</i> = 70)</td><td><i>P</i> value</td></tr><tr><td>Total complications</td><td>15</td><td>31</td><td>0.003</td></tr><tr><td> Patients affected</td><td>15 (20.8%)</td><td>31 (42.9%)</td><td>0.003</td></tr><tr><td>Medical complications</td><td>3</td><td>5</td><td>0.442</td></tr><tr><td> Patients affected</td><td>3 (4.2%)</td><td>5 (7.1%)</td><td>0.442</td></tr><tr><td>Urinary tract infection</td><td>1</td><td>1</td><td>1.000</td></tr><tr><td>Pulmonary embolism</td><td>0</td><td>2</td><td>0.241</td></tr><tr><td>Atrial fibrillation</td><td>2</td><td>0</td><td>0.497</td></tr><tr><td>Acute renal failure</td><td>0</td><td>2</td><td>0.241</td></tr><tr><td>Orthopaedic complications</td><td>12</td><td>26</td><td>0.011</td></tr><tr><td> Patients affected</td><td>12 (16.7%)</td><td>26 (37.1%)</td><td>0.011</td></tr><tr><td>Periprosthetic fracture</td><td>3 (4.2%)</td><td>11 (15.7%)</td><td>0.021</td></tr><tr><td>Prosthetic instability</td><td>1</td><td>2</td><td>0.617</td></tr><tr><td>Dislocation</td><td>1</td><td>3</td><td>0.363</td></tr><tr><td>Limb length discrepancy (&gt;2.5 cm)</td><td>1</td><td>2</td><td>0.617</td></tr><tr><td>Abductor tendon deficiency</td><td>2</td><td>2</td><td>1.000</td></tr><tr><td>Heterotopic ossification</td><td>1</td><td>1</td><td>1.000</td></tr><tr><td>Intraoperative nerve injury</td><td>1</td><td>1</td><td>1.000</td></tr><tr><td>Aseptic loosening</td><td>0</td><td>1</td><td>0.241</td></tr><tr><td>Periprosthetic infection</td><td>2</td><td>2</td><td>1.000</td></tr></table>
a56bdd2457876e0c53975bc81be5c96aa15f16a05bd47f78f7e4eafb59194064.png
simple
<table><tr><td>WHO AFRO SLIPTA Checklist Audit Score Sheet (Section)</td><td>Total Points</td></tr><tr><td>Section 1: Documents &amp; Records</td><td>25</td></tr><tr><td>Section 2: Management Reviews</td><td>17</td></tr><tr><td>Section 3: Organization &amp; Personnel</td><td>20</td></tr><tr><td>Section 4: Client Management &amp; Customer Service</td><td>8</td></tr><tr><td>Section 5: Equipment</td><td>30</td></tr><tr><td>Section 6: Internal Audit</td><td>10</td></tr><tr><td>Section 7: Purchasing and Inventory</td><td>30</td></tr><tr><td>Section 8: Process Control and Internal &amp; External Quality Audit</td><td>33</td></tr><tr><td>Section 9: Information Management</td><td>18</td></tr><tr><td>Section 10: Corrective Action</td><td>12</td></tr><tr><td>Section 11: Occurrence/Incident Management &amp; Process Improvement</td><td>12</td></tr><tr><td>Section 12: Facilities and Safety</td><td>43</td></tr><tr><td>Total Score</td><td>258</td></tr></table>
eaaf5ef211b002e6d45624dd8674d0882ec9a12054b10229d82a040d5955a40c.png
complex
<table><tr><td>Correlate</td><td>OR</td><td>95 % CI</td><td><i>p</i>-value</td></tr><tr><td colspan="4">Socio-demographic factors</td></tr><tr><td colspan="4"> Age</td></tr><tr><td>(base) 18&#8211;29</td><td>1.00</td><td></td><td></td></tr><tr><td>30&#8211;39</td><td>0.95</td><td>0.77,1.17</td><td>0.613</td></tr><tr><td>40&#8211;49</td><td>1.12</td><td>0.92,1.38</td><td>0.263</td></tr><tr><td>50&#8211;55</td><td>1.11</td><td>0.88,1.40</td><td>0.370</td></tr><tr><td> <i>Married/</i><i>de facto</i></td><td><i>0.69</i></td><td><i>0.58, 0.81</i></td><td><i>0.000</i></td></tr><tr><td colspan="4"> Socioeconomic disadvantage<sup>a</sup></td></tr><tr><td>(base) 1st quintile</td><td>1.00</td><td></td><td></td></tr><tr><td>2nd quintile</td><td>1.09</td><td>0.87,1.35</td><td>0.456</td></tr><tr><td>3rd quintile</td><td>0.90</td><td>0.73,1.11</td><td>0.330</td></tr><tr><td>4th quintile</td><td>0.97</td><td>0.78,1.21</td><td>0.819</td></tr><tr><td><i>5th quintile</i></td><td><i>0.73</i></td><td><i>0.58,0.93</i></td><td><i>0.010</i></td></tr><tr><td colspan="4">Clinical factors</td></tr><tr><td> <i>Depression (12 month)</i></td><td><i>4.49</i></td><td><i>3.74,5.40</i></td><td><i>0.000</i></td></tr><tr><td> <i>Anxiety (12 month)</i></td><td><i>1.27</i></td><td><i>1.02,1.57</i></td><td><i>0.025</i></td></tr><tr><td> <i>Alcohol Harmful/Hazardous Use</i></td><td><i>1.38</i></td><td><i>1.20,1.59</i></td><td><i>0.000</i></td></tr><tr><td colspan="4">Life Events (12 month)</td></tr><tr><td> <i>Serious personal injury</i></td><td><i>1.27</i></td><td><i>1.07,1.51</i></td><td><i>0.006</i></td></tr><tr><td> <i>Relationship end</i></td><td><i>1.46</i></td><td><i>1.18,1.80</i></td><td><i>0.001</i></td></tr><tr><td> <i>Family conflict</i></td><td><i>1.95</i></td><td><i>1.64,2.32</i></td><td><i>0.000</i></td></tr><tr><td> <i>Difficulty finding work</i></td><td><i>1.95</i></td><td><i>1.65,2.39</i></td><td><i>0.000</i></td></tr><tr><td> <i>Legal troubles</i></td><td><i>1.27</i></td><td><i>1.00,1.60</i></td><td><i>0.046</i></td></tr><tr><td> <i>Loss of personal property</i></td><td><i>1.66</i></td><td><i>1.23,2.23</i></td><td><i>0.001</i></td></tr></table>
d5c196793d500ddbd135e7e4b663cedad54e5b8efe36a15542c74193966fa1fe.png
simple
<table><tr><td></td><td>Left hemisphere</td><td>Right hemisphere</td></tr><tr><td>V1</td><td></td><td></td></tr><tr><td>Smooth objects</td><td>0.92 &#177; 0.09</td><td>0.82 &#177; 0.09</td></tr><tr><td>Textured objects</td><td>1.63 &#177; 0.11</td><td>1.50 &#177; 0.13</td></tr><tr><td>V2</td><td></td><td></td></tr><tr><td>Smooth objects</td><td>0.92 &#177; 0.06</td><td>0.88 &#177; 0.06</td></tr><tr><td>Textured objects</td><td>1.33 &#177; 0.07</td><td>1.28 &#177; 0.09</td></tr><tr><td>V3</td><td></td><td></td></tr><tr><td>Smooth objects</td><td>0.98 &#177; 0.09</td><td>0.92 &#177; 0.06</td></tr><tr><td>Textured objects</td><td>1.26 &#177; 0.11</td><td>1.18 &#177; 0.09</td></tr><tr><td>LOC</td><td></td><td></td></tr><tr><td>Smooth objects</td><td>0.99 &#177; 0.09</td><td>1.00 &#177; 0.08</td></tr><tr><td>Textured objects</td><td>0.81 &#177; 0.09</td><td>0.82 &#177; 0.06</td></tr><tr><td>FFA</td><td></td><td></td></tr><tr><td>Smooth objects</td><td>0.96 &#177; 0.17</td><td>1.10 &#177; 0.10</td></tr><tr><td>Textured objects</td><td>0.79 &#177; 0.19</td><td>1.05 &#177; 0.15</td></tr></table>
86496f27884e5e8ff74e7da31f7c6e64679ee9d1c0f78294521fa57b6ab18bb1.png
complex
<table><tr><td colspan="2">Parameter</td><td>UM</td><td>SM</td><td>Total</td><td>RR (95% CI)</td><td><i>p</i>-value</td><td>&#967;<sup>2</sup></td><td><i>p</i>-value</td></tr><tr><td rowspan="4">Age</td><td>&lt;60</td><td>64 (61.5)</td><td>40 (38.5)</td><td>104 (42.7)</td><td>2.2 (1.3&#8211;3.7)</td><td>0.003</td><td rowspan="4">9.326</td><td rowspan="4">0.009</td></tr><tr><td>60&#8211;119</td><td>65 (82.3)</td><td>14 (17.7)</td><td>79 (33.1)</td><td>1.00</td><td></td></tr><tr><td>120+</td><td>42 (71.2)</td><td>17 (28.8)</td><td>59 (24.2)</td><td>1.6 (0.8&#8211;3.0)</td><td>0.150</td></tr><tr><td>Total</td><td>171 (70.7)</td><td>71 (29.3)</td><td>242</td><td></td><td></td></tr><tr><td rowspan="3">Gender</td><td>Male</td><td>85 (68.6)</td><td>39 (31.5)</td><td>124 (51.5)</td><td>1.2 (0.8&#8211;1.7)</td><td>0.483</td><td rowspan="3">0.548</td><td rowspan="3">0.459</td></tr><tr><td>Female</td><td>86 (72.9)</td><td>32 (27.1)</td><td>118 (48.5)</td><td></td><td></td></tr><tr><td>Total</td><td>171 (70.7)</td><td>71 (29.3)</td><td>242</td><td></td><td></td></tr><tr><td rowspan="6">Study sites</td><td>Bamenda</td><td>33 (71.7)</td><td>13 (28.3)</td><td>46 (19.0)</td><td>1.3 (0.7&#8211;2.4)</td><td>0.523</td><td rowspan="6">5.540</td><td rowspan="6">0.236</td></tr><tr><td>Limbe</td><td>67 (77.9)</td><td>19 (22.1)</td><td>86 (36.0)</td><td>1.00</td><td></td></tr><tr><td>Yaounde</td><td>39 (62.9)</td><td>23 (37.1)</td><td>62 (25.6)</td><td>1.7 (1.0&#8211;2.8)</td><td>0.064</td></tr><tr><td>Maroua</td><td>11 (57.9)</td><td>8 (42.1)</td><td>19 (7.9)</td><td>1.9 (1.0&#8211;3.7)</td><td>0.086</td></tr><tr><td>Ngaoundere</td><td>21 (72.4)</td><td>8 (27.6)</td><td>29 (12.4)</td><td>1.3 (0.6&#8211;2.5)</td><td>0.614</td></tr><tr><td>Total</td><td>171 (70.7)</td><td>71 (29.3)</td><td>242</td><td></td><td></td></tr></table>
f192539ddee8d0bf62253ac1c9512532e264150d2463124d777e3fbd5aceea1b.png
simple
<table><tr><td>Study</td><td>Main perspective</td><td>Subject</td><td>Method</td></tr><tr><td>Hansen, Hegrenes, Larsen, Sehested, &amp; Stokstad, 2005</td><td>Biological Economic</td><td>Financial impact of technical herd performance indicators</td><td>Mathematical and statistical modelling</td></tr><tr><td>Kristensen, &#216;stergaard, Krogh, &amp; Enevoldsen, 2007</td><td>Biological Economic</td><td>Financial impact of technical herd performance indicators</td><td>Mathematical modelling</td></tr><tr><td>Kristensen &amp; Enevoldsen, 2008</td><td>Managerial</td><td>Farmers&#8217; goals, beliefs attitudes and behaviour</td><td>Interviews and survey</td></tr><tr><td>Kristensen, Nielsen, Jensen, Vaarst, &amp; Enevoldsen, 2008</td><td>Biological Managerial</td><td>Risk for metritis. Veterinarians perceptions and decision making</td><td>Interviews combined with quantitative analysis of herd data</td></tr><tr><td>Jansen, van den Borne, Renes, van Schaik, Lam, &amp; Leeuwis, 2009</td><td>Biological Managerial</td><td>Farmers&#8217; attitudes and behaviour</td><td>Survey</td></tr><tr><td>Lastein, Vaarst, &amp; Enevoldsen, 2009</td><td>Managerial</td><td>Veterinarians&#8217; perceptions and decision making</td><td>Field observations and interviews</td></tr><tr><td>Vaarst &amp; Tind S&#248;rensen, 2009</td><td>Biological Managerial</td><td>Dairy farmers&#8217; perceptions and attitudes related to calf management</td><td>Semi-structured interviews</td></tr><tr><td>Van Asseldonk, Renes, Lam, &amp; Hogeveen, 2010</td><td>Managerial</td><td>Farmers&#8217; perceptions, intentions, actions and decision makings</td><td>Interviews</td></tr></table>
862f5e92e2fc2c379835e45541620bb51d3adf9ee2d0422b906d50690110fe15.png
simple
<table><tr><td>Illumina cg ID</td><td>Chromosome</td><td>Genomic location</td><td>Gene<sup>a</sup></td><td>Gene region</td><td>HR (95 % CI)<sup>b</sup></td><td><i>P</i> value</td></tr><tr><td>cg15786837</td><td>17</td><td>46806935</td><td><i>HOXB13</i></td><td>TSS1500</td><td>1.86 (1.37&#8211;2.53)</td><td>6.97E-05</td></tr><tr><td>cg22030072</td><td>2</td><td>119603673</td><td><i>EN1</i></td><td>Body</td><td>3.61 (1.90&#8211;6.88)</td><td>9.54E-05</td></tr><tr><td>cg13604794</td><td>17</td><td>48050338</td><td><i>DLX4</i></td><td>Body</td><td>1.92 (1.37&#8211;2.69)</td><td>1.47E-04</td></tr><tr><td>cg18944010</td><td>1</td><td>119522855</td><td><i>TBX15</i></td><td>5&#8242;UTR</td><td>2.12 (1.43&#8211;3.15)</td><td>1.88E-04</td></tr><tr><td>cg01002529</td><td>3</td><td>69591807</td><td></td><td></td><td>2.35 (1.50&#8211;3.70)</td><td>2.23E-04</td></tr><tr><td>cg08261841</td><td>7</td><td>142982463</td><td><i>TMEM139</i></td><td>5&#8242;UTR</td><td>0.56 (0.41&#8211;0.77)</td><td>2.82E-04</td></tr><tr><td>cg02926307</td><td>12</td><td>106520198</td><td><i>NUAK1</i></td><td>Body</td><td>0.40 (0.25&#8211;0.67)</td><td>3.60E-04</td></tr><tr><td>cg05075579</td><td>11</td><td>121421206</td><td><i>SORL1</i></td><td>Body</td><td>3.60 (1.77&#8211;7.30)</td><td>3.99E-04</td></tr><tr><td>cg15350661</td><td>12</td><td>322641</td><td><i>SLC6A12</i></td><td>5&#8242;UTR</td><td>2.31 (1.45&#8211;3.70)</td><td>4.10E-04</td></tr><tr><td>cg02770983</td><td>11</td><td>31822341</td><td><i>PAX6</i></td><td>Body</td><td>2.11 (1.39&#8211;3.19)</td><td>4.66E-04</td></tr><tr><td>cg00232535</td><td>7</td><td>5593287</td><td></td><td></td><td>0.47 (0.30&#8211;0.72)</td><td>4.79E-04</td></tr><tr><td>cg18343474</td><td>1</td><td>229566908</td><td></td><td></td><td>1.93 (1.33&#8211;2.80)</td><td>4.87E-04</td></tr><tr><td>cg00725138</td><td>22</td><td>19716556</td><td></td><td></td><td>0.50 (0.34&#8211;0.74)</td><td>5.34E-04</td></tr><tr><td>cg03695909</td><td>X</td><td>47346601</td><td></td><td></td><td>0.30 (0.15&#8211;0.59)</td><td>5.49E-04</td></tr><tr><td>cg26236177</td><td>14</td><td>61110649</td><td></td><td></td><td>1.77 (1.28&#8211;2.44)</td><td>5.60E-04</td></tr><tr><td>cg13434989</td><td>13</td><td>78493305</td><td><i>EDNRB</i></td><td>TSS1500</td><td>1.83 (1.30&#8211;2.58)</td><td>5.67E-04</td></tr><tr><td>cg24006505</td><td>6</td><td>41337238</td><td></td><td></td><td>1.95 (1.33&#8211;2.58)</td><td>6.04E-04</td></tr><tr><td>cg04636194</td><td>X</td><td>49594154</td><td><i>PAGE4</i></td><td>5&#8242;UTR</td><td>0.43 (0.27&#8211;0.70)</td><td>6.07E-04</td></tr><tr><td>cg23429749</td><td>14</td><td>102050815</td><td></td><td></td><td>0.47 (0.31&#8211;0.73)</td><td>6.12E-04</td></tr><tr><td>cg05231018</td><td>17</td><td>46806763</td><td><i>HOXB13</i></td><td>TSS1500</td><td>1.70 (1.25&#8211;2.29)</td><td>6.18E-04</td></tr><tr><td>cg02492708</td><td>16</td><td>2005062</td><td><i>RPL3L</i></td><td>TSS1500</td><td>0.50 (0.34&#8211;0.75)</td><td>6.24E-04</td></tr><tr><td>cg21211271</td><td>1</td><td>6265071</td><td><i>RNF207</i></td><td>TSS1500</td><td>2.37 (1.44&#8211;3.90)</td><td>6.48E-04</td></tr><tr><td>cg16009714</td><td>17</td><td>70241415</td><td></td><td></td><td>3.48 (1.70&#8211;7.12)</td><td>6.60E-04</td></tr><tr><td>cg00321709</td><td>10</td><td>135341933</td><td><i>CYP2E1</i></td><td>Body</td><td>2.04 (1.35&#8211;3.08)</td><td>6.69E-04</td></tr><tr><td>cg20401252</td><td>2</td><td>5834062</td><td><i>SOX11</i></td><td>1stExon</td><td>1.90 (1.31&#8211;2.73)</td><td>6.70E-04</td></tr><tr><td>cg19827511</td><td>14</td><td>93580644</td><td><i>ITPK1</i></td><td>Body</td><td>0.56 (0.39&#8211;0.78)</td><td>6.86E-04</td></tr><tr><td>cg10827488</td><td>11</td><td>113953838</td><td><i>ZBTB16</i></td><td>Body</td><td>3.42 (1.68&#8211;6.96)</td><td>6.97E-04</td></tr><tr><td>cg04327247</td><td>9</td><td>100564659</td><td></td><td></td><td>0.50 (0.34&#8211;0.75)</td><td>7.84E-04</td></tr><tr><td>cg26511386</td><td>7</td><td>142982262</td><td><i>TMEM139</i></td><td>5&#8242;UTR</td><td>0.52 (0.36&#8211;0.76)</td><td>8.02E-04</td></tr><tr><td>cg00332067</td><td>12</td><td>55004429</td><td><i>GLYCAM1</i></td><td>TSS200</td><td>2.10 (1.36&#8211;3.24)</td><td>8.30E-04</td></tr></table>
53f9dd1a7e9374a106d38d4b7f8b64879ac9be99661cbbd0ba04b2565e785a68.png
simple
<table><tr><td>Parameter</td><td>Value</td><td>Parameter</td><td>Value</td></tr><tr><td>Radio chip</td><td>CC 2420</td><td>TsRxWait</td><td>2.2 ms</td></tr><tr><td>Transmit power (0 dBm)</td><td>57.42 mW</td><td>TsAck (26 bytes)</td><td>0.832 ms</td></tr><tr><td>Receive power</td><td>62.04 mW</td><td>TsCCA</td><td>0.128 ms</td></tr><tr><td>Listen power</td><td>62.04 mW</td><td>TsRxTx (TxRx turnaround)</td><td>0.192 ms</td></tr><tr><td>TsMaxPacket (133 bytes)</td><td>4.256 ms</td><td></td><td></td></tr></table>
8e7283b62387965d56efc301862b2d42730e429c1820729bb6d49ad17b7d777d.png
simple
<table><tr><td></td><td>RD CsA (<i>n</i> = 99)</td><td>ST CsA (<i>n</i> = 100)</td></tr><tr><td>Everolimus dose (mg/day)</td><td></td><td></td></tr><tr><td>Month 1</td><td>1.3 &#177; 0.5</td><td>1.4 &#177; 0.6</td></tr><tr><td>Month 6</td><td>1.4 &#177; 0.6</td><td>1.3 &#177; 0.5</td></tr><tr><td>Everolimus trough concentration (ng/mL)</td><td></td><td></td></tr><tr><td>Month 1</td><td>5.8 &#177; 3.6</td><td>5.8 &#177; 2.5</td></tr><tr><td>Month 6</td><td>4.8 &#177; 1.7</td><td>5.3 &#177; 2.3</td></tr><tr><td>Cyclosporine dose (mg/kg/day)</td><td></td><td></td></tr><tr><td>Month 1</td><td>3.8 &#177; 1.3</td><td>4.0 &#177; 1.4</td></tr><tr><td>Month 6</td><td>2.5 &#177; 1.0</td><td>2.8 &#177; 0.8</td></tr><tr><td>Cyclosporine trough concentration (ng/mL)</td><td></td><td></td></tr><tr><td>Months 1-2</td><td>195 &#177; 78</td><td>209 &#177; 87</td></tr><tr><td>Month 6</td><td>120 &#177; 63</td><td>154 &#177; 68</td></tr><tr><td>Cyclosporine C<sub>2</sub> concentration (ng/mL)</td><td></td><td></td></tr><tr><td>Months 1-2</td><td>742 &#177; 272</td><td>693 &#177; 244</td></tr><tr><td>Month 6</td><td>566 &#177; 278</td><td>707 &#177; 284</td></tr><tr><td>Steroid dose<sup>a</sup></td><td>0.50 &#177; 1.40</td><td>0.32 &#177; 0.25</td></tr><tr><td>Induction therapy</td><td></td><td></td></tr><tr><td>Antithymocyte globulin</td><td>60 (60.6%)</td><td>61 (61.0%)</td></tr><tr><td>Interleukin-2 receptor antagonist</td><td>21 (21.2%)</td><td>20 (20.0%)</td></tr></table>
7d5006dd02e7d169db2f20b697fa6adc5c5e29c8fcf5267bbe63a00bdfc561be.png
simple
<table><tr><td></td><td>Overall, n (%) n = 1096</td><td>Male n (%) n = 460 (42.0)</td><td>Female n (%) n = 636 (58.0)</td><td><i>p</i>-Value</td></tr><tr><td>Age in years</td><td></td><td></td><td></td><td></td></tr><tr><td> 10&#8211;12</td><td>635 (57.9)</td><td>259 (56.3)</td><td>376 (59.1)</td><td></td></tr><tr><td> 13&#8211;14</td><td>461 (42.1)</td><td>201 (43.7)</td><td>260 (40.9)</td><td>0.351</td></tr><tr><td>Pubertal age (Tanner 1&#8211;5)</td><td></td><td></td><td></td><td></td></tr><tr><td> Tanner 1 or 2</td><td>509 (46.4)</td><td>217 (47.2)</td><td>292 (45.9)</td><td>1</td></tr><tr><td> Tanner stage &gt;2 </td><td>584 (53.6)</td><td>243 (52.8)</td><td>344 (54.1)</td><td></td></tr><tr><td>Education level</td><td></td><td></td><td></td><td></td></tr><tr><td> Primary 5</td><td>563 (51.4)</td><td>240 (52.2)</td><td>323 (50.8)</td><td></td></tr><tr><td> Primary 6</td><td>533 (48.6)</td><td>220 (47.8)</td><td>313 (49.2)</td><td>0.650</td></tr><tr><td>Socio-economic status</td><td></td><td></td><td></td><td></td></tr><tr><td> Low</td><td>315 (29.0)</td><td>128 (28.2)</td><td>187 (29.6)</td><td></td></tr><tr><td> Medium</td><td>511 (47.1)</td><td>215 (47.4)</td><td>296 (46.8)</td><td></td></tr><tr><td> High</td><td>260 (23.9)</td><td>111 (24.4)</td><td>149 (23.6)</td><td>0.871</td></tr><tr><td>Religion</td><td></td><td></td><td></td><td></td></tr><tr><td> Moslem</td><td>101 (9.2)</td><td>48 (10.5)</td><td>53 (8.3)</td><td></td></tr><tr><td> Anglican/Pentecostal</td><td>587 (53.7)</td><td>245 (53.5)</td><td>342 (53.9)</td><td></td></tr><tr><td> Catholic</td><td>405 (37.1)</td><td>165 (36.0)</td><td>240 (37.8)</td><td>0.462</td></tr><tr><td>Family and school factors</td><td></td><td></td><td></td><td></td></tr><tr><td>Location of school</td><td></td><td></td><td></td><td></td></tr><tr><td> Rural</td><td>896 (81.8)</td><td>368 (80)</td><td>529 (83.2)</td><td></td></tr><tr><td> Urban</td><td>199 (18.2)</td><td>92 (20)</td><td>107 (16.8)</td><td>0.178</td></tr><tr><td> School absenteeism (truancy)</td><td>249 (22.7)</td><td>100 (21.7)</td><td>149 (23.4)</td><td>0.510</td></tr><tr><td> Ever experienced bullying at school</td><td>79 (17.3)</td><td>119 (18.7)</td><td>198 (18.1)</td><td>0.528</td></tr><tr><td>Number of parents alive</td><td></td><td></td><td></td><td></td></tr><tr><td> Both alive</td><td>905 (82.5)</td><td>378 (82.2)</td><td>527 (82.8)</td><td></td></tr><tr><td> None/Single parent</td><td>124 (11.3)</td><td>48 (10.4)</td><td>76 (12.0)</td><td>0.350</td></tr><tr><td>Access to media (TV, Social media or Tabloids) </td><td></td><td></td><td></td><td></td></tr><tr><td> Television</td><td>458 (41.8)</td><td>217(47.3)</td><td>241 (37.9)</td><td>0.002</td></tr><tr><td> Tabloid newspapers</td><td>222 (20.3)</td><td>125 (27.2)</td><td>97 (15.3)</td><td>&lt;0.0001</td></tr><tr><td> Social media </td><td>70 (6.4)</td><td>27 (5.9)</td><td>43 (6.8)</td><td>0.558</td></tr><tr><td> Ever watched pornographic content</td><td>389 (35.5)</td><td>191 (41.5)</td><td>198 (31.2)</td><td>&lt;0.0001</td></tr><tr><td>Sexual behavior</td><td></td><td></td><td></td><td></td></tr><tr><td> Ever had sex</td><td>83 (7.6)</td><td>67 (14.6)</td><td>16 (2.5)</td><td>&lt;0.0001</td></tr></table>
1f092d40640a75802a3954fa77e9f76bec4fd46eb789c0b2386ee4e890a2dae2.png
complex
<table><tr><td>Features</td><td colspan="4">Missense mutations identified as divergent variants based on the analysis of whole-genome sequence datasets from Churra and Australian Merino samples</td></tr><tr><td>SNP position (Oar_v3.1)</td><td>52,429,848</td><td>37,308,727</td><td>37,3557,21</td><td>37,356,400</td></tr><tr><td>Chromosome</td><td>2</td><td>6</td><td>6</td><td>6</td></tr><tr><td>dbSNP_ID</td><td><i>rs160159505</i></td><td><i>rs159958168</i></td><td><i>rs419074913</i></td><td><i>rs159958380</i></td></tr><tr><td>Gene</td><td><i>NPR2</i></td><td><i>NCAPG</i></td><td><i>LCORL</i><sup>a</sup></td><td><i>LCORL</i><sup>a</sup></td></tr><tr><td>Ref. (Texel Oar_v3.1) &#8594; Alt<sup>b</sup></td><td>T &#8594; C</td><td>C &#8594; T</td><td>T &#8594; A</td><td>A &#8594; T</td></tr><tr><td>Position in CDS</td><td>c.2540</td><td>c.1754</td><td>c.4321<sup>c</sup></td><td>c.3642<sup>c</sup></td></tr><tr><td>Base pair substitution in CDS</td><td>T &#8594; C</td><td>C &#8594; T</td><td>A &#8594; T</td><td>T &#8594; A</td></tr><tr><td>Breed (mutant allele)<sup>d</sup></td><td>Merino</td><td>Merino</td><td>Churra</td><td>Merino</td></tr><tr><td>Codon change</td><td>cAc &#8594; cGc</td><td>TCC &#8594; TTC</td><td>ATA &#8594; TTA</td><td>GAT &#8594; GAA</td></tr><tr><td>Amino acid change</td><td>Histitine (H) &#8594; Arginine (R)</td><td>Serine (S)&#8594; Phenilalanine (F)</td><td>Isoleucine (I)&#8594; Leucine (L)</td><td>Aspartate (D) &#8594; Glutamate (E)</td></tr><tr><td>Protein change</td><td><i>NPR2_His847Arg</i></td><td><i>NCAPG_Ser585Phe</i></td><td><i>LCORL_Ile1441Leu</i></td><td><i>LCORL_Asp1214Glu</i></td></tr><tr><td>Functional impact (ensemblVEP_Oarv3.1)</td><td>Moderate</td><td>Moderate</td><td>Moderate</td><td>Moderate</td></tr><tr><td>Functional impact (Polyphen-2)</td><td>Benign</td><td>Benign (score = 0.252; sensitivity: 0.91; specificity: 0.88)</td><td>Benign</td><td>Benign</td></tr><tr><td>Functional impact (SIFT_Oarv3.1)</td><td>Tolerated</td><td>Deleterious</td><td>Tolerated (low confidence)</td><td>Tolerated</td></tr><tr><td>Properties of wild aminoacid</td><td>Moderate hydropathy, charge &#8220;+&#8221;</td><td>Hydrophilic, polar, no charge</td><td>Hydrophobic, no charge</td><td>Hydrophilic, charge &#8220;&#8722;&#8221;</td></tr><tr><td>Properties of mutant aminoacid</td><td>Hydrophilic, charge &#8220;+&#8221;</td><td>Hydrophobic, apolar, no charge</td><td>Hydrophobic, no charge</td><td>Hydrophilic,, charge &#8220;&#8722;&#8221;</td></tr><tr><td>Churra genotypes</td><td>TT (15)</td><td>CC (14), CT (1)</td><td>AT (1), TT (14)</td><td>AA (14), AT (1)</td></tr><tr><td>Australian Merino genotypes</td><td>CC (9), TC (4)</td><td>TT (9), TC (3), CC (1)</td><td>AA (9), AT (3), TT (1)</td><td>TT (9), TA (3), AA (1)</td></tr></table>
ba45bc2ec25ab07b7bb2150af4a9c90a351b622ac728ea76916d1dc14de52eb6.png
complex
<table><tr><td rowspan="2">SNPs</td><td rowspan="2">Alleles</td><td>CAD</td><td>Control</td><td rowspan="2">OR</td><td rowspan="2">95% CI</td><td rowspan="2"><i>p</i></td></tr><tr><td><i>n</i> (%)</td><td><i>n</i> (%)</td></tr><tr><td rowspan="2">rs6510599</td><td>C</td><td>324 (59.3)</td><td>157 (56.5)</td><td rowspan="2">1.125</td><td rowspan="2">0.840&#8211;1.507</td><td rowspan="2">0.455</td></tr><tr><td>T</td><td>222 (40.7)</td><td>121 (43.5)</td></tr><tr><td rowspan="2"> rs35369365</td><td>G</td><td>182 (35.5)</td><td>96 (32.8)</td><td rowspan="2">1.172</td><td rowspan="2">0.866&#8211;1.586</td><td rowspan="2">0.320</td></tr><tr><td>A</td><td>330 (64.5)</td><td>204 (67.2)</td></tr><tr><td rowspan="2">rs9282860</td><td>T</td><td>76 (13.7)</td><td>40 (13.9)</td><td rowspan="2">1.014</td><td rowspan="2">0.672&#8211;1.532</td><td rowspan="2">1.000</td></tr><tr><td>C</td><td>478 (86.3)</td><td>248 (86.1)</td></tr><tr><td rowspan="2">rs3764640</td><td>G</td><td>176 (35.9)</td><td>104 (38.2)</td><td rowspan="2">1.104</td><td rowspan="2">0.813&#8211;1.500</td><td rowspan="2">0.531</td></tr><tr><td>T</td><td>314 (64.1)</td><td>168 (61.8)</td></tr><tr><td rowspan="2">rs12977689</td><td>C</td><td>341 (65.1)</td><td>199 (70.6)</td><td rowspan="2">1.287</td><td rowspan="2">0.941&#8211;1.759</td><td rowspan="2">0.117</td></tr><tr><td>A</td><td>183 (34.9)</td><td>83 (29.4)</td></tr></table>
ae605bf9827c48a61d3f2a2bc3d37ebf376b7fafbb1f9f2b4f2d0aa6043679e4.png
complex
<table><tr><td rowspan="2">Predictors of analgesia/sedation</td><td colspan="2">Univariate</td><td colspan="2">Multivariate</td></tr><tr><td><i>p</i>-value</td><td>OR (95% CI)</td><td><i>p</i>-value</td><td>OR (95% CI)</td></tr><tr><td>Gestational age (weeks) &#8804;32</td><td>&lt;.0001</td><td>3.54 (2.15&#8211;5.83)</td><td></td><td></td></tr><tr><td>CRIB score</td><td>&lt;.0001</td><td>2.03 (1.66&#8211;2.48)</td><td>0.0002</td><td>1.46 (1.20&#8211;1.77)</td></tr><tr><td>Asphyxia, APGAR &lt;5 at 5&#8217;</td><td>&lt;.0001</td><td>33.17 (6.17&#8211;178.29)</td><td></td><td></td></tr><tr><td>Sex, female</td><td>0.2999</td><td>0.78 (0.49&#8211;1.25)</td><td></td><td></td></tr><tr><td>Born in same hospital as NICU</td><td>0.0307</td><td>0.497 (0.26&#8211;0.96)</td><td></td><td></td></tr><tr><td>Type of ventilation</td><td></td><td></td><td></td><td></td></tr><tr><td> Invasive vs Spontaneous</td><td rowspan="2">&lt;.0001</td><td>117.16 (43.88&#8211;312.82)</td><td rowspan="2">&lt;.0001</td><td>62.59 (22.01&#8211;177.97)</td></tr><tr><td> Noninvasive vs Spontaneous</td><td>2.61 (1.14&#8211;5.98)</td><td>2.60 (1.02&#8211;6.61)</td></tr><tr><td>Use of pain scales</td><td>&lt;.0001</td><td>19.04 (5.92&#8211;61.19)</td><td>0.0046</td><td>5.38 (1.69&#8211;17.16)</td></tr><tr><td>Pain specialist physician</td><td>0.2891</td><td>0.50 (0.14 &#8211; 1.81)</td><td></td><td></td></tr><tr><td>Pain specialist nurse</td><td>0.1111</td><td>0.41 (0.14&#8211;1.23)</td><td></td><td></td></tr><tr><td>Pain management team</td><td>0.4972</td><td>1.42 (0.52&#8211;3.91)</td><td></td><td></td></tr><tr><td>Local guidelines for pain assessment</td><td>0.8953</td><td>1.10 (0.27&#8211;4.55)</td><td></td><td></td></tr><tr><td>NICU beds (&#8804; 15 beds vs &gt;15 beds)</td><td>0.0089</td><td>3.68 (1.39&#8211;9.77)</td><td>0.0372</td><td>3.55 (1.08&#8211;11.69)</td></tr><tr><td>Number of NICU admission</td><td>0.0677</td><td>0.99 (0.98&#8211;1.00)</td><td></td><td></td></tr></table>
a836f240fc6017bb8b4f400a2abecf013bcf0e7ccbb08a5e0864e9d10d957a42.png
complex
<table><tr><td></td><td colspan="3">Control (<i>n</i> = 10)</td><td colspan="3">TP4 (<i>n</i> = 10)</td></tr><tr><td>Time (Day)</td><td>1</td><td>3</td><td>6</td><td>1</td><td>3</td><td>6</td></tr><tr><td>GOT (U/L)</td><td>42.1 &#177; 1.3 <sup>A</sup></td><td>44.2 &#177; 2.1 <sup>A</sup></td><td>41.6 &#177; 1.5 <sup>A</sup></td><td>102.1 &#177; 32.1 <sup>C</sup></td><td>43.2 &#177; 1.5 <sup>A</sup></td><td>45 &#177; 6.1 <sup>A</sup></td></tr><tr><td>GPT (U/L)</td><td>45.2 &#177; 1.1 <sup>A</sup></td><td>43.4 &#177; 4.3 <sup>A</sup></td><td>46.1 &#177; 3.3 <sup>A</sup></td><td>81.2 &#177; 5.2 <sup>C</sup></td><td>41.2 &#177; 4.7 <sup>A</sup></td><td>48 &#177; 3.7 <sup>A</sup></td></tr><tr><td>CRE (mg/dL)</td><td>0.2 &#177; 0.1 <sup>A</sup></td><td>0.6 &#177; 0.3 <sup>A</sup></td><td>0.4 &#177; 0.2 <sup>A</sup></td><td>0.3 &#177; 0.1 <sup>A</sup></td><td>0.5 &#177; 0.1 <sup>A</sup></td><td>0.5 &#177; 0.1 <sup>A</sup></td></tr><tr><td>BUN (mg/dL)</td><td>13.1 &#177; 2.1 <sup>A</sup></td><td>14 &#177; 0.3 <sup>AB</sup></td><td>16.1 &#177; 1 <sup>A</sup></td><td>14.2 &#177; 1.4 <sup>A</sup></td><td>15.4 &#177; 1.3 <sup>A</sup></td><td>16.2 &#177; 1 <sup>A</sup></td></tr><tr><td>GLU (mg/dL)</td><td>206.0 &#177; 11.1 <sup>A</sup></td><td>213.1 &#177; 11.3 <sup>A</sup></td><td>208 &#177; 13.1 <sup>A</sup></td><td>238.6 &#177; 32.1 <sup>AB</sup></td><td>209.1 &#177; 7.2 <sup>A</sup></td><td>220.1 &#177; 23.5 <sup>A</sup></td></tr><tr><td>CPK (U/L)</td><td>101.3 &#177; 1.7 <sup>A</sup></td><td>110.1 &#177;6.3 <sup>A</sup></td><td>104.9 &#177; 4.2 <sup>A</sup></td><td>109 &#177; 11.1 <sup>A</sup></td><td>108.1 &#177; 3.2 <sup>A</sup></td><td>109 &#177; 25.3 <sup>AB</sup></td></tr></table>
bb6dfe6c6a1c91865b69248672f6f2d7ba914f47f5cb8b75403d172365a73ebc.png
complex
<table><tr><td>Condition</td><td>Number (%) of cases</td><td colspan="2">Mean number of coded diagnoses by coding volume</td><td colspan="2">Mean number of coded diagnoses by employment status</td><td colspan="2">Hospital level</td></tr><tr><td></td><td></td><td>Low</td><td>High</td><td>Part time</td><td>Full time</td><td>Non tertiary</td><td>Tertiary</td></tr><tr><td><i>Most complex</i>Diabetes with complications</td><td>2007(0.5%)</td><td>7.9</td><td>7.9</td><td>7.7</td><td>7.9</td><td>7.0</td><td>9.5</td></tr><tr><td>Alcohol abuse</td><td>2511(0.6%)</td><td>5.3</td><td>5.4</td><td>5.6</td><td>5.3</td><td>5.1</td><td>5.9</td></tr><tr><td>Diabetes uncomplicated</td><td>1802(0.4%)</td><td>5.0</td><td>4.9</td><td>4.4</td><td>5.2</td><td>4.4</td><td>6.8</td></tr><tr><td>Depression</td><td>5860(1.4%)</td><td>4.4</td><td>4.3</td><td>4.7</td><td>4.2</td><td>4.2</td><td>4.7</td></tr><tr><td>Calculus of ureter</td><td>3616(0.9%)</td><td>1.5</td><td>1.7</td><td>1.5</td><td>1.7</td><td>1.6</td><td>1.4</td></tr><tr><td>Singleton born in hospital<i>Least Complex</i></td><td>38,307(9.1)</td><td>1.3</td><td>1.6</td><td>1.5</td><td>1.2</td><td>1.6</td><td>1.1</td></tr></table>
d668c2c12b756fbbfaf75e637b0c8575ffbe3ef04b9f7e1768b07ecd447e198e.png
simple
<table><tr><td><i>Campylobacter</i> phage</td><td>CP68</td><td>CP75</td><td>CP84</td><td>CP7</td><td>CP83</td><td>CP21</td><td>IBB_35 <sup>a</sup></td></tr><tr><td>Infected strains</td><td>31 (255)</td><td>30 (255)</td><td>34 (255)</td><td>19 (255)</td><td>15 (255)</td><td>17 (255)</td><td>12 (90)<sup>a</sup></td></tr><tr><td>% positive</td><td>12.2</td><td>11.8</td><td>13.3</td><td>7.5</td><td>5.9</td><td>6.7</td><td>13.3</td></tr><tr><td><i>C. jejuni s</i>trains</td><td>21 (227)</td><td>20 (227)</td><td>24 (227)</td><td>14 (227)</td><td>13 (227)</td><td>13 (227)</td><td>5 (76)<sup>a</sup></td></tr><tr><td>% positive</td><td>9.3</td><td>8.8</td><td>10.6</td><td>6.2</td><td>5.7</td><td>5.7</td><td>6.6</td></tr><tr><td><i>C. coli</i> strains</td><td>10 (18)</td><td>10 (18)</td><td>10 (18)</td><td>5 (18)</td><td>2 (18)</td><td>4 (18)</td><td>7 (14)<sup>a</sup></td></tr><tr><td>% positive</td><td>55.6</td><td>55.6</td><td>55.6</td><td>27.8</td><td>11.1</td><td>22.2</td><td>50.0</td></tr><tr><td><i>C. lari</i> strains</td><td>0 (5)</td><td>0 (5)</td><td>0 (5)</td><td>0 (5)</td><td>0 (5)</td><td>0 (5)</td><td>0 (5)</td></tr><tr><td>% positive</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td><i>C. fetus</i> strains</td><td>0 (2)</td><td>0 (2)</td><td>0 (2)</td><td>0 (2)</td><td>0 (2)</td><td>0 (2)</td><td>0 (2)</td></tr><tr><td>% positive</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td><i>C. sputorum</i> strains</td><td>0 (2)</td><td>0 (2)</td><td>0 (2)</td><td>0 (2)</td><td>0 (2)</td><td>0 (2)</td><td>0 (2)</td></tr><tr><td>% positive</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td><i>C. hyointestinalis</i> strains</td><td>0 (1)</td><td>0 (1)</td><td>0 (1)</td><td>0 (1)</td><td>0 (1)</td><td>0 (1)</td><td>0 (1)</td></tr><tr><td>% positive</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Phage subgroup</td><td>A</td><td>A</td><td>A</td><td>B</td><td>B</td><td>B</td><td>(A)</td></tr></table>
429c9f7f68bd19bf9525d01f4ec4c213b7e48ce1affd8763e63936ed5870622f.png
simple
<table><tr><td>Sample</td><td>Accession no.</td><td>ciHHV-6</td><td>Integration site<sup><i>a</i></sup></td><td>Population or country</td></tr><tr><td>LEI-1501<sup><i>b</i></sup></td><td>KT355575</td><td>A</td><td>19q</td><td>Leicester area (England)</td></tr><tr><td>HAPMAP NA18999</td><td>KY316047</td><td>A</td><td></td><td>Japan</td></tr><tr><td>3A-10q26.3<sup><i>c</i></sup></td><td>KY316049</td><td>A</td><td>10q26.3 and junction isolated by PCR</td><td>Southeast England</td></tr><tr><td>GLA_4298<sup><i>d</i></sup></td><td>KY316056</td><td>A</td><td></td><td>Newcastle (England)</td></tr><tr><td>GLA_15137<sup><i>e</i></sup></td><td>KY316055</td><td>A</td><td></td><td>Scotland</td></tr><tr><td>GLA_ 25506<sup><i>e</i></sup></td><td>KY316054</td><td>A</td><td></td><td>Scotland</td></tr><tr><td>7A-17p13.3<sup><i>c</i></sup></td><td>KY316048</td><td>A</td><td>17p13.3</td><td>Southeast England</td></tr><tr><td>HGDP00092</td><td>KY316037</td><td>B</td><td></td><td>Balochi (Pakistan)</td></tr><tr><td>HGDP00813</td><td>KY316036</td><td>B</td><td></td><td>Han (China)</td></tr><tr><td>HGDP01065</td><td>KY316035</td><td>B</td><td>Junction isolated by PCR</td><td>Sardinia (Italy)</td></tr><tr><td>HGDP01077</td><td>KY316034</td><td>B</td><td>Junction isolated by PCR</td><td>Sardinia (Italy)</td></tr><tr><td>HAPMAP NA07022 (CEPH 1340.11)</td><td>KY316039</td><td>B</td><td></td><td>Utah Mormon (north European)</td></tr><tr><td>HAPMAP NA10863 (CEPH-1375.02)</td><td>KY316038</td><td>B</td><td></td><td>Utah Mormon (north European)</td></tr><tr><td>4B-11p15.5<sup><i>c</i></sup></td><td>KY316044</td><td>B</td><td>11p15.5</td><td>Southeast England</td></tr><tr><td>BAN519<sup><i>f</i></sup></td><td>KY316043</td><td>B</td><td></td><td>Banff (Scotland)</td></tr><tr><td>COR264<sup><i>f</i></sup></td><td>KY316042</td><td>B</td><td></td><td>Cornwall (England)</td></tr><tr><td>CUM082<sup><i>f</i></sup></td><td>KY316041</td><td>B</td><td></td><td>Cumbria (England)</td></tr><tr><td>DER512<sup><i>f</i></sup></td><td>KY316040</td><td>B</td><td>Junction isolated by PCR</td><td>Derbyshire (England)</td></tr><tr><td>2B-9q34.3<sup><i>c</i></sup></td><td>KY316045</td><td>B</td><td>9q34.3</td><td>Southeast England</td></tr><tr><td>1-ciHHV-6B<sup><i>c</i></sup></td><td>KY316046</td><td>B</td><td>Junction isolated by PCR</td><td>Southeast England</td></tr><tr><td>LEI-ALD</td><td>KY316033</td><td>B</td><td></td><td>Leicester area (England)</td></tr><tr><td>ORCA1622</td><td>KY316031</td><td>B</td><td></td><td>Orkney</td></tr><tr><td>ORCA1340</td><td>KY316032</td><td>B</td><td></td><td>Orkney</td></tr><tr><td>ORCA3835</td><td>KY316030</td><td>B</td><td></td><td>Orkney</td></tr><tr><td>GLA_3986<sup><i>d</i></sup></td><td>KY316053</td><td>B</td><td></td><td>Newcastle (England)</td></tr><tr><td>GLA_29221<sup><i>e</i></sup></td><td>KY316052</td><td>B</td><td></td><td>Scotland</td></tr><tr><td>GLA_34108<sup><i>e</i></sup></td><td>KY316051</td><td>B</td><td></td><td>Scotland</td></tr><tr><td>GLA_35629<sup><i>e</i></sup></td><td>KY316050</td><td>B</td><td></td><td>Scotland</td></tr></table>
2398faa68e304276e811df9aa859ec52af6c58c824f2e1d69b8cef740a3615ce.png
complex
<table><tr><td colspan="2">Variable</td><td>Adjusted odds ratio</td><td>95% confidence interval</td></tr><tr><td>Age (years)</td><td>65-74 vs &lt;65</td><td>1.82</td><td>1.49, 2.23</td></tr><tr><td> </td><td>75-84 vs &lt;65</td><td>2.52</td><td>2.11, 3.02</td></tr><tr><td> </td><td>85+ vs &lt; 65</td><td>3.31</td><td>2.76, 3.95</td></tr><tr><td colspan="2">Female</td><td>1.14</td><td>1.04, 1.24</td></tr><tr><td>MAPLe score<sup>&#8225;</sup></td><td>2 vs 1</td><td>1.45</td><td>1.16, 1.81</td></tr><tr><td> </td><td>3 vs 1</td><td>2.82</td><td>2.38, 3.33</td></tr><tr><td> </td><td>4 vs 1</td><td>3.42</td><td>2.88, 4.06</td></tr><tr><td> </td><td>5 vs 1</td><td>4.86</td><td>4.02, 5.88</td></tr><tr><td colspan="2">Dementia</td><td>1.79</td><td>1.63, 1.98</td></tr><tr><td colspan="2">Injurious fall</td><td>1.31</td><td>1.15, 1.49</td></tr><tr><td colspan="2">Sepsis</td><td>0.43</td><td>0.26, 0.72</td></tr><tr><td colspan="2">Pneumonia</td><td>0.70</td><td>0.65, 0.97</td></tr></table>
e0fd03b0292284788003ded461fb690db6f6265525e32ac8d39b9b8a6187cd92.png
complex
<table><tr><td>Items</td><td colspan="2">Low-Fps:Cps</td><td colspan="2">High-Fps:Cps</td><td></td><td colspan="3"><i>P</i>-value</td></tr><tr><td>FA, g/d</td><td>0</td><td>24</td><td>0</td><td>24</td><td>SEM</td><td>Fps:Cps</td><td>FA</td><td>(Fps:Cps) &#215; FA</td></tr><tr><td>CH<sub>4</sub>, L/d</td><td>23.14</td><td>15.80</td><td>22.84</td><td>18.75</td><td>1.245</td><td>0.552</td><td>0.021</td><td>0.466</td></tr><tr><td>CH<sub>4</sub>/DMI, L/kg</td><td>21.03</td><td>14.54</td><td>20.94</td><td>17.95</td><td>1.044</td><td>0.365</td><td>0.020</td><td>0.341</td></tr><tr><td>pH</td><td>6.38</td><td>6.52</td><td>6.40</td><td>6.51</td><td>0.027</td><td>0.887</td><td>0.020</td><td>0.817</td></tr><tr><td>Total VFA, mmol/L</td><td>89.19</td><td>85.89</td><td>87.01</td><td>80.53</td><td>1.326</td><td>0.633</td><td>&lt; 0.001</td><td>0.187</td></tr><tr><td colspan="9">Individual VFA molar proportion, %</td></tr><tr><td> Acetate</td><td>70.24</td><td>65.50</td><td>66.93</td><td>63.50</td><td>0.526</td><td>0.009</td><td>&lt; 0.001</td><td>0.518</td></tr><tr><td> Propionate</td><td>14.80</td><td>20.58</td><td>19.07</td><td>21.98</td><td>0.437</td><td>0.001</td><td>&lt; 0.001</td><td>0.074</td></tr><tr><td> Butyrate</td><td>11.93<sup>a</sup></td><td>10.79<sup>b</sup></td><td>10.82<sup>b</sup></td><td>11.20<sup>ab</sup></td><td>0.170</td><td>0.303</td><td>0.259</td><td>0.026</td></tr><tr><td> A:P</td><td>4.89<sup>a</sup></td><td>3.62<sup>b</sup></td><td>3.74<sup>b</sup></td><td>3.15<sup>c</sup></td><td>0.095</td><td>&lt; 0.001</td><td>&lt; 0.001</td><td>0.048</td></tr></table>
e33a2891009a0e8f72f19e489746e466af3dc699f138a95bb38f6dff681513b2.png
simple
<table><tr><td>Case vignette</td><td>Respondents, <i>n</i></td><td>Rank sum</td></tr><tr><td>1</td><td>19</td><td>460.50</td></tr><tr><td>2</td><td>16</td><td>564.50</td></tr><tr><td>3</td><td>19</td><td>860.50</td></tr><tr><td>4</td><td>19</td><td>815.50</td></tr></table>
a41d3d12a17e122d02f007213adfac1d95712dc886aa8a383c8d683206ff5fc5.png
complex
<table><tr><td colspan="2">Collaborative Problem Solving Skills</td><td>N</td><td>Mean</td><td>Standard Deviation</td></tr><tr><td rowspan="3">Social Skills</td><td>Participation</td><td>210</td><td>3.07</td><td>1.316</td></tr><tr><td>Perspective Taking</td><td>210</td><td>3.09</td><td>1.347</td></tr><tr><td>Social Regulation</td><td>210</td><td>3.10</td><td>1.364</td></tr><tr><td rowspan="2">Cognitive skills</td><td>Task Regulation</td><td>210</td><td>3.00</td><td>1.334</td></tr><tr><td>Knowledge Building</td><td>210</td><td>2.92</td><td>1.326</td></tr></table>
7a06836b6455de3c37f08f5e25f2253f89ba8fe08d93086490566516734aeb1b.png
complex
<table><tr><td></td><td colspan="3">Recall</td></tr><tr><td></td><td>25 %</td><td>50 %</td><td>75 %</td></tr><tr><td>Precision to benign</td><td>82 %</td><td>66 %</td><td>52 %</td></tr><tr><td>Precision to malignant</td><td>86 %</td><td>74 %</td><td>62 %</td></tr><tr><td></td><td>Precision (<i>n</i>=30)</td><td></td><td></td></tr><tr><td>Benign</td><td>85 %</td><td></td><td></td></tr><tr><td>Malignant</td><td>87 %</td><td></td><td></td></tr></table>
b7d43e2463d5d12ad42080f842ff6896ac63bb4f87f4bb752f0331ce574b0279.png
simple
<table><tr><td><i>Variable</i></td><td><i>Whole sample</i><i>N = 3033</i><i>n (%)</i></td><td><i>Public facilities</i><i>n = 2751</i><i>n (%)</i></td><td><i>Private facilities</i><i>n = 282</i><i>n (%)</i></td><td><i>P-Value</i></td></tr><tr><td>Age in years</td><td></td><td></td><td></td><td>&lt; 0.001</td></tr><tr><td>15-24</td><td>1444(48.4)</td><td>1378(50.9)</td><td>66(23.8)</td><td></td></tr><tr><td>&gt; 25</td><td>1541(51.6)</td><td>1330(49.1)</td><td>211(76.2)</td><td></td></tr><tr><td>Education/grades completed</td><td></td><td></td><td></td><td>&lt; 0.001</td></tr><tr><td>0 - 4</td><td>1061(35.1)</td><td>1060(38.7)</td><td>1(0.4)</td><td></td></tr><tr><td>5 - 8</td><td>857(28.4)</td><td>846(30.9)</td><td>11(3.9)</td><td></td></tr><tr><td>&gt; 9</td><td>1103(36.5)</td><td>834(30.4)</td><td>269(95.7)</td><td></td></tr><tr><td>Number of pregnancies</td><td></td><td></td><td></td><td>&lt; 0.01</td></tr><tr><td>1</td><td>1524(50.3)</td><td>1357(49.3)</td><td>167(59.2)</td><td></td></tr><tr><td>&gt; 2</td><td>1508(49.7)</td><td>1393(50.7)</td><td>115(40.8)</td><td></td></tr><tr><td>PMTCT knowledge</td><td></td><td></td><td></td><td>&lt; 0.001</td></tr><tr><td>Knowledgeable</td><td>2240(76.5)</td><td>1987(75.0)</td><td>253(91.0)</td><td></td></tr><tr><td>Not knowledgeable</td><td>687(23.5)</td><td>662(25.0)</td><td>25(9.0)</td><td></td></tr><tr><td>Previous HIV testing experience</td><td></td><td></td><td></td><td>&lt; 0.001</td></tr><tr><td>Yes</td><td>2450(81.0)</td><td>2185(79.7)</td><td>265(94.0)</td><td></td></tr><tr><td>No</td><td>575(19.0)</td><td>558(20.3)</td><td>17(6.0)</td><td></td></tr><tr><td>Previous HIV testing experiencewith partner</td><td></td><td></td><td></td><td>&lt; 0.001</td></tr><tr><td>Yes</td><td>1673(57.2)</td><td>1465(55.3)</td><td>208(75.6)</td><td></td></tr><tr><td>No</td><td>1250(42.8)</td><td>1183(44.7)</td><td>67(24.4)</td><td></td></tr><tr><td>Type of pre-test counselling</td><td></td><td></td><td></td><td>&lt; 0.001</td></tr><tr><td>Group pre-test information</td><td>2130(73.8)</td><td>2098(77.1)</td><td>32(19.4)</td><td></td></tr><tr><td>Individual counselling</td><td>757(26.2)</td><td>624(22.9)</td><td>133(80.6)</td><td></td></tr></table>
69eadfa82d5352629f7ac0563062b4b331a4f1078ccf1b6501a4f97ae42cabd0.png
complex
<table><tr><td></td><td></td><td colspan="2"><underline>Factor Loadings</underline>*</td><td></td></tr><tr><td>Items</td><td></td><td>Benefits</td><td>Barriers</td><td>Unique Variance</td></tr><tr><td>Osteoporosis drug treatment benefits&#8224;</td><td></td><td></td><td></td><td></td></tr><tr><td>1</td><td>Drug treatments can help to build strong bones</td><td>0.80</td><td>0.07</td><td>0.36</td></tr><tr><td>2</td><td>You would feel good about taking drug treatments to prevent osteoporosis</td><td>0.94</td><td>-0.06</td><td>0.11</td></tr><tr><td>3</td><td>Drug treatments can cut down the chances of broken bones</td><td>0.87</td><td>0.10</td><td>0.25</td></tr><tr><td>6</td><td>You would consider taking drug treatments to prevent broken bones</td><td>0.90</td><td>-0.06</td><td>0.17</td></tr><tr><td>11</td><td>If your doctor advised you to, you would take drug treatments to prevent broken bones</td><td>0.78</td><td>-0.12</td><td>0.36</td></tr><tr><td>Drug treatment barriers&#8224;</td><td></td><td></td><td></td><td></td></tr><tr><td>8<sup>&#8225;</sup></td><td>You are taking too many medications</td><td>-0.12</td><td>0.85</td><td>0.25</td></tr><tr><td>9<sup>&#8225;</sup></td><td>You have stomach problems that limit your ability to take drug treatment</td><td>0.14</td><td>0.56</td><td>0.69</td></tr></table>
554f5370c72b841105ab5ea44cb1d68aa159ec4f8c6c89219f861e32a6ef17f2.png
simple
<table><tr><td></td><td>&#946;</td><td>S.E.</td><td>OR</td><td>CI 95%</td><td>p-value</td></tr><tr><td>Pulse oximetry (SpO2 &lt; 95%)</td><td>1.39</td><td>0.63</td><td>4.02</td><td>1.16&#8211;13.85</td><td>0.022</td></tr><tr><td>Clinical stage (III vs. IV)</td><td>0.78</td><td>0.43</td><td>2.18</td><td>0.93&#8211;5.06</td><td>0.070</td></tr><tr><td>Appetite (10 mm)</td><td>0.13</td><td>0.06</td><td>1.14</td><td>1.01&#8211;1.30</td><td>0.041</td></tr><tr><td>Fatigue (10 mm)</td><td>0.21</td><td>0.09</td><td>1.23</td><td>1.03&#8211;1.47</td><td>0.019</td></tr></table>
7dd550311a2318e65e05d61c1ac9a84feea99232a0f34a2ea0b955e77ac2105d.png
complex
<table><tr><td>Responders</td><td>Biofeedback group</td><td>Control group</td></tr><tr><td colspan="3">T2</td></tr><tr><td><i>n</i> (%)</td><td>10 (67 %)</td><td>2 (17 %)</td></tr><tr><td colspan="3">T3</td></tr><tr><td><i>n</i> (%)</td><td>12 (80 %)</td><td>3 (25 %)</td></tr><tr><td colspan="3">T4</td></tr><tr><td><i>n</i> (%)</td><td>7 (47 %)</td><td>2 (17 %)</td></tr></table>
da7e76bca195dff9e0ad941f157387d5ad59e69dde6ec14c57e336c172165bfd.png
complex
<table><tr><td> </td><td colspan="5">Category</td></tr><tr><td>Occupation</td><td>Documentation (N = 38) fraction %</td><td>Interactions (N = 36) fraction %</td><td>Adverse effects (N = 16) fraction %</td><td>Pregnancy and breastfeeding (N = 9) fraction %</td><td>Contraindications (N = 1) fraction %</td></tr><tr><td>Physicians (N = 54)</td><td>23/54 42.6</td><td>15/54 27.8</td><td>12/54 22.2*</td><td>3/54 5.6</td><td>1/54 1.9</td></tr><tr><td>Pharmacists (N = 33)</td><td>10/33 30.3</td><td>20/33 60.6**</td><td>1/33 3.0</td><td>2/33 6.1</td><td> </td></tr><tr><td>Midwifes (N = 3)</td><td> </td><td> </td><td> </td><td>3/3 100.0</td><td> </td></tr><tr><td>Nurses (N = 2)</td><td>1/2 50.0</td><td> </td><td> </td><td>1/2 50.0</td><td> </td></tr><tr><td>Other (N = 8)<sup>a</sup></td><td>4/8 50.0</td><td>1/8 12.5</td><td>3/8 37.5</td><td> </td><td> </td></tr></table>